TRPM3-modulating derivatives

TRPM3-modulating derivatives, such as benzofuran and thienopyridine compounds, address the need for effective treatments for TRPM3 mediated disorders by modulating TRPM3 channels to treat pain and epilepsy with reduced side-effects and improved pharmacokinetics.

WO2026239365A1PCT designated stage Publication Date: 2026-11-19BIOHAVEN THERAPEUTICS LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/054922
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-08-11
Filing Date
2026-05-18
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

There is a significant medical need for novel, alternative, and/or better therapeutics for TRPM3 mediated disorders, particularly for pain such as inflammatory pain and epilepsy, with a focus on compounds that have good potency, low side-effects, and favorable pharmacokinetic or -dynamic properties.

Method used

Development of TRPM3-modulating derivatives, including benzofuran, benzothiophene, and thienopyridine derivatives, which act as antagonists to modulate TRPM3 channels, thereby preventing or treating disorders like pain, inflammatory pain, or hypersensitivity, and epilepsy.

Benefits of technology

The TRPM3-modulating derivatives effectively prevent or treat TRPM3 mediated disorders by providing potent analgesic effects with minimal side-effects and improved pharmacokinetic properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000003_0002
    Figure IMGF000003_0002
  • Figure IMGF000005_0001
    Figure IMGF000005_0001
Patent Text Reader

Abstract

The invention relates to TRPM3-modulating derivatives having a fused cycle at the 4,5 positions of the derivatives as described herein. The compounds are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders including pain, such as migraine pain, inflammatory pain or inflammatory hypersensitivity, and epilepsy. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.
Need to check novelty before this filing date? Find Prior Art

Description

TRPM3-MODULATING DERIVATIVESCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is an International Patent Application claiming priority to United States Provisional Patent Application No. 63 / 807,481, filed May 16, 2025, and to United States Provisional Patent Application No.63 / 861,862, filed August 11, 2025, each of which are hereby incorporated by reference in their entirety herein.FIELD OF THE INVENTION

[0002] The invention relates to compounds and pharmaceutical compositions which are useful for the prevention or treatment of TRPM3 mediated disorders, more particularly disorders selected from pain, such as migraine pain, inflammatory hypersensitivity, and epilepsy. The invention also relates to methods for the prevention or treatment of said TRPM3 mediated disorders.BACKGROUND OF THE INVENTION

[0003] The TRP superfamily consists of proteins with six transmembrane domains (6TM) that assemble as homo-or heterotetramers to form cation-permeable ion channels. The name TRP originates from the Drosophila trp (transient receptor potential) mutant, which is characterized by a transient receptor potential in the fly photoreceptors in the response to sustained light. In the last 15 years, trp-related channels have been identified in yeast, worms, insects, fish and mammals, including 27 TRPs in humans. Based on sequence homology, TRP channels can be divided into seven subfamilies: TRPC, TRPV, TRPM, TRP A, TRPP, TRPML and TRPN.

[0004] Members of the TRP superfamily are expressed in probably all mammalian organs and cell types, and in recent years great progress has been made in the understanding of their physiological role. The tailored selectivity of certain TRP channels enables them to play key roles in the cellular uptake and / or transepithelial transport of Ca2+, Mg2+and trace metal ions. Moreover, the sensitivity of TRP channels to a broad array of chemical and physical stimuli, allows them to function as dedicated biological sensors involved in processes ranging from vision to taste, and tactile sensation. In particular, several members of the TRP superfamily exhibit a very high sensitivity to temperature. These so-called thermoTRPs are highly expressed in sensory neurons and / or skin keratinocytes, where they act as primary thermosensors for the detection of innocuous and noxious (painful) temperatures.

[0005] It is becoming increasingly clear that TRP channel dysfunction is directly involved in the etiology of various inherited and acquired diseases. Indeed, both loss-of-function and gain-of-function mutations in the TRP channel genes have been identified as the direct cause of inherited diseases, including brachyolmia, hypomagnesemia with secondary hypocalcemia, polycystic kidney disease, mucolipidosis type IV and familial focal segmental glomerulosclerosis. Moreover, TRP channel function / dysfunction has been directly linked to a wide range of pathological conditions, including chronic pain, hypertension, cancer and neurodegenerative disorders.

[0006] TRPM3 (Transient receptor potential melastatin 3) represents a promising pharmacological target. TRPM3 is expressed in a large subset of small-diameter sensory neurons from dorsal root and trigeminal ganglia, and is involved in heat sensing. The neurosteroid pregnenolone sulfate is a potent known activator of TRPM3 (Wagner et al., 2008). The neurosteroid pregnenolone sulfate evoked pain in wild type mice but not in knock-out TRPM3 mice. It was also recently shown that CFA induced inflammation and inflammatory pain are eliminated20308-WO-PCT / 30175-102410 1in TRPM3 knock-out mice. Therefore, TRPM3 antagonists could be used as analgesic drugs to counteract pain, such as inflammatory pain (Vriens J. et al. Neuron, May 2011).

[0007] A few TRPM3 antagonists are known, but none of them points towards the compounds disclosed herein (Straub I et al. Mol Pharmacol, November 2013). For instance, Liquiritigenin, a postulated TRPM3 blocker has been described to decrease mechanical and cold hyperalgesia in a rat pain model (Chen L et al. Scientific reports, July 2014). There is still a great medical need for novel, alternative and / or better therapeutics for the prevention or treatment of TRPM3 mediated disorders, more in particular for pain such as inflammatory pain, or for epilepsy. Therapeutics with good potency on a certain type of pain, low level or no side-effects (such as no possibilities for addiction as with opioates, no toxicity) and / or good or better pharmacokinetic or -dynamic properties are highly needed.

[0008] The invention provides a class of novel compounds which are antagonists of TRPM3 and can be used as modulators of TRPM3 mediated disorders.SUMMARY OF THE INVENTION

[0009] The invention provides TRPM3 -modulating derivatives (including benzofuran, benzothiophene, thienopyridine, and furopyridine derivatives) and pharmaceutical compositions comprising such derivatives. The invention also provides TRPM3 -modulating derivatives for use as a medicament, more particularly for use in the prevention and / or treatment of TRPM3 mediated disorders, especially for use in the prevention and / or treatment of pain and / or inflammatory pain or hypersensitivity; and / or for treating or preventing epilepsy; and / or for counteracting pain and / or inflammatory pain or hypersensitivity.

[0010] The invention also provides the use of TRPM3 -modulating derivatives for the manufacture of pharmaceutical compositions or medicaments for the prevention and / or treatment of TRPM3 mediated disorders, especially for the prevention and / or treatment of pain and / or inflammatory pain or hypersensitivity; and / or for treating or preventing epilepsy; and / or for counteracting pain and / or inflammatory pain or hypersensitivity.

[0011] The invention also provides a method for the prevention or treatment of a TRPM3 mediated disorder by administering the TRPM3 -modulating derivatives according to the invention to a subject in need thereof. More particularly, the invention relates to such method for the prevention and / or treatment of pain and / or inflammatory pain or hypersensitivity; and / or for treating or preventing epilepsy; and / or for counteracting pain and / or inflammatory pain or hypersensitivity.

[0012] The invention further provides a method for the preparation of the TRPM3 -modulating derivatives of the invention, comprising the synthetic procedures described herein.DETAILED DESCRIPTION OF THE INVENTION

[0013] The invention will be further described and in some instances with respect to particular embodiments, but the invention is not limited thereto..

[0014] In an aspect, the disclosure provides for benzofuran compounds having a fused ring(s) attached at the 4 and 5 positions of the aromatic benzofuran ring. The below structure shows exemplary numbering of the benzofuran ring atoms.20308-WO-PCT / 30175-102410 2

[0015] In further aspects, and as further described herein, the disclosure provides for other aromatic scaffolds having a fused ring(s) attached at the 4 and 5 positions thereof, including benzothiophene, thienopyridine, and furopyridine derivatives:

[0016] A first aspect of the invention is the provision of a compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereofpreferably for use in the treatment of pain or epilepsy or methods of treating pain or epilepsy;wherein:R1represents -F, -Cl, -Br, -I, -CN, -Rw, -ORW, -OC(=O)RW, -NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX;R3represents -OH or -RY;Q represents a ring selected from 5-8-membered cycloalkyl, saturated or unsaturated, 5-8-membered heterocycloalkyl, saturated or unsaturated, 6-8-membered aryl, and 5-8-membered heteroaryl;n is an integer ranging from 0 to 10, or from 0 to 8, or from 0 to 6, or from 0 to 5, or from 0 to 4, or from 0 to 3, or from 0 to 2, or from 0 to 1;R6and R7independently of one another represent -F, -Cl, -Br, -I, -CN, -NO2, -SF5, -RW, -ORW, -OC(=O)RW,-NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX,R8independently at each occurrence represents -F, -Cl, -Br, -I, -CN, -NO2, -SF5, =O, -RQ, -ORY, -OC(=O)RY,-NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ, optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;or two occurrences of R8together form 3-6-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono-or poly substituted with R11; 3-6-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; phenyl, unsubstituted, mono- or polysubstituted with R11; or 5-6-membered heteroaryl,20308-WO-PCT / 30175-102410unsubstituted, mono- or polysubstituted with R11;whereinRwand Rxindependently of one another in each case independently represent-H;-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RQin each case independently represents-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;6-14-membered aryl, unsubstituted, mono- or polysubstituted with R11; wherein said 6-14-membered aryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11; wherein said 5-14-membered heteroaryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RYand Rzindependently of one another in each case independently represent -H or -RQ, or RYand Rztogether form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted with R11;and wherein "mono- or polysubstituted with R11" in each case independently means substituted with one or more, e.g. 1, 2, 3, 4, or more substituents independently of one another selected from (that is, R11is independently at each occurrence selected from) -F, -Cl, -Br, -I, -CN, -Ci-e-alkyl, -CFs, -CF2H, -CFH2, -CF2Cl, -CFCl2, -C1-6-alkylene-CF3, -C1-6-alkylene-CF2H, -C1-6-alkylene-CFH2, -C1-6-alkylene-O-CF3, -Ci-6-alkylene-O-CF2H, -Ci-e-alkylene-O-CFH2, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3,-Ci-6-alkylene-N(Ci-6-alkyl)-Ci-6-alkylene-CF3, -C(=O)-Ci-e-alkyl, -Ci-6-alkylene-C(=O)-Ci-6-alkyl, -C(=O)OH, -Ci-6-alkylene-C(=O)-OH, -C(=O)-OCi-6-alkyl, -Ci-e-alkylene-C(=O)-OCi-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3,-C(=O)-NH2, -Ci-6-alkylene-C(=O)-NH2, -C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-C(=O)-NH(Ci-6-alkyl), -C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-C(=O)-N(Ci-6-alkyl)2, -C(=O)-NH(OH), -Ci-6-alkylene-C(=O)-NH(OH), -OH, -Ci-6-alkylene-OH, =0, -OCF3, -OCF2H, -OCFH2, -OCF2CI, -OCFCb, -O-Ci-6-alkyl, -Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-e-20308-WO-PCT / 30175-102410 4alkylene-NH2, -O-Ci-6-alkylene-NH-Ci-6-alkyl, -O-Ci-6-alkylene-N(Ci-6-alkyl)2, -O-C(=O)-Ci-6-alkyl, -Ci-e-alkylene-O-C(=O)-Ci-6-alkyl, -O-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-O-C(=O)-O-Ci-6-alkyl,alkyl), -Ci-6-alkylene-O-C(=O)-NH(Ci-6-alkyl), -O-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-C(=O)-N(Ci-6-alkyl)2, -O-S(=O)2-NH2, -Ci-6-alkylene-O-S(=O)2-NH2, -O-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-O-S(=O)2-NH(Ci-6-alkyl), -O-S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-S(=O)2-N(Ci-6-alkyl)2, -NH2, -NO, -NO2, -Ci-6-alkylene-NH2, -NH(Ci-6-alkyl), -N(3-14-membered cycloalkyl)(Ci-6-alkyl), -N(Ci-6-alkyl)-Ci-6-alkylene-OH, -N(H)-Ci-6-alkylene-OH, -Ci-6-alkylene-NH(Ci-6-alkyl), -N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)2,alkyl, -Ci-6-alkylene-NH-C(=O)-Ci-6-alkyl, -NH-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-NH-C(=O)-O-Ci-6-alkyl, -NH-C(=O)-NH2, -Ci-6-alkylene-NH-C(=O)-NH2, -NH-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-NH-C(=O)-NH(Ci-e-alkyl), -NH-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-C(=O)-N(Ci-6-alkyl)2, -N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -N(Ci-6-alkyl)-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-O-Ci-6-alkyl, -N(Ci-6-alkyl)-C(=O)-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH2, -N(Ci-6-alkyl)-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -Ci-e-alkylene-N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -NH-S(=O)2OH, -Ci-6-alkylene-NH-S(=O)2OH,alkyl, -Ci-6-alkylene-NH-S(=O)2-Ci-6-alkyl, -NH-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-NH-S(=O)2-O-Ci-6-alkyl, -NH-S(=O)2-NH2, -Ci-6-alkylene-NH-S(=O)2-NH2, -NH-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-NH-S(=O)2-NH(Ci-6-alkyl), -NH-S(=O)2N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-S(=O)2N(Ci-6-alkyl)2, -N(Ci-6-alkyl)-S(=O)2-OH, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-OH, -N(Ci-6-alkyl)-S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-Ci-e-alkyl, -N(Ci-6-alkyl)-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-O-Ci-6-alkyl, -N(Ci-6-alkyl)-S(=O)2-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH2, -N(Ci-6-alkyl)-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -SH, =S, -SF5, -SCF3, -SCF2H, -SCFH2, -S-Ci-e-alkyl, -C1-6-alkylene-S-C1-6-alkyl, -S(=O)-C1-6-alkyl, -Ci-6-alkylene-S(=O)-Ci-6-alkyl, -S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-S(=O)2-Ci-6-alkyl, -S(=O)2-OH, -Ci-e-alkylene-S(=O)2-OH, -S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-S(=O)2-O-Ci-6-alkyl, -S(=O)2-NH2, -Ci-6-alkylene-S(=O)2-NH2, -S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-S(=O)2-NH(Ci-6-alkyl), -S(=O)2-N(Ci-6-alkyl)2, -Ci-e-alkylene-S(=O)2-N(Ci-6-alkyl)2, 3-14-membered cycloalkyl, -Ci-6-alkylene-(3-14-membered cycloalkyl), 3 to 14-membered heterocycloalkyl, -Ci-6-alkylene-(3 to 14-membered heterocycloalkyl), -phenyl, -Ci-6-alkylene-phenyl, 5 to 14-membered heteroaryl, -Ci-6-alkylene-(5 to 14-membered heteroaryl), -O-(3-14-membered cycloalkyl), -O-(3 to 14-membered heterocycloalkyl), -O-phenyl, -O-(5 to 14-membered heteroaryl), -C(=O)-(3- 14-membered cycloalkyl), -C(=O)-(3 to 14-membered heterocycloalkyl), -C(=O)-phenyl, -C(=O)-(5 to 14-membered heteroaryl), -S(=O)2-(3-14-membered cycloalkyl), -S(=O)2-(3 to 14-membered heterocycloalkyl), -S(=O)2-phenyl, -S(=O)2-(5 to 14-membered heteroaryl). It is generally contemplated herein in various embodiments that moieties which are monosubstituted, disubstituted, and / or polysubstituted may be so substituted with one or more R11.

[0017] Q may generally be saturated or unsaturated, and is generally coordinated at each ring atom with either -H or -R8to complete the coordination of each atom. For example, in the case of two R8substituents (i.e., n=2), various atoms in the ring system Q depending upon the coordination requirements of the atoms may be saturatively coordinated with either R8or -H such that the two R8are bound to atoms of the ring system and -H completes the coordination requirements of the ring atoms. While various embodiments define substituents R8to the ring system, it should be understood that in other embodiments ring Q may be mono-, di-, or polysubstituted with any substituent described herein (such as those of R11or others).20308-WO-PCT / 30175-102410 5

[0018] In some embodiments, two occurrences of R8together form 3-6-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; 3-6-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; phenyl, unsubstituted, mono- or polysubstituted with R11; or 5-6-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11. Said cycloalkyl, heterocycloalkyl, phenyl, or heteroaryl may be fused (i.e., attached at two different atoms of Q) or spiro (i.e., attached at one atom of Q).

[0019] In some embodiments, R1is selected from -Ci-Ce-alkyl. In some embodiments, R1is selected from methyl, ethyl, and propyl. In some embodiments, R1is methyl.

[0020] In some embodiments, R1is not phenyl. In some embodiments, R1does not comprise an aryl or heteroaryl group (i.e., R1is a non-aromatic group). For example, any embodiment herein (i.e., for Formula I, or any other formula) may further include the proviso that R1is not phenyl, or the proviso that R1does not comprise an aryl or heteroaryl group.

[0021] In some embodiments, R3represents -CR9R9R9, wherein R9, R9', and R9are independently RY, optionally wherein at least one of R9, R9, and R9are not -H, or Ci-ealkyl or Ci-eheteroalkyl optionally substituted with one or more RY, optionally wherein two of R9, R9', and R9" together form a 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl, said 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl optionally monosubstituted or polysubstituted with one or more RY.

[0022] In some embodiments, R6and R7are independently selected from H, Ci-Ce-alkyl, and Ci-Ce-heteroalkyl. In some embodiments, R6and R7are preferably each -H.

[0023] In some embodiments, R8is selected from halogen, Ci-Ce alkyl, Ci-Ce alkoxy, and Ci-ehaloalkyl. In some embodiments, R8is selected from F, methyl, ethyl, -CH2-CH2-O-CH3, and -CH2-O-CH3.

[0024] In some embodiments, R6is selected from cyano, carbonyl, carboxylic acid, carboxylic esters, nitro, ammonium, aldehyde, and sulfonyl.

[0025] In some embodiments, Q represents a 5-8-membered cycloalkyl, optionally substituted with one or more R8. In some embodiments, Q represents a 5 membered cycloalkyl (i.e., cyclopentyl), substituted or unsubstituted. In some embodiments, Q represents a 6 membered cycloalkyl (i.e., cyclohexyl), substituted or unsubstituted. In some embodiments, Q represents a 7 membered cycloalkyl (i.e., cycloheptyl), substituted or unsubstituted. In some embodiments, Q represents an 8 membered cycloalkyl (i.e., cyclooctyl), substituted or unsubstituted. In some embodiments, the 5-8-membered cycloalkyl is saturated. In some embodiments, the 5-8-membered cycloalkyl contains one or more unsaturations (i.e., double bonds). In some embodiments, the cycloalkyl of Q comprises one ring. In some embodiments, the cycloalkyl of Q comprises two rings which are bridged, fused, or spiro.

[0026] In some embodiments, Q represents a 5-8-membered heterocycloalkyl, optionally substituted with one or more R8. In some embodiments, Q represents a 5 membered heterocycloalkyl, substituted or unsubstituted. In some embodiments, Q represents a 6 membered heterocycloalkyl, substituted or unsubstituted. In some embodiments, Q represents a 7 membered heterocycloalkyl, substituted or unsubstituted. In some embodiments, Q represents an 8 membered heterocycloalkyl, substituted or unsubstituted. In some embodiments, the 5-8-membered heterocycloalkyl is saturated. In some embodiments, the 5-8-membered heterocycloalkyl contains one or more unsaturations (i.e., double bonds). In some embodiments, the heterocycloalkyl of Q comprises one ring. In some embodiments, the heterocycloalkyl of Q comprises two rings which are bridged, fused, or spiro. In some20308-WO-PCT / 30175-102410 6embodiments, the 5-8-membered heterocycloalkyl of Q comprises one or more heteroatoms selected from N, O, and S. In some embodiments, the 5-8-membered heterocycloalkyl of Q comprises one, two, or three N atoms. In some embodiments, the 5-8-membered heterocycloalkyl of Q comprises one, two, or three O atoms. In some embodiments, the 5-8-membered heterocycloalkyl of Q comprises one, two, or three S atoms.

[0027] In some embodiments, the 5-8-membered heterocycloalkyl of Q comprises one N atom and one or two O atoms. In some embodiments, the 5-8-membered heterocycloalkyl of Q comprises one or two N atoms and one O atom. In some embodiments, the 5-8-membered heterocycloalkyl of Q comprises one or two N atoms and one S atom. In some embodiments, the 5-8-membered heterocycloalkyl of Q comprises one N atom and one or two S atoms. In some embodiments, the 5-8-membered heterocycloalkyl of Q comprises one O atom and one or two S atoms. In some embodiments, the 5-8-membered heterocycloalkyl of Q comprises one or two O atoms and one S atom. In some embodiments, the 5-8-membered heterocycloalkyl of Q comprises one N atom, one O atom, and one S atom.

[0028] In some embodiments, Q represents a 6-8-membered aryl, optionally substituted with one or more R8. In some embodiments, Q represents a 6-membered aryl (i.e., phenyl), substituted or unsubstituted. In some embodiments, Q represents a 7-membered aryl, substituted or unsubstituted. In some embodiments, Q represents an 8-membered aryl, substituted or unsubstituted. In some embodiments, the 6-8-membered aryl of Q comprises one ring, or comprises two fused rings.

[0029] In some embodiments, Q represents a 5-8-membered heteroaryl, optionally substituted with one or more R8. In some embodiments, Q represents a 5 membered heteroaryl, substituted or unsubstituted. In some embodiments, Q represents a 6 membered heteroaryl, substituted or unsubstituted. In some embodiments, Q represents a 7 membered heteroaryl, substituted or unsubstituted. In some embodiments, Q represents an 8 membered heteroaryl, substituted or unsubstituted. In some embodiments, the 5-8-membered heteroaryl of Q comprises one ring, or comprises two fused rings.

[0030] In some embodiments, the 5-8-membered heteroaryl of Q comprises one or more heteroatoms selected from N, O, and S. In some embodiments, the 5-8-membered heteroaryl of Q comprises one, two, or three N atoms. In some embodiments, the 5-8-membered heteroaryl of Q comprises one, two, or three O atoms. In some embodiments, the 5-8-membered heteroaryl of Q comprises one, two, or three S atoms. In some embodiments, the 5-8-membered heteroaryl of Q comprises one N atom and one or two O atoms. In some embodiments, the 5-8-membered heteroaryl of Q comprises one or two N atoms and one O atom. In some embodiments, the 5-8-membered heteroaryl of Q comprises one or two N atoms and one S atom. In some embodiments, the 5-8-membered heteroaryl of Q comprises one N atom and one or two S atoms. In some embodiments, the 5-8-membered heteroaryl of Q comprises one O atom and one or two S atoms. In some embodiments, the 5-8-membered heteroaryl of Q comprises one or two O atoms and one S atom. In some embodiments, the 5-8-membered heteroaryl of Q comprises one N atom, one O atom, and one S atom.

[0031] In some embodiments, Q is 5-membered cycloalkyl, 6-membered cycloalkyl, 5-membered heterocycloalkyl, 6-membered heterocycloalkyl, 6-membered aryl, 5 -membered heteroaryl, or 6 membered heteroaryl, wherein said heterocycloalkyl and heteroaryl comprise one, two, or three heteroatoms selected from O and N. In some embodiments, Q includes one or more cycloalkyl, heterocycloalkyl, aryl, or heteroaryl rings, wherein, for Q having more than one cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring, said rings may share one or more atoms in a spiro or fused system, or may be optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-20308-WO-PCT / 30175-102410 7heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0032] In an embodiment, Q represents 5-8-membered heteroaryl, unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO2, =0, =S, -SF5. -RQ, -ORY, -OC(=O)RY, -NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ.

[0033] In an alternative embodiment, Q represents a 5-14-membered heteroaryl. In some embodiments, the 5-14-membered heteroaryl or aryl within the definition of Q is selected from azulene, benzimidazole, benzisoxazole, benzoazole, benzodioxole, benzofuran, benzothiadiazole, benzothiazole, benzothiophene, carbazole, cinnoline, dibenzofuran, furane, furazane, imidazole, imidazopyridine, indazole, indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [l,2,4]triazolo[4,3-a]pyrimidine; in each case unsubstituted, mono- or poly substituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO2, =0, =S, -SF5, -RQ, -ORY, -OC(=O)RY, -NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ.

[0034] In some embodiments, the 5-14-membered heteroaryl within the definition of Q is selected from the group consisting of furane, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, triazole, pyridine, isoquinoline, benzothiazole, pyridazine, pyrimidine, imidazopyridine; in each case unsubstituted, mono- orpolysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO2, =0, =S, -SF5, -RQ, -ORY, -OC(=O)RY, -NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ.

[0035] In some embodiments, the 5-14-membered heteroaryl within the definition of Q is selected from the group consisting of furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, pyrazol-5-yl, oxazol-5-yl, isoxazol-4-yl, thiazol-2-yl, thiazol-5-yl, l,2,4-triazol-3-yl, l,2,3-triazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, isoquinolin- 1-yl, isoquinolin-5-yl, benzo [d]thiazol-2-yl, pyridazin-3-yl, pyrimidin-5-yl, and imidazo[l,2-a]pyridin-6-yl; in each case unsubstituted, mono- or poly substituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO2, =0, =S, -SF5, -RQ, -ORY, -OC(=O)RY, -NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ.

[0036] In an alternative embodiment, Q represents 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO2, =0, =S, -SF5, -RQ, -ORY, -OC(=O)RY, -NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ.

[0037] In some embodiments, the 3-14-membered heterocycloalkyl within the definition of Q is selected from azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1 -dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro- IH-pyrrolizine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[l,2-a]pyrazine; in each case unsubstituted, mono- or20308-WO-PCT / 30175-102410 8poly substituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO2, =0, =S, -SF5, -RQ, -ORY, -OC(=O)RY, -NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ.

[0038] In some embodiments, the 3-14-membered heterocycloalkyl within the definition of Q is tetrahydropyran or pyrrolidine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO2, =0, =S, -SF5, -RQ, -ORY, -OC(=O)RY, -NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ

[0039] In some embodiments, the 3-14-membered heterocycloalkyl within the definition of Q is tetrahydropyran-4-yl or pyrrolidin-3-yl; in each case unsubstituted, mono- or poly substituted with substituents independently of one another selected from -F, -Cl, -Br, -I, -CN, -NO, -NO2, =0, =S, -SF5, -RQ, -ORY, -OC(=O)RY, -NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ

[0040] In some embodiments, Q is unsubstituted, mono- or polysubstituted with substituents R8independently of one another selected from-F, -Cl, -Br, -I, -CN, -C(=O)OH, -NH2, -NO2, -OH, =0, -SF5;-Ci-e-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-C(=0)0-Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-NHCi-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-N(Ci-6-alkyl)2, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-O-Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-S(=O)2-Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0041] In some embodiments, Q is unsubstituted, mono- or polysubstituted with substituents R8independently of one another selected from-OH, -F, -Cl, -Br, -I, -SH, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -CN, -NO2, -C(=O)OH, -NH2, or -N(CH3)2;-Ci-e-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -Ci-e-alkyl, C2-e-alkenyl, -C2-e-alkynyl, -OH, =0, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, C(=O)CHF2, and -C(=O)NH2;-Ci-6-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -Ci-e-alkyl, C2-e-alkenyl, -C2-e-alkynyl, -OH, =0, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, C(=O)CHF2, and -C(=O)NH2;-OCi-e-alkyl, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -Ci-e-alkyl, C2-e-alkenyl, -C2-e-alkynyl, -OH, =0, -SH, =S, -CN, -CF3,20308-WO-PCT / 30175-102410 9-CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SF5, -NO2, -C(=O)OH, -NH2, C(=O)CHF2, and -C(=O)NH2; -0(C=0)Ci-6-alkyl, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -Ci-e-alkyl, C2-e-alkenyl, -C2-6-alkynyl, -OH, =0, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, C(=O)CHF2, and -C(=O)NH2; -C(=0)0Ci-6-alkyl, unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -Ci-e-alkyl, C2-e-alkenyl, -C2-6-alkynyl, -OH, =0, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, C(=O)CHF2, and -C(=O)NH2; 3-14-membered cycloalkyl selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -Ci-e-alkyl, C2-e-alkenyl, -C2-6-alkynyl, -OH, =0, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, C(=O)CHF2, and -C(=0)NH2; 3-14-membered heterocycloalkyl selected from the group consisting of azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1-dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro- IH-pyrrolizine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[l,2-a]pyrazine, in each case unsubstituted, mono- or poly substituted with substituents independently of one another, selected from the group consisting of -F, -Cl, -Br, -I, -Ci-e-alkyl, C2-6-alkenyl, -C2-6-alkynyl, -OH, =0, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs. -NO2, -C(=O)OH, -NH2, C(=O)CHF2, and -C(=O)NH2.

[0042] In some embodiments, Q is unsubstituted, mono- or polysubstituted with substituents R8independently of one another selected from -F, -Cl, -CN, -OH, =0, -Ci-e-alkyl, -CHF2, -CF3, -Ci-6-alkylene-NH2, -Ci-6-alkylene-NHC(=0)0-Ci-6-alkyl, -Ci-6-alkylene-OH, -Ci-6-alkylene-NHC(=O)-O-Ci-6-alkyl, -C(=0)0-Ci-6-alkyl, -N(Ci-e-alkyl)2, -OCi-e-alkyl, -OCF3, -O-Ci-6-alkylene-N(Ci-6-alkyl)2, -S(=O)2-Ci-6-alkyl, -azetidine, -Ci-6-alkylene-O-tetrahydropyran, or -piperazine substituted with -Ci-e-alkyl.

[0043] In some embodiments, the integer n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, the integer n is 0. In some embodiments, the integer n is 1. In some embodiments, the integer n is 2. In some embodiments, the integer n is 3. In some embodiments, the integer n is 4. In some embodiments, the integer n is 5. In some embodiments, the integer n is 6. In some embodiments, the integer n is 7. In some embodiments, the integer n is 8. In some embodiments, the integer n is 9. In some embodiments, the integer n is 10. In some embodiments, n is an integer ranging from 0 to 10, or from 0 to 8, or from 0 to 6, or from 0 to 5, or from 0 to 4, or from 0 to 3, or from 0 to 2, or from 0 to 1.

[0044] In some embodiments, Q represents C3-C8cycloalkyl, phenyl, C5-C8heterocycloalkyl, or C5-C8heteroaryl, optionally substituted with one or more of halogen, C1-C3-haloalkyl. hydroxy, acyl, carboxamide, methyl, methoxy, ethyl, ethoxy, propyl, cyclopropyl, butyl, cyclobutyl, oxetane, pyrrole, or diazole, said carboxamide, acyl, cyclopropyl, cyclobutyl, oxetane, pyrrole and diazole optionally being further substituted with halogen, C1-C3-haloalkyl, hydroxy, phenyl, methyl, methoxy, ethyl, ethoxy, or propyl, optionally connected through Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-.20308-WO-PCT / 30175-102410 10

[0045] A further aspect of the invention is the provision of a compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate, and / or polymorph thereof:dashed lines independently indicate the presence or absence of a double bond,wherein:R1represents -F, -Cl, -Br, -I, -CN, -Rw, -ORW, -OC(=O)RW, -NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX, optionally C1-C2 alkyl, C1-C2 haloalkyl, or cyclopropyl; R3is selected from -CR9R9R9", wherein R9, R9', and R9" are independently RY, or Ci-ealkyl or Ci-eheteroalkyl optionally substituted with one or more RY, optionally wherein two of R9, R9', and R9" together form a 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl, said 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl optionally monosubstituted or polysubstituted with one or more RY;R6, and R7independently of one another represent -F, -Cl, -Br, -I, -CN, -NO2, -SF5, -Rw, -ORW, -OC(=O)RW,-NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX,R8independently at each occurrence represents -F, -Cl, -Br, -I, -CN, -NO2, -SF5, =0, -RQ, -ORY, -OC(=O)RY,-NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ, optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;or two occurrences of R8together form 3-6-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono-or poly substituted with R11; 3-6-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; phenyl, unsubstituted, mono- or polysubstituted with R11; or 5-6-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11;X1, X2and Z represent, independently of one another and in each case, an atom selected from C, N, O, and S; n is an integer ranging from 0 to 10, or from 0 to 8, or from 0 to 6, or from 0 to 5, or from 0 to 4, or from 0 to 3, or from 0 to 2, or from 0 to 1;m is an integer ranging from 1 to 4, wherein when m is greater than 1, the bonds formed between respective pairs of adjacent Z atoms are independently single bonds or double bonds;whereinRwand Rxindependently of one another in each case independently represent-H;-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;20308-WO-PCT / 30175-102410-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RQin each case independently represents-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;6-14-membered aryl, unsubstituted, mono- or polysubstituted with R11; wherein said 6-14-membered aryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11; wherein said 5-14-membered heteroaryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RYand Rzindependently of one another in each case independently represent -H or -RQ,or RYand Rztogether form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted with R11;and wherein R11is independently selected from, at each occurrence, halogen, carbonyl, hydroxy, amino, cyano, nitro, sulfate, sulfonate, sulfonyl, phosphate, phosphonate, phosphonyl, Ci-Ce haloalkyl, Ci-Ce alkyl, Ci-Ce heteroalkyl, and Ci-Ce alkoxy.

[0046] In embodiments, X1, X2, and Z independently and in each case represent an atom selected from C, N, O and S. As should be apparent, said C atom will have two substituents (independently -H or, when present, R8) when C is connected by two single bonds, and said C atom will have one substituent (-H or, when present, R8) when C is connected by one single bond and one double bond. As should also be apparent said N atom will have one substituent when N is connected by two single bonds (-H or, when present, R8), or will generally be unsubstituted when N is connected by one single bond and one double bond (although, in some instances, N may be quaternary as per C). As should also be apparent, said S may be unsubstituted and connected by single bonds, or may be substituted with R8, such as =0 in sulfinamide, sulfinate, or other groups, or other R8. As should also be apparent, said O atom is unsubstituted.

[0047] In some further embodiments, R11is independently selected from, at each occurrence, -F, -Cl, -Br, -I, -CN, -Ci-e-alkyl, -CF3, -CF2H, -CFH2, -CF2Cl, -CFCl2, -Ci-6-alkylene-CF3, -Ci-6-alkylene-CF2H, -Ci-6-alkylene-CFH2, -Ci-6-alkylene-O-CF3, -Ci-6-alkylene-O-CF2H, -Ci-6-alkylene-O-CFH2, -Ci-6-alkylene-NH-Ci-6-alkylene-20308-WO-PCT / 30175-102410 12CFs, -Ci-6-alkylene-N(Ci-6-alkyl)-Ci-6-alkylene-CF3, -C(=0)-Ci-6-alkyl, -Ci-6-alkylene-C(=O)-Ci-6-alkyl, -C(=O)OH, -Ci-6-alkylene-C(=O)-OH, -C(=0)-0Ci-6-alkyl, -Ci-6-alkylene-C(=O)-OCi-6-alkyl, -C(=O)O-Ci-e-alkylene-CF3, -C(=O)-NH2, -Ci-6-alkylene-C(=O)-NH2, -C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-C(=O)-NH(Ci-6-alkyl), -C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-C(=O)-N(Ci-6-alkyl)2, -C(=O)-NH(OH), -Ci-6-alkylene-C(=O)-NH(OH), -OH, -Ci-6-alkylene-OH, =0, -OCF3, -OCF2H, -OCFH2, -OCF2Cl, -OCFCl2, -O-Ci-6-alkyl, -Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-6-alkylene-NH2, -O-Ci-6-alkylene-NH-Ci-6-alkyl, -O-Ci-6-alkylene-N(Ci-6-alkyl)2, -O-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-O-C(=O)-Ci-6-alkyl, -0-C(=0)-0-Ci-6-alkyl, -Ci-6-alkylene-O-C(=O)-O-Ci-6-alkyl, -O-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-O-C(=O)-NH(Ci-6-alkyl), -O-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-C(=O)-N(Ci-6-alkyl)2, -O-S(=O)2-NH2, -Ci-6-alkylene-O-S(=O)2-NH2, -O-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-O-S(=O)2-NH(Ci-6-alkyl), -O-S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-S(=O)2-N(Ci-6-alkyl)2, -NH2, -NO, -NO2, -Ci-6-alkylene-NH2, -NH(Ci-6-alkyl), -N(3- 14-membered cycloalkyl)(Ci-6-alkyl), -N(Ci-6-alkyl)-Ci-6-alkylene-OH, -N(H)-Ci-6-alkylene-OH, -Ci-6-alkylene-NH(Ci-6-alkyl), -N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)2, -NH-C(=0)-Ci-6-alkyl, -Ci-6-alkylene-NH-C(=O)-Ci-6-alkyl, -NH-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-NH-C(=O)-O-Ci-6-alkyl, -NH-C(=O)-NH2, -Ci-6-alkylene-NH-C(=O)-NH2, -NH-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-NH-C(=O)-NH(Ci-6-alkyl), -NH-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-C(=O)-N(Ci-6-alkyl)2, -N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -N(Ci-6-alkyl)-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-O-Ci-6-alkyl, -N(Ci-6-alkyl)-C(=O)-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH2, -N(Ci-6-alkyl)-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -NH-S(=O)2OH, -Ci-6-alkylene-NH-S(=O)2OH, -NH-S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-NH-S(=O)2-Ci-6-alkyl, -NH-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-NH-S(=O)2-O-Ci-6-alkyl, -NH-S(=O)2-NH2, -Ci-6-alkylene-NH-S(=O)2-NH2, -NH-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-NH-S(=O)2-NH(Ci-6-alkyl), -NH-S(=O)2N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-S(=O)2N(Ci-6-alkyl)2, -N(Ci-6-alkyl)-S(=O)2-OH, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-OH, -N(Ci-6-alkyl)-S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-Ci-6-alkyl, -N(Ci-6-alkyl)-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-O-Ci-6-alkyl, -N(Ci-6-alkyl)-S(=O)2-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH2, -N(Ci-6-alkyl)-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -SH, =S, -SF5, -SCF3, -SCF2H, -SCFH2, -S-Ci-6-alkyl, -Ci-6-alkylene-S-Ci-6-alkyl, -S(=O)-Ci-6-alkyl, -Ci-6-alkylene-S(=O)-Ci-6-alkyl, -S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-S(=O)2-Ci-6-alkyl, -S(=O)2-OH, -Ci-6-alkylene-S(=O)2-OH, -S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-S(=O)2-O-Ci-6-alkyl, -S(=O)2-NH2, -Ci-6-alkylene-S(=O)2-NH2, -S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-S(=O)2-NH(Ci-6-alkyl), -S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-S(=O)2-N(Ci-6-alkyl)2, 3-14-membered cycloalkyl, -Ci-6-alkylene-(3-14-membered cycloalkyl), 3 to 14-membered heterocycloalkyl, -Ci-6-alkylene-(3 to 14-membered heterocycloalkyl), -phenyl, -Ci-6-alkylene-phenyl, 5 to 14-membered heteroaryl, -Ci-6-alkylene-(5 to 14-membered heteroaryl), -O-(3-14-membered cycloalkyl), -0-(3 to 14-membered heterocycloalkyl), -O-phenyl, -0-(5 to 14-membered heteroaryl), -C(=0)-(3- 14-membered cycloalkyl), -C(=0)-(3 to 14-membered heterocycloalkyl), -C(=O)-phenyl, -C(=0)-(5 to 14-membered heteroaryl), -S(=O)2-(3-14-membered cycloalkyl), -S(=O)2-(3 to 14-membered heterocycloalkyl), -S(=O)2-phenyl, -S(=O)2-(5 to 14-membered heteroaryl).

[0048] The dashed lines of Formula II indicates the presence or absence of a double bond, i.e., either a single bond or a double bond. Unless stated otherwise, a double bond present as a constituent bond of a ring will be adjacent to single constituent bonds of the ring. Generally, the ring containing constituent atoms X and Z may20308-WO-PCT / 30175-102410 13saturated or unsaturated, and the ring is generally substituted at each ring atom with either -H or -R8to complete the coordination of each atom. In the case where integer m is greater than one (i.e., when two or more atoms Z are bonded together), the bond formed between atoms Z may be a single bond or a double bond. In some embodiments, the bond formed between atoms Z is a single bond. In some embodiments, the bond formed between atoms Z is a double bond.

[0049] In some embodiments, R6and R7are independently selected from -H, halogen, and Ci-ehaloalkyl. In some embodiments, R6and R7are independently selected from -H and -F.

[0050] In some further aspects, TRPM3 modulating analogs having a fused tricyclic aromatic ring system are provided. In some embodiments, the aromatic tricyclic ring analogue is a compound according to Formula (Ill-a) or Formula (Ill-b), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereofwherein:R1represents -F, -Cl, -Br, -I, -CN, -Rw, -ORW, -OC(=O)RW, -NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX, optionally C1-C2 alkyl, C1-C2 haloalkyl, or cyclopropyl; R3is selected from -CR9R9R9", wherein R9, R9', and R9" are independently RY, or Ci-ealkyl or Ci-eheteroalkyl optionally substituted with one or more RY, optionally wherein two of R9, R9', and R9" together form a 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl, said 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl optionally monosubstituted or polysubstituted with one or more RY;R6, and R7independently of one another represent -F, -Cl, -Br, -I, -CN, -NO2, -SF5, -Rw, -ORW, -OC(=O)RW,-NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX,R8independently at each occurrence represents -F, -Cl, -Br, -I, -CN, -NO2, -SF5, =0, -RQ, -ORY, -OC(=O)RY,-NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ, optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;or two occurrences of R8together form 3-6-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono-or poly substituted with R11; 3-6-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; phenyl, unsubstituted, mono- or polysubstituted with R11; or 5-6-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11;A1, A2. A3, and A4represent, independently of one another and in each case, N, CH, or CR8;E represents O, S, NH, NR8,Rwand Rxindependently of one another in each case independently represent20308-WO-PCT / 30175-102410 14-H;-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RQin each case independently represents-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;6-14-membered aryl, unsubstituted, mono- or polysubstituted with R11; wherein said 6-14-membered aryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11; wherein said 5-14-membered heteroaryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RYand Rzindependently of one another in each case independently represent -H or -RQ,or RYand Rztogether form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted with R11;and wherein R11is independently selected from, at each occurrence, halogen, carbonyl, hydroxy, amino, cyano, nitro, sulfate, sulfonate, sulfonyl, phosphate, phosphonate, phosphonyl, Ci-Ce haloalkyl, Ci-Ce alkyl, Ci-Ce heteroalkyl, and Ci-Ce alkoxy.

[0051] In some further embodiments of Formula Illa or Formula Illb, R11is independently selected from, at each occurrence, -F, -Cl, -Br, -I, -CN, -Ci-e-alkyl, -CF3, -CF2H, -CFH2, -CF2Cl, -CFCl2, -Ci-6-alkylene-CF3, -Ci-6-alkylene-CF2H, -Ci-6-alkylene-CFH2, -Ci-6-alkylene-O-CF3, -Ci-6-alkylene-O-CF2H, -Ci-6-alkylene-O-CFH2, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3, -Ci-6-alkylene-N(Ci-6-alkyl)-Ci-6-alkylene-CF3, -C(=O)-Ci-6-alkyl, -Ci-6-alkylene-C(=O)-Ci-6-alkyl, -C(=O)OH, -Ci-6-alkylene-C(=O)-OH, -C(=O)-OCi-6-alkyl, -Ci-6-alkylene-C(=O)-OCi-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3, -C(=O)-NH2, -Ci-6-alkylene-C(=O)-NH2, -C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-C(=O)-NH(Ci-6-alkyl), -C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-C(=O)-N(Ci-6-alkyl)2, -C(=O)-NH(OH), -Ci-6-alkylene-C(=O)-NH(OH), -OH, -Ci-6-alkylene-OH, =0, -OCF3, -OCF2H, -OCFH2, -OCF2Cl, -OCFCl2, -O-Ci-6-alkyl, -Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-6-alkylene-NH2, -O-Ci-6-alkylene-NH-Ci-6-alkyl, -O-Ci-6-alkylene-N(Ci-6-alkyl)2, -O-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-O-C(=O)-Ci-6-alkyl, -O-20308-WO-PCT / 30175-102410 15C(=0)-0-Ci-6-alkyl, -Ci-6-alkylene-O-C(=O)-O-Ci-6-alkyl, -0-C(=0)-NH(Ci-6-alkyl), -Ci-6-alkylene-O-C(=O)-NH(Ci-6-alkyl), -O-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-C(=O)-N(Ci-6-alkyl)2, -O-S(=O)2-NH2, -Ci-e-alkylene-O-S(=O)2-NH2, -O-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-O-S(=O)2-NH(Ci-6-alkyl), -O-S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-S(=O)2-N(Ci-6-alkyl)2, -NH2, -NO, -NO2, -Ci-6-alkylene-NH2, -NH(Ci-6-alkyl), -N(3-14-membered cycloalkyl)(Ci-6-alkyl), -N(Ci-6-alkyl)-Ci-6-alkylene-OH, -N(H)-Ci-6-alkylene-OH, -Ci-6-alkylene-NH(Ci-6-alkyl), -N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)2, -NH-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-NH-C(=O)-Ci-e-alkyl, -NH-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-NH-C(=O)-O-Ci-6-alkyl, -NH-C(=O)-NH2, -Ci-6-alkylene-NH-C(=O)-NH2, -NH-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-NH-C(=O)-NH(Ci-6-alkyl), -NH-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-C(=O)-N(Ci-6-alkyl)2, -N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -N(Ci-6-alkyl)-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-O-Ci-6-alkyl, -N(Ci-6-alkyl)-C(=O)-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH2, -N(Ci-6-alkyl)-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -NH-S(=O)2OH, -Ci-6-alkylene-NH-S(=O)2OH, -NH-S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-NH-S(=O)2-Ci-6-alkyl, -NH-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-NH-S(=O)2-O-Ci-6-alkyl, -NH-S(=O)2-NH2, -Ci-6-alkylene-NH-S(=O)2-NH2, -NH-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-NH-S(=O)2-NH(Ci-6-alkyl), -NH-S(=O)2N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-S(=O)2N(Ci-6-alkyl)2, -N(Ci-6-alkyl)-S(=O)2-OH, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-OH, -N(Ci-6-alkyl)-S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-Ci-6-alkyl, -N(Ci-6-alkyl)-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-O-Ci-6-alkyl, -N(Ci-6-alkyl)-S(=O)2-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH2, -N(Ci-6-alkyl)-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -SH, =S, -SF5, -SCF3, -SCF2H, -SCFH2, -S-Ci-6-alkyl, -Ci-6-alkylene-S-Ci-6-alkyl, -S(=O)-Ci-6-alkyl, -Ci-6-alkylene-S(=O)-Ci-6-alkyl, -S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-S(=O)2-Ci-6-alkyl, -S(=O)2-OH, -Ci-6-alkylene-S(=O)2-OH, -S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-S(=O)2-O-Ci-6-alkyl, -S(=O)2-NH2, -Ci-6-alkylene-S(=O)2-NH2, -S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-S(=O)2-NH(Ci-6-alkyl), -S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-S(=O)2-N(Ci-6-alkyl)2, 3-14-membered cycloalkyl, -Ci-6-alkylene-(3- 14-membered cycloalkyl), 3 to 14-membered heterocycloalkyl, -Ci-6-alkylene-(3 to 14-membered heterocycloalkyl), -phenyl, -Ci-6-alkylene-phenyl, 5 to 14-membered heteroaryl, -Ci-6-alkylene-(5 to 14-membered heteroaryl), -O-(3- 14-membered cycloalkyl), -O-(3 to 14-membered heterocycloalkyl), -O-phenyl, -O-(5 to 14-membered heteroaryl), -C(=O)-(3- 14-membered cycloalkyl), -C(=O)-(3 to 14-membered heterocycloalkyl), -C(=O)-phenyl, -C(=O)-(5 to 14-membered heteroaryl), -S(=O)2-(3-14-membered cycloalkyl), -S(=O)2-(3 to 14-membered heterocycloalkyl), -S(=O)2-phenyl, -S(=O)2-(5 to 14-membered heteroaryl).

[0052] In some embodiments of Formula Ill-a, one of A1and A2is N, and the other of A1and A2is C-H or C-R8. In some embodiments of Formula Ill-a, E is N-H or N-R8. In some embodiments of Formula Ill-b, A1, A2. A3, and A4are C-H or CR8. In some embodiments of Formula Ill-b, one or more of A1, A2. A3, and A4is N. In some embodiments of Formula Ill-b, one of A1, A2. A3, and A4is N. In some embodiments of Formula Ill-b, two of A1, A2. A3, and A4is N.

[0053] A further aspect of the invention is the provision of a compound of Formula (IV), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof20308-WO-PCT / 30175-102410 16preferably for use in the treatment of pain or epilepsy or methods of treating pain or epilepsy,;whereinT represents O or S;J represents N or C-R6;R1represents -F, -Cl, -Br, -I, -CN, -Rw, -ORW, -OC(=O)RW, -NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX;R3represents -OH or -RY;Q represents a ring selected from 5-8-membered cycloalkyl, saturated or unsaturated, 5-8-membered heterocycloalkyl, saturated or unsaturated, 6-8-membered aryl, and 5-8-membered heteroaryl;n is an integer ranging from 0 to 10, or from 0 to 8, or from 0 to 6, or from 0 to 5, or from 0 to 4, or from 0 to 3, or from 0 to 2, or from 0 to 1;R6and R7independently represent -F, -Cl, -Br, -I, -CN, -NO2, -SF5, -RW, -ORW, -OC(=O)RW,-NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX,R8independently at each occurrence represents -F, -Cl, -Br, -I, -CN, -NO2, -SF5, =O, -RQ, -ORY, -OC(=O)RY,-NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ, optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;or two occurrences of R8together form 3-6-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono-or poly substituted with R11; 3-6-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; phenyl, unsubstituted, mono- or polysubstituted with R11; or 5-6-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11;whereinRwand Rxindependently of one another in each case independently represent-H;-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;20308-WO-PCT / 30175-102410 17RQin each case independently represents-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;6-14-membered aryl, unsubstituted, mono- or polysubstituted with R11; wherein said 6-14-membered aryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11; wherein said 5-14-membered heteroaryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RYand Rzindependently of one another in each case independently represent -H or -RQ, or RYand Rztogether form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted with R11;and wherein "mono- or polysubstituted with R11" in each case independently means substituted with one or more, e.g. 1, 2, 3, 4, or more substituents independently of one another selected from (that is, R11is independently at each occurrence selected from) -F, -Cl, -Br, -I, -CN, -Ci-e-alkyl, -CFs, -CF2H, -CFH2, -CF2Cl, -CFCl2, -C1-6-alkylene-CF3, -Ci-6-alkylene-CF2H, -Ci-e-alkylene-CFFF,-Ci-e-alkylene-O-CFs, -Ci-6-alkylene-O-CF2H, -Ci-e-alkylene-O-CFFF, -C1-6-alkylene-NH-C1-6-alkylene-CF3, -Ci-6-alkylene-N(Ci-6-alkyl)-Ci-6-alkylene-CF3, -C(=O)-Ci-6-alkyl, -Ci-6-alkylene-C(=O)-Ci-6-alkyl, -C(=O)OH, -Ci-6-alkylene-C(=O)-OH, -C(=O)-OCi-6-alkyl, -Ci-6-alkylene-C(=O)-OCi-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3, -C(=O)-NH2, -Ci-6-alkylene-C(=O)-NH2, -C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-C(=O)-NH(Ci-6-alkyl), -C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-C(=O)-N(Ci-6-alkyl)2, -C(=O)-NH(OH), -Ci-6-alkylene-C(=O)-NH(OH), -OH, -Ci-6-alkylene-OH, =0, -OCF3, -OCF2H, -OCFH2, -OCF2Cl, -OCFCl2, -O-Ci-6-alkyl, -Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-6-alkylene-NH2, -O-Ci-6-alkylene-NH-Ci-6-alkyl, -O-Ci-6-alkylene-N(Ci-6-alkyl)2, -O-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-O-C(=O)-Ci-6-alkyl, -O-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-O-C(=O)-O-Ci-6-alkyl, -O-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-O-C(=O)-NH(Ci-6-alkyl), -O-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-C(=O)-N(Ci-6-alkyl)2, -O-S(=O)2-NH2, -Ci-6-alkylene-O-S(=O)2-NH2, -O-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-O-S(=O)2-NH(Ci-6-alkyl), -O-S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-S(=O)2-N(Ci-6-alkyl)2, -NH2, -NO, -NO2, -Ci-6-alkylene-NH2, -NH(Ci-6-alkyl), -N(3- 14-membered cycloalkyl)(Ci-6-alkyl), -N(Ci-6-alkyl)-Ci-6-alkylene-OH, -N(H)-Ci-6-alkylene-OH, -Ci-6-alkylene-NH(Ci-6-alkyl), -N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)2, -NH-C(=0)-Ci-6-alkyl, -Ci-6-alkylene-NH-C(=O)-Ci-6-alkyl, -NH-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-NH-C(=O)-O-Ci-6-alkyl, -NH-C(=O)-NH2, -Ci-6-alkylene-NH-C(=O)-NH2, -NH-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-NH-C(=O)-NH(Ci-6-alkyl), -NH-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-C(=O)-N(Ci-6-alkyl)2, -N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -N(Ci- 6-alkyl)-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-O-Ci-6-alkyl, -N(Ci-6-alkyl)-C(=O)-NH2, -Ci-e-20308-WO-PCT / 30175-102410 18alkylene-N(Ci-6-alkyl)-C(=O)-NH2, -N(Ci-6-alkyl)-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -NH-S(=O)2OH, -Ci-6-alkylene-NH-S(=O)2OH, -NH-S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-NH-S(=O)2-Ci-6-alkyl, -NH-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-NH-S(=O)2-O-Ci-6-alkyl, -NH-S(=O)2-NH2, -Ci-6-alkylene-NH-S(=O)2-NH2, -NH-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-NH-S(=O)2-NH(Ci-6-alkyl), -NH-S(=O)2N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-S(=O)2N(Ci-6-alkyl)2, -N(Ci-6-alkyl)-S(=O)2-OH, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-OH, -N(Ci-6-alkyl)-S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-Ci-6-alkyl, -N(Ci-6-alkyl)-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-O-Ci-6-alkyl, -N(Ci-6-alkyl)-S(=O)2-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH2, -N(Ci-6-alkyl)-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -SH, =S, -SF5, -SCF3, -SCF2H, -SCFH2, -S-Ci-6-alkyl, -Ci-6-alkylene-S-Ci-6-alkyl, -S(=O)-Ci-6-alkyl, -Ci-6-alkylene-S(=O)-Ci-6-alkyl, -S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-S(=O)2-Ci-6-alkyl, -S(=O)2-OH, -Ci-6-alkylene-S(=O)2-OH, -S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-S(=O)2-O-Ci-6-alkyl, -S(=O)2-NH2, -Ci-6-alkylene-S(=O)2-NH2, -S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-S(=O)2-NH(Ci-6-alkyl), -S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-S(=O)2-N(Ci-6-alkyl)2, 3-14-membered cycloalkyl, -Ci-6-alkylene-(3-14-membered cycloalkyl), 3 to 14-membered heterocycloalkyl, -Ci-6-alkylene-(3 to 14-membered heterocycloalkyl), -phenyl, -Ci-6-alkylene-phenyl, 5 to 14-membered heteroaryl, -Ci-6-alkylene-(5 to 14-membered heteroaryl), -O-(3-14-membered cycloalkyl), -O-(3 to 14-membered heterocycloalkyl), -O-phenyl, -O-(5 to 14-membered heteroaryl), -C(=O)-(3-14-membered cycloalkyl), -C(=O)-(3 to 14-membered heterocycloalkyl), -C(=O)-phenyl, -C(=O)-(5 to 14-membered heteroaryl), -S(=O)2-(3-14-membered cycloalkyl), -S(=O)2-(3 to 14-membered heterocycloalkyl), -S(=O)2-phenyl, -S(=O)2-(5 to 14-membered heteroaryl).

[0054] In some embodiments, the compound according to Formula IV is a compound according to Formula IV-a, IV-b, IV-c, or IV-d:

[0055] In some further embodiments, the compound according to Formula IV is a compound according toFormula IV-e, IV-f, IV-g, or IV-h:

[0056] In some further aspects, provided for are aromatic tricyclic ring analogues according to Formula (V-a) or Formula (V-b), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof20308-WO-PCT / 30175-102410 19wherein:T represents O or S;J represents N or C-R6;R1represents -F, -Cl, -Br, -I, -CN, -Rw, -ORW, -OC(=O)RW, -NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX, optionally C1-C2 alkyl, C1-C2 haloalkyl, or cyclopropyl; R3is selected from -CR9R9R9", wherein R9, R9', and R9" are independently RY, or Ci-ealkyl or Ci-eheteroalkyl optionally substituted with one or more RY, optionally wherein two of R9, R9', and R9" together form a 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl, said 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl optionally monosubstituted or polysubstituted with one or more RY;R6, and R7independently of one another represent -F, -Cl, -Br, -I, -CN, -NO2, -SF5, -Rw, -ORW, -OC(=O)RW,-NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX,R8independently at each occurrence represents -F, -Cl, -Br, -I, -CN, -NO2, -SF5, =0, -RQ, -ORY, -0C(=0)RY,-NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ, optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;or two occurrences of R8together form 3-6-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono-or poly substituted with R11; 3-6-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; phenyl, unsubstituted, mono- or polysubstituted with R11; or 5-6-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11;A1, A2. A3, and A4represent, independently of one another and in each case, N, CH, or CR8;E represents O, S, NH, or NR8,Rwand Rxindependently of one another in each case independently represent-H;-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RQin each case independently represents20308-WO-PCT / 30175-102410 20-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;6-14-membered aryl, unsubstituted, mono- or polysubstituted with R11; wherein said 6-14-membered aryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11; wherein said 5-14-membered heteroaryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RYand Rzindependently of one another in each case independently represent -H or -RQ,or RYand Rztogether form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted with R11;and wherein R11is independently selected from, at each occurrence, halogen, carbonyl, hydroxy, amino, cyano, nitro, sulfate, sulfonate, sulfonyl, phosphate, phosphonate, phosphonyl, Ci-Ce haloalkyl, Ci-Ce alkyl, Ci-Ce heteroalkyl, and Ci-Ce alkoxy.

[0057] In some embodiments, the compound according to Formula V-a is a compound according to Formula V-a-i, V-a-ii, V-a-iii, or V-a-iv:

[0058] In some embodiments, the compound according to Formula V-b is a compound according to Formula V-b-i, V-b-ii, V-b-iii, or V-b-iv

[0059] In some embodiments, R6and R7are selected from cyano, carbonyl, carboxylic acid, carboxylic esters, nitro, ammonium, aldehyde, and sulfonyl.

[0060] In some embodiments, X1is selected from O and N. In some embodiments, X1is O. In some embodiments, X1is N. In some embodiments, X1is selected from O and N. In some embodiments, X1is O. In some embodiments, X1is N.20308-WO-PCT / 30175-102410 21

[0061] In some embodiments, the ring including ring atoms X and Z is a 5-8-membered cycloalkyl, optionally substituted with one or more R8. In some embodiments, said ring is a 5 membered cycloalkyl (i.e., cyclopentyl), substituted or unsubstituted. In some embodiments, said ring is a 6 membered cycloalkyl (i.e., cyclohexyl), substituted or unsubstituted. In some embodiments, said ring is a 7 membered cycloalkyl (i.e., cycloheptyl), substituted or unsubstituted. In some embodiments, said ring is an 8 membered cycloalkyl (i.e., cyclooctyl, substituted or unsubstituted. In some embodiments, said 5-8-membered cycloalkyl ring is saturated. In some embodiments, said 5-8-membered cycloalkyl ring contains one or more unsaturations (i.e., double bonds).

[0062] In some embodiments, the ring including ring atoms X and Z is a 5-8-membered heterocycloalkyl, optionally substituted with one or more R8. In some embodiments, said ring is a 5 membered heterocycloalkyl, substituted or unsubstituted. In some embodiments, said ring is a 6 membered heterocycloalkyl, substituted or unsubstituted. In some embodiments, said ring is a 7 membered heterocycloalkyl, substituted or unsubstituted. In some embodiments, said ring is an 8 membered heterocycloalkyl, substituted or unsubstituted. In some embodiments, said 5-8-membered heterocycloalkyl ring is saturated. In some embodiments, said 5-8-membered heterocycloalkyl ring contains one or more unsaturations (i.e., double bonds). In some embodiments, said 5-8-membered heterocycloalkyl ring comprises one or more heteroatoms selected from N, O, and S. In some embodiments, said 5-8-membered heterocycloalkyl ring comprises one, two, or three N atoms. In some embodiments, said 5-8-membered heterocycloalkyl ring comprises one, two, or three O atoms. In some embodiments, said 5-8-membered heterocycloalkyl ring comprises one, two, or three S atoms.

[0063] In some embodiments, said 5-8-membered heterocycloalkyl comprises one N atom and one or two O atoms. In some embodiments, said 5-8-membered heterocycloalkyl comprises one or two N atoms and one O atom. In some embodiments, said 5-8-membered heterocycloalkyl comprises one or two N atoms and one S atom. In some embodiments, said 5-8-membered heterocycloalkyl comprises one N atom and one or two S atoms. In some embodiments, said 5-8-membered heterocycloalkyl comprises one O atom and one or two S atoms. In some embodiments, said 5-8-membered heterocycloalkyl comprises one or two O atoms and one S atom. In some embodiments, said 5-8-membered heterocycloalkyl comprises one N atom, one O atom, and one S atom.

[0064] In some embodiments, the ring including ring atoms X and Z is a 6-8-membered aryl, optionally substituted with one or more R8. In some embodiments, said ring is a 6-membered aryl (i.e., phenyl), substituted or unsubstituted. In some embodiments, said ring is a 7-membered aryl, substituted or unsubstituted. In some embodiments, said ring is an 8-membered aryl, substituted or unsubstituted.

[0065] In some embodiments, the ring including ring atoms X and Z is a 5-8-membered heteroaryl, optionally substituted with one or more R8. In some embodiments, the ring is a 5 membered heteroaryl, substituted or unsubstituted. In some embodiments, the ring is a 6 membered heteroaryl, substituted or unsubstituted. In some embodiments, the ring is a 7 membered heteroaryl, substituted or unsubstituted. In some embodiments, the ring is an 8 membered heteroaryl, substituted or unsubstituted.

[0066] In some embodiments, said 5-8-membered heteroaryl comprises one or more heteroatoms selected from N, O, and S. In some embodiments, said 5-8-membered heteroaryl comprises one, two, or three N atoms. In some embodiments, said 5-8-membered heteroaryl comprises one, two, or three O atoms. In some embodiments, said 5-8-membered heteroaryl comprises one, two, or three S atoms. In some embodiments, said 5-8-membered heteroaryl comprises one N atom and one or two O atoms. In some embodiments, the 5-8-membered heteroaryl comprises one or two N atoms and one O atom. In some embodiments, said 5-8-membered heteroaryl comprises20308-WO-PCT / 30175-102410 22one or two N atoms and one S atom. In some embodiments, said 5-8-membered heteroaryl comprises one N atom and one or two S atoms. In some embodiments, said 5-8-membered heteroaryl comprises one O atom and one or two S atoms. In some embodiments, said 5-8-membered heteroaryl comprises one or two O atoms and one S atom. In some embodiments, said 5-8-membered heteroaryl comprises one N atom, one O atom, and one S atom.

[0067] In some embodiments, ring Q, or atoms X or Z, may be substituted with one or more cycloalkyl, heterocycloalkyl, aryl, or heteroaryl rings, wherein said rings may share one or more atoms in a spiro or fused system, or may be optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted. Where atoms X or Z are substituted by various groups, said groups may be contemplated under the definition of R8.

[0068] In some embodiments, ring Q, or atoms X or Z may be substituted with a 3-14-membered cycloalkyl (preferably 3, 4, 5 or 6-membered cycloalkyl), saturated or unsaturated, in each case unsubstituted, mono- or

[0069] In some embodiments, ring Q, or atoms X or Z may be substituted with a 3-14-membered aryl, in each case unsubstituted, mono- or polysubstituted; optionally a residue selected from the group consisting of:20308-WO-PCT / 30175-102410 23

[0070] In some embodiments, ring Q, or atoms X or Z may be substituted with a 3-14-membered heterocycloalkyl (optionally 4, 5 or 6-membered heterocycloalkyl), saturated or unsaturated; or 5-14-membered heteroaryl (optionally 5 or 6-membered heteroaryl); in each case unsubstituted, mono- or polysubstituted; optionally a residue selected from the group consisting of:20308-WO-PCT / 30175-102410 24

[0072] In some embodiments, ring Q, or atoms X or Z may be substituted with a residue according to general formula (E)whereinYE1represents -N=, -NRE2-, S, O, or -CRE3=; YE2represents -N=, -NRE3-, S, O, or -CRE4=; and YE3represent - N=, -NRE4-, S, O, or -CRE5=; with the proviso that at least one of YE1, YE2, and YE3is not -CRE3=, -CRE4=, and - CRE5=, respectively. In another embodiment, Cy represents a residue according to general formula (E) wherein YE1 represents -N=, -NRE2-, S, or -CRE3=; YE2 represents -N=, -NRE3-, S, or -CRE4=; and YE3 represent -N=, -NRE4-, S, or -CRE5=; with the proviso that at least one of YE1, YE2, and YE3 is not -CRE3=, - CRE4=, and -CRE5=, respectively.RE1, RE2, RE3, and RE4independently of one another represent -H, -CH3,-CH2-cyclopropyl, -CH2CF3, -CH2CHF2 or -CF3; more in particular RE1, RE2, RE3, and RE4independently of one another represent -H, -CH3. or -CF3; preferably with the proviso that only one of RE1, RE2, RE3, and RE4represents a residue that is not -H.

[0073] In some embodiments, ring Q, or atoms X or Z may be substituted with 2-pyridine, unsubstituted, mono- or polysubstituted. In preferred embodiments, ring Q, or atoms X or Z may be substituted with a residue selected from the group consisting of:20308-WO-PCT / 30175-102410

[0074] In some embodiments, ring Q, or atoms X or Z may be substituted with 3 -pyridine, unsubstituted, mono-or polysubstituted. In some embodiments, ring Q, or atoms X or Z may be substituted with a residue selectedor poly substituted. In some embodiments, ring Q, or atoms X or Z may be substituted with a residue selected from the group consisting of:

[0076] In some embodiments, ring Q, or atoms X or Z may be substituted with a residue selected from the group

[0077] In some embodiments, ring Q, or atoms X or Z may be substituted with a bicyclic heteroaryl, unsubstituted, mono- or polysubstituted, selected from the group consisting of:20308-WO-PCT / 30175-102410 26

[0078] In some embodiments, ring Q, or atoms X or Z may be substituted with a residue according to general formula (F’)whereinYF1represents -N= or -CRF4=; and YF2represents -N= or -CRF5=; and YF3represents -N= or -CRF3=; with the proviso that at least one of YF1and YF2is not -CRF4= and -CRF5=, respectively;RF1, RF2, RF3, RF4, and RF5independently of one another represent -H, -CH3, -CF3,-OH, -OCH3, -OCH2CH3, -Cl, or -azetidinyl; preferably with the proviso that only one of RF1, RF2, RF3, RF4, and RF5represents a residue that is not -H.In another embodiment, ring Q, or atoms X or Z may be substituted with a residue according to general formulawhereinYF1represents -N= or -CRF4=; and YF2represents -N= or -CRF5=; with the proviso that at least one of YF1and YF2is not -CRF4= and -CRF5=, respectively;RF1, RF2, RF3, RF4, and RF5independently of one another represent -H, -CH3, -CF3,-OH, -OCH3, -OCH2CH3, -Cl, or -azetidinyl; preferably with the proviso that only one of RF1, RF2, RF3, RF4, and RF5represents a residue that is not -H.

[0079] In some embodiments, ring Q, or atoms X or Z may be substituted with a residue according to general formula (G) or (H)20308-WO-PCT / 30175-102410(G) (H)wherein RG1and RH1are selected from the group consisting of -H, -CH3, -CF3, -OH, -OCH3, -OCH2CH3, -Cl, azetidinyl, -cyclopropyl, -O-cyclopropyl, and -CHF2; or wherein RG1and RH1are selected from the group consisting of -H, -CH3, -CF3, -OH, -OCH3, -OCH2CH3, -Cl, and azetidinyl.In other preferred embodiments, ring Q, or atoms X or Z may be substituted with a residue according to general formula (G’) or (H’)wherein RG1and RH1are selected from the group consisting of -H, -CH3, -CF3, -OH, -OCH3, -OCH2CH3, -Cl, azetidinyl, -cyclopropyl, -O-cyclopropyl, and -CHF2; or wherein RG1and RH1are selected from the group consisting of -H, -CH3, -CF3, -OH, -OCH3, -OCH2CH3, -Cl, and azetidinyl;

[0080] In some embodiments, R1represents-H, -F, -Cl, -Br, -I, -CN;-Ci-e-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -O-Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-C(=O)Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-C(=O)OCi-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-C(=O)NHCi-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-C(=O)N(Ci-6-alkyl)2, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-S(=O)Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-S(=O)2-Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0081] In some embodiments, R1represents -H, -F, -Cl, -Br, -I, -Ci-e-alkyl, -O-Ci-6-alkyl, -Ci-6-alkylene-O-Ci-6-alkyl, -Ci-6-alkylene-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)2, -CF3, -CF2H, -CFH2, -CF2Cl, -CFCl2, -C1-6-alkylene-CF3, -C1-6-alkylene-CF2H, -C1-6-alkylene-CFH2, -C1-6-alkylene-NH-C1-6-alkylene-CF3, -C1-6-alkylene-N(C1-6-alkyl)-C1-6-alkylene-CF3, -C(=O)Ci-6-alkyl, -C(=O)OCi-6-alkyl, -C(=O)NH2, -C(=O)NHCi-6-alkyl, -C(=O)N(Ci-6-alkyl)2, -S(=O)-Ci-6-alkyl, -S(=O)2-Ci-6-alkyl, -O-Ci-6-alkyl, -cyclopropyl unsubstituted, cyclobutyl unsubstituted, cyclopentyl unsubstituted or cyclohexyl unsubstituted.20308-WO-PCT / 30175-102410 28

[0082] In some embodiments, R1represents -H, -Ci-e-alkyl, -Ci-6-alkylene-O-Ci-6-alkyl, -CH2F, -CHF2, -CF3, -cyclopentyl, unsubstituted, or -cyclopropyl. In some embodiments, R1represents -H, -Ci-e-alkyl, -Ci-6-alkylene-O-Ci-6-alkyl, -CH2F, -CHF2, -CF3, -cyclopentyl, or unsubstituted. In some embodiments, R1represents -CH3.

[0083] In some embodiments, R1represents -CH2F, -CHF2, -CH3. or -cyclopropyl. In some embodiments, R1represents -CH2F, -CHF2, or -CH3. In some embodiments, R1represents -C(=O)NH2, or -CHF2.

[0084] In some embodiments, R1represents -H, -Ci-3-alkyl, -CF3, -CF2H, -CFH2, -CF2Cl, -CFCl2, -Ci-3-alkylene-CF3, -Ci-3-alkylene-CF2H, -Ci-3-alkylene-CFH2. or -cyclopropyl; in some embodiments, R1represents -H, -C1-3-alkyl, -CF3, -CF2H, -CFH2, -CF2Cl, -CFCl2, -Ci-s-alkylene-CFs, -Ci-3-alkylene-CF2H, or -Ci-s-alkylene-CFFF; more preferably -CH3.

[0085] In some embodiments, R1represents methyl, ethyl, or propyl.

[0086] In some embodiments, R1represents methyl.

[0087] In some embodiments, R3optionally represents -H, -OH, -Ci-e-alkyl, -Ci-6-alkylene-OH, -Ci-6-alkylene-O-Ci-6-alkyl, -Ci-6-alkylene-NH2, -Ci-6-alkylene-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)2, -CF3, -CF2H, -CFH2, -CF2CI, -CFCb, -Ci-e-alkylene-CFs, -Ci-6-alkylene-CF2H, -Ci-6-alkylene-CFH2, -Ci-e-alkylene-NH-C1-6-alkylene-CF3, or -Ci-6-alkylene-N(Ci-6-alkyl)-Ci-6-alkylene-CF3, optionally unsubstituted, monosubstituted, or poly substituted.

[0088] In some embodiments, R3represents -H, -OH, or -Ci-e-alkyl, saturated, unsubstituted or monosubstituted with -OH. In some embodiments, R3represents -H.

[0089] In some embodiments, R3is connected to the N to which it is attached through a -C1-C4-alkylene-, saturated or unsaturated, unsubstituted, monosubstituted, or polysubstituted, or through a -C1-C4-heteroalkylene-, saturated or unsaturated, unsubstituted, monosubstituted, or polysubstituted. In some embodiments, R3instead represents -CR10R10’R10’’ (i.e., in embodiments where R10is specified, R3may represent -C-R10R10’R10”). In various embodiments, when R10, R10’, and / or R10” independently represent one or more substituents herein, one or more of R10, R10’, and R10’’ may be -H or any other substituent disclosed for R10, R10’, and R10

[0090] In some embodiments, R10, R10’, and / or R10’’ independently represent:-H;-S(=O)Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-S(=O)2-Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted;6-14-membered aryl, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted; or5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is20308-WO-PCT / 30175-102410 29optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0091] In some embodiments, R10, R10’, and / or R10’’ independently represent-S(=O)2Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -Ci-e-alkyl, -C1-6-alkylene-CF3, -OH, =0, -OCi-e-alkyl, -Ci-6-alkylene-OH, -Ci-6-alkylene-O-Ci-6-alkyl, -NH2, -NHCi-e-alkyl, -N(Ci-6-alkyl)2, -NHC(=O)O-Ci-6-alkyl, -N(Ci-6-alkyl)C(=O)O-Ci-6-alkyl, -Ci-6-alkylene-NHC(=O)O-Ci-6-alkyl, -Ci-6-alkylene-NH2, -Ci-e-alkylene-NH-Ci-e-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)2, -C1-6-alkylene-NH-C1-6-alkylene-CF3, -C(=O)-Ci-e-alkyl, -C(=O)OH, -C(=0)0-Ci-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3, -C(=O)NH2, -C(=O)NH(Ci-6-alkyl), -C(=O)N(Ci-6-alkyl)2, -S(=O)2Ci-6-alkyl, -phenyl, -Ci-6-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;-S(=O)2(3-14-membered cycloalkyl), wherein said 3-14-membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case saturated or unsaturated, unsubstituted, mono- or poly substituted with substituents independently of one another selected from the group consisting of -F, -Cl, -Ci-e-alkyl, -C1-6-alkylene-CF3, -OH, =0, -OCi-e-alkyl, -Ci-6-alkylene-OH, -Ci-6-alkylene-O-Ci-6-alkyl, -NH2, -NHCi-e-alkyl, -N(Ci-6-alkyl)2, -NHC(=O)O-Ci-6-alkyl, -N(Ci-6-alkyl)C(=O)O-Ci-6-alkyl, -Ci-6-alkylene-NHC(=O)O-Ci-6-alkyl, -Ci-6-alkylene-NH2, -Ci-e-alkylene-NH-Ci-e-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3, -C(=0)-Ci-6-alkyl, -C(=O)OH, -C(=0)0-Ci-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3, -C(=O)NH2, -C(=O)NH(Ci-6-alkyl), -C(=O)N(Ci-6-alkyl)2, -S(=O)2Ci-6-alkyl, -phenyl, -Ci-6-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;-Ci-e-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -Ci-e-alkyl, -Ci-6-alkylene-CF3, -OH, =0, -OCi-e-alkyl, -Ci-6-alkylene-OH, -Ci-6-alkylene-O-Ci-6-alkyl, -NH2, -NHCi-e-alkyl, -N(Ci-6-alkyl)2, -NHC(=O)O-Ci-6-alkyl, -N(Ci-6-alkyl)C(=O)O-Ci-6-alkyl, -Ci-6-alkylene-NHC(=O)O-Ci-6-alkyl, -Ci-6-alkylene-NH2, -Ci-e-alkylene-NH-Ci-e-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3, -C(=0)-Ci-6-alkyl, -C(=O)OH, -C(=0)0-Ci-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3, -C(=O)NH2, -C(=O)NH(Ci-6-alkyl), -C(=O)N(Ci-6-alkyl)2, -S(=O)2Ci-6-alkyl, -phenyl, -Ci-6-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;3-14-membered cycloalkyl or -Ci-6-alkylene-(3-14-membered cycloalkyl), wherein -Ci-6-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, in each case saturated or unsaturated, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -Ci-e-alkyl, -Ci-6-alkylene-CF3, -OH, =0, -OCi-e-alkyl, -Ci-6-alkylene-OH, -Ci-6-alkylene-O-Ci-6-alkyl, -NH2, -NHCi-e-alkyl, -N(Ci-6-alkyl)2, -NHC(=O)O-Ci-6-alkyl, -N(Ci-e-alkyl)C(=0)0-Ci-6-alkyl, -Ci-6-alkylene-NHC(=O)O-Ci-6-alkyl, -Ci-6-alkylene-NH2, -Ci-e-alkylene-NH-Ci-e-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3, -C(=0)-Ci-6-alkyl, -C(=O)OH, -C(=0)0-Ci-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3, -C(=0)NH2, -C(=0)NH(Ci-6-alkyl), -C(=O)N(Ci-6-alkyl)2, -S(=O)2Ci-6-alkyl, -phenyl, -Ci-6-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;20308-WO-PCT / 30175-102410 303-14-membered heterocycloalkyl or -Ci-6-alkylene-(3-14-membered heterocycloalkyl), wherein -Ci-6-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered heterocycloalkyl in each case is selected from the group consisting of azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1 -dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro- IH-pyrrolizine, hexa-hydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[l,2-a]pyrazine; in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -Ci-e-alkyl, -C1-6-alkylene-CF3, -OH, =0, -OCi-e-alkyl, -Ci-6-alkylene-OH, -Ci-6-alkylene-O-Ci-6-alkyl, -NH2, -NHCi-e-alkyl, -N(Ci-6-alkyl)2, -NHC(=0)0-Ci-6-alkyl, -N(Ci-6-alkyl)C(=O)O-Ci-6-alkyl, -Ci-e-alkylene-NHC(=0)0-Ci-6-alkyl, -Ci-6-alkylene-NH2, -Ci-e-alkylene-NH-Ci-e-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3, -C(=0)-Ci-6-alkyl, -C(=O)OH, -C(=O)O-Ci-e-alkyl, -C(=O)O-Ci-e-alkylene-CF3, -C(=0)NH2, -C(=0)NH(Ci-6-alkyl), -C(=O)N(Ci-e-alkyl)2, -S(=O)2Ci-6-alkyl, -phenyl, -Ci-e-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;-phenyl unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -Cl, -CN, -Ci-e-alkyl, -Ci-6-alkylene-CF3, -OH, =0, -OCi-e-alkyl, -Ci-6-alkylene-OH, -Ci-6-alkylene-O-Ci-6-alkyl, -NH2, -NHCi-e-alkyl, -N(Ci-e-alkyl)2, -NHC(=0)0-Ci-6-alkyl, -N(Ci-6-alkyl)C(=0)0-Ci-e-alkyl, -Ci-6-alkylene-NHC(=O)O-Ci-6-alkyl, -Ci-6-alkylene-NH2, -Ci-e-alkylene-NH-Ci-e-alkyl, -Ci-e-alkylene-N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3, -C(=0)-Ci-6-alkyl, -C(=O)OH, -C(=0)0-Ci-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3, -C(=0)NH2, -C(=0)NH(Ci-6-alkyl), -C(=O)N(Ci-6-alkyl)2, -S(=O)2Ci-6-alkyl, -phenyl, -Ci-6-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted;5-14-membered heteroaryl or -Ci-6-alkylene-(5-14-membered heteroaryl), wherein -Ci-6-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 5-14-membered heteroaryl in each case is selected from the group consisting of benzimidazole, benzisoxazole, benzoazole, benzodioxole, benzofuran, benzothiadiazole, benzothiazole, benzothiophene, carbazole, cinnoline, dibenzofuran, furane, furazane, imidazole, imidazopyridine, indazole, indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [l,2,4]triazolo[4,3-a]pyrimidine; in each case unsubstituted, mono- or poly substituted with substituents independently of one another selected from the group consisting of -F, -Cl, -CN, -Ci-e-alkyl, -Ci-6-alkylene-CF3, -OH, =0, -OCi-e-alkyl, -Ci-6-alkylene-OH, -Ci-6-alkylene-O-Ci-6-alkyl, -NH2, -NHCi-e-alkyl, -N(Ci-e-alkyl)2, -NHC(=O)O-Ci-e-alkyl, -N(Ci-6-alkyl)C(=0)0-Ci-e-alkyl, -Ci-6-alkylene-NHC(=0)0-Ci-e-alkyl, -Ci-e-alkylene-NH2, -Ci-e-alkylene-NH-Ci-e-alkyl, -Ci-6-alkylene-N(Ci-e-alkyl)2, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3, -C(=0)-Ci-e-alkyl, -C(=O)OH, -C(=O)O-Ci-e-alkyl, -C(=O)O-Ci-e-alkylene-CF3, -C(=0)NH2, -C(=O)NH(Ci-e-alkyl), -C(=O)N(Ci-e-alkyl)2, -S(=O)2Ci-e-alkyl, -phenyl, -Ci-e-alkylene-phenyl, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted; and 5-14-membered heteroaryl, unsubstituted.20308-WO-PCT / 30175-102410 31

[0092] In some embodiments, R10, R10’, and / or R10’’ independently represent-H;-S(=O)2Ci-6-alkyl, saturated, unsubstituted, monosubstituted or poly substituted with -F;-S(=O)2(3-14-membered cycloalkyl), saturated, unsubstituted;-Ci-e-alkyl, saturated, unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -OH, =0, -NH2, -NHCi-e-alkyl, -N(Ci-6-alkyl)2, -OCi-e-alkyl, -Ci-e-alkylene-NH2, -Ci-e-alkylene-NH-Ci-e-alkyl, -C(=O)NH2, -C(=O)-NH-Ci-3-alkyl, -C(=O)-N(Ci-3-alkyl)2, -phenyl unsubstituted;3-14-membered cycloalkyl or -Ci-6-alkylene-(3-14-membered cycloalkyl), wherein -Ci-6-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered cycloalkyl is saturated, unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -Ci-e-alkyl, -Ci-6-alkylene-NH2, -C1-6-alkylene-NH-C1-6-alkylene-CF3, -Ci-6-alkylene-OH, -Ci-6-alkylene-NHC(=O)O-Ci-6-alkyl, -OH, -OCi-e-alkyl, -NH2, -N(Ci-6-alkyl)2, -NHC(=O)O-Ci-6-alkyl;3-14-membered heterocycloalkyl or -Ci-6-alkylene-(3-14-membered heterocycloalkyl), wherein -Ci-6-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered heterocycloalkyl in each case is selected from azetane, 1,4-oxazepane, pyrrolidine, piperidine, azepane, diazepane, tetrahydrofuran, tetrahydropyran, oxetane, morpholine, piperazine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, octahydro-pyrrolo[l,2-a]pyrazine, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, quinuclidine, hexahydro-lH-pyrrolizine, 2-oxaspiro[3.3]heptane, 2-azaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 1,1-dioxothiacyclohexane, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -OH, =0, -Ci-e-alkyl, -C1-6-alkylene-CF3, -Ci-6-alkylene-OH, -Ci-6-alkylene-O-Ci-6-alkyl, -NH2, -N(Ci-6-alkyl)2, -Ci-6-alkylene-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)2, -C(=0)-Ci-6-alkyl, -C(=O)OH, -C(=0)0-Ci-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3, -C(=O)NH2, -C(=O)NH(Ci-6-alkyl), -S(=O)2Ci-6-alkyl, oxetanyl, pyrimidinyl, -Ci-6-alkylene-phenyl;-phenyl unsubstituted;5-14-membered heteroaryl or -Ci-6-alkylene-(5-14-membered heteroaryl), wherein -Ci-6-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 5-14-membered heteroaryl in each case is selected from the group consisting of pyridine, pyridazine, pyrazine, pyrazole, isoxazole, triazole, and [l,2,4]triazolo[4,3-a]pyrimidine, in each case unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -Ci-e-alkyl, -OH.

[0093] In some embodiments, R3represents -H.

[0094] In some embodiments, R3represents a residue selected from the group consisting of:20308-WO-PCT / 30175-102410 32

[0095] In some embodiments, R3represents a residue -CR'R"-(CH2)m-OH, wherein m is an integer of from 1 to6, preferably from 1 to 3; and wherein R' and R" independently of one another represent -H, -Ci-3-alkyl, -CFs, -CF2H, -CFH2, -Ci-s-alkylene-CFs, -Ci-3-alkylene-CF2H, -Ci-3-alkylene-CFH2, -Ci-3-alkylene-O-Ci-3-alkyl, -C1-3-alkylene-OH, -C(=O)-NH2, or C(=O)-NH-Ci-3-alkyl; preferably -H, -CH3, -Ci-3-alkylene-OH, -C(=O)-NH2, or C(=O)-NH-Ci-3-alkyl. In a preferred embodiment, at least R' or R" does not represent -H. In some embodiments, neither R' nor R" represents -H.

[0096] In other embodiments, R10, R10’, and / or R10’’ independently represent a 3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0097] In some embodiments, R10, R10’, and / or R10” independently represent a 3 -membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted; or a 3 -membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted. In some embodiments, R3represents, or R10, R10’, and / or R10” represent, a residue selected from the group consisting of:

[0098] In some embodiments, R3, R10, R10’, and / or R10’’ independently represent a 3-14-membered cycloalkyl(in some cases a 4-membered cycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3-14-membered heterocycloalkyl (in some cases a 4-membered heterocycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted. In preferred embodiments, R3, R10, R10’, and / or R10” independently represent a residue selected from the group consisting of:20308-WO-PCT / 30175-102410 33

[0099] In some embodiments, R3, R10, R10’, and / or R10” independently represent a residue according to general formula (A),whereinmAis 0 or 1;YAis selected from -O-, -NRA6- and -CRA7RA8-; andRA1, RA2, RA3, RA4, RA5, RA6, RA7, and RA8independently of one another represent -H, F, -Ci-3-alkyl, -C1-3-alkylene-OH, -Ci-3-alkylene-NH2, -Ci-3-alkylene-NH(Ci-3-alkyl), -Ci-3-alkylene-N(Ci-3-alkyl)2, -Ci-3-alkylene-NH(Ci-3-alkylene-CF3), -Ci-3-alkylene-C(=O)NH2, -Ci-3-alkylene-NH-C(=O)OCi-4-alkyl, -C(=O)NH2, -C(=O)-NH-Ci-3-alkyl, -C(=O)-N(Ci-3-alkyl)2, -3-oxetanyl, or -CHF2; preferably, RA1, RA2, RA3, RA4, RA5, RA6, RA7, and RA8independently of one another represent -H, F, -Ci-3-alkyl, -Ci-3-alkylene-OH, -C1-3-alkylene-NH2, -C1-3-alkylene-NH(Ci-3-alkyl), -Ci-3-alkylene-N(Ci-3-alkyl)2, -Ci-3-alkylene-NH(Ci-3-alkylene-CF3), -Ci-3-alkylene-C(=O)NH2, -Ci-3-alkylene-NH-C(=O)OCi-4-alkyl, -C(=O)NH2, -C(=O)-NH-Ci-3-alkyl, -C(=O)-N(Ci-3-alkyl)2, or -3-oxetanyl; or RA7and RA8together with the carbon atom to which they are attached form a ring and represent -CH2OCH2-, -CH2OCH2CH2- or -CH2CH2OCH2CH2-, -CH2NHCH2-, -CH2NHCH2CH2- or -CH2CH2NHCH2CH2-.

[0100] In some embodiments, R3or R10, R10’, and / or R10” independently represent a residue according to general formula (A) as defined above, whereinmAis 0 or 1;YAis selected from -O- and -CRA7RA8-; andRA1, RA2, RA3, RA4, RA5, RA7, and RA8independently of one another represent -H, -Ci-3-alkylene-OH, -C1-3-alkylene-N(Ci-3-alkyl)2, -C(=O)NH2.or -CHF2; preferably RA1, RA2, RA3, RA4, RA5, RA7, and RA8independently of one another represent -H, -Ci-3-alkylene-OH, -Ci-3-alkylene-N(Ci-3-alkyl)2, or -C(=O)NH2; preferably with the proviso that only one of RA1, RA2, RA3, RA4, RA5, RA7, and RA8represents a residue that is not -H.

[0101] In some embodiments, R3or R4represent a residue according to general formula (A) as defined above, whereinmAis 0 or 1;YAis selected from -O- and -CRA7RA8-; andRA1represents -Ci-3-alkylene-OH, -Ci-3-alkylene-N(Ci-3-alkyl)2, -C(=O)NH2, or -CHF2; preferably RA1represents -Ci-3-alkylene-OH, -Ci-3-alkylene-N(Ci-3-alkyl)2, or -C(=O)NH2; and20308-WO-PCT / 30175-102410 34RA2, RA3, RA4, RA5, RA7, and RA8represent -H.

[0102] In some embodiments, R3, R10, R10’, and / or R10’’ independently represent a 3-14-membered cycloalkyl (in some cases, a 5-membered cycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3-14-membered heterocycloalkyl (in some cases, a 5-membered heterocycloalkyl), saturated or unsaturated, unsubstituted, mono- or poly substituted; or a 5-14-membered heteroaryl (in some cases, a 5-membered heteroaryl), unsubstituted, mono- or poly substituted. In some embodiments, R3, R10, R10’, and / or R10” independently represent a residue selected from the group consisting of:

[0103] In some embodiments, R3, R10, R10’, and / or R10” independently represent a residue according to general formula (B),20308-WO-PCT / 30175-102410 35whereinYBis selected from -O-, -NRB8- and -CRB9RB10-; andRB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8, RB9and RB1° independently of one another represent -H, -F, -OH, -C1-3-alkyl, -Ci-3-alkylene-OH, -Ci-3-alkylene-O-Ci-3-alkyl, -C1-3-alkylene-CF3, -C1-3-alkylene-CO2H, -Ci-3-alkylene-C(=O)O-Ci-3-alkyl, -C(=O)NH2, -C(=O)NH-Ci-3-alkyl, or -C(=O)N(Ci-3-alkyl)2; or RB2and RB3together represent =0; or RB4and RB5together represent =0.

[0104] In some embodiments, R3or R10, R10’, and / or R10” independently represent a residue according to general formula (B) as defined above, whereinYBis selected from -O- and -NRB8-; andRB1, RB2, RB3, RB4, RB5, RB6, RB7, RB8independently of one another represent -H, -F, -Ci-3-alkyl, -Ci-3-alkylene-OH, -Ci-s-alkylene-CFs or -C(=O)NH2; or RB2and RB3together represent =0; or RB4and RB5together represent =0; preferably with the proviso that only 1, 2 or 3 of RA1, RA2, RA3, RA4, RA5, RA7, and RA8represent a residue that is not -H; preferably with the proviso that at least one of RA1, RA2, RA3, RA4, RA5, RA7, and RA8represent a residue that is not -H.

[0105] In some embodiments, R3, R10, R10’, and / or R10’’ independently represent a 3-14-membered cycloalkyl (in some cases, a 6-membered cycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 3-14-membered heterocycloalkyl (in some cases, a 6-membered heterocycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 6-14-membered aryl (in some cases, a 6-membered aryl), unsubstituted, mono- or poly substituted; or a 5-14-membered heteroaryl (in some cases, a 6-membered heteroaryl), unsubstituted, mono- or poly substituted. In some embodiments, R3, R10, R10’, and / or R10” independently represent a residue selected from the group consisting of:20308-WO-PCT / 30175-102410 36

[0106] In some embodiments, R3, R10, R10’, and / or R10” independently represent a residue according to general formula (C),whereinYC1is selected from -O-, -S(=O)2-, -NRC8- and -CRC9RC1°- and YC2represents -CRC11RC12-; or YC1represents - CRC9RC1°- and YC2is selected from -O-, -S(=O)2-, and -NRC8-;RC1, RC2, RC3, RC4, RC5, RC6, RC7, RC8, RC9, RC10, RC11, and RC12independently of one another represent-H, -F, -OH, -C(=O)OCi-3-alkyl, -NH2, -NH(Ci-3-alkyl), -N(Ci-3-alkyl)2, -Ci-3-alkyl, -Ci-3-alkylene-OH, -C1-3-alkylene-CF3, -C(=O)NH2, -C(=O)NH-Ci-3-alkyl, or -C(=O)N(Ci-3-alkyl)2: or RC2and RC3together represent =0; orRC4and RC5together represent =0; or RC9and RC1° together represent =0; or RC11and RC12together represent=0.

[0107] In some embodiments, R3or R10, R10’, and / or R10” independently represent a residue according to general formula (C) as defined above, whereinYC1is selected from -O- or -NRC8- and YC2represents -CRC11RC12-; or YC1represents -CRC9RC1°- and YC2is selected from -O-, and -NRC8-;RC1, RC2, RC3, RC4, RC5, RC6, RC7, RC8, RC9, RC10, RC11, and RC12independently of one another represent -H, -F,20308-WO-PCT / 30175-102410 37-Ci-3-alkyl, -Ci-3-alkylene-OH, or -C(=0)NH2; preferably with the proviso that only 1, 2 or 3 of RC1, RC2, RC3, RC4, RC5, RC6, RC7, RC8, RC9, RC1°, RC11and RC12represent a residue that is not -H; preferably with the proviso that at least one of RC1, RC2, RC3, RC4, RC5, RC6, RC7, RC8, RC9, RC1°, RC11and RC12represent a residue that is not -H.

[0108] In some embodiments, R3, R10, R10’, and / or R10’’ independently represent a 7-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 7-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted. In some embodiments, R3, R10, R10’, and / or R10” independently represent the residue:

[0109] In some embodiments, R3, R10, R10’, and / or R10’’ independently represent a 3-14-membered cycloalkyl (in some cases, a 4, 5 or 6-membered cycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered cycloalkyl is connected through -Ci-Ce-alkylene-, saturated or unsaturated, unsubstituted, mono- or poly substituted; or a 3-14-membered heterocycloalkyl (in some cases, a 4, 5 or 6-membered heterocycloalkyl), saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-14-membered heterocycloalkyl is connected through -Ci-Ce-alkylene-, saturated or unsaturated, unsubstituted, mono- or poly substituted; or a 6-14-membered aryl (in some cases, a 6-membered aryl), unsubstituted, mono- or polysubstituted; wherein said 36-14-membered aryl is connected through -Ci-Ce-alkylene-, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5-14-membered heteroaryl (in some cases, a 5 or 6-membered heteroaryl), unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl is connected through -Ci-Ce-alkylene-, saturated or unsaturated, unsubstituted, mono- or polysubstituted. In some embodiments, R3, R10, R10’, and / or R10” independently represent a residue selected from the group consisting of:

[0110] In some embodiments, R3, R10, R10’, and / or R10’’ independently represent a 5-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 5-membered heterocycloalkyl is connected through -Ci-Ce-alkylene-, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5-20308-WO-PCT / 30175-102410 38membered heteroaryl, unsubstituted, mono- or polysubstituted; wherein said 5-membered heteroaryl is connected through -Ci-Ce-alkylene-, saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0111] In some embodiments, R3, R10, R10’, and / or R10” independently represent a residue selected from the group consisting of:

[0112] In some embodiments, R3, R10, R10’, and / or R10’’ independently represent(i) a residue -CR'R"-(CH2)m-OH, wherein m is an integer of from 1 to 6, preferably from 1 to 3; and wherein R' and R" independently of one another represent -H, -Ci-3-alkyl, -CFs, -CF2H, -CFH2, -Ci-s-alkylene-CFs, -Ci-3-alkylene-CF2H, -Ci-3-alkylene-CFH2, -Ci-3-alkylene-O-Ci-3-alkyl, or -Ci-3-alkylene-OH; preferably -H, -CH3, or -Ci-3-alkylene-OH. In some embodiments, at least R' or R" does not represent -H. In a preferred embodiment, neither R' nor R" represents -H; or(ii) a residue according to general formula (D),whereinmDand nDindependently of one another are 0, 1, 2, or 3; preferably with the proviso that mD+ nD< 3;YD1is selected from -O-, -S(=O)2-, -S(=O)(=NH)-, -NRD8- and -CRD9RD1°- and YD2represents -CRD11RD12-; or YD1is selected from -O-, -S(=O)2-, -NRD8- and -CRD9RD1°- and YD2represents -CRD11RD12-; or YD1represents -CRD9RD1°- and YD2is selected from -O-, -S(=O)2-, and -NRD8-;RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD1°, RD11and RD12independently of one another represent -H, -F, -OH, -Ci-3-alkylene-OH, -C(=O)NH2, -Ci-3-alkylene-C(O)NH2, -C(=O)O-Ci-3-alkyl, -NH2, -C1-3- alkylene-NH2, -NH(Ci-3-alkyl), -N(Ci-3-alkyl)2, -NH(Ci-i-alkylcnc-CFi). -C1-3-alkylene-OCH3, -Ci-3-alkyl, - Ci-s-alkylene-CFs: or RD2and RD3together represent =0; or RD4and RD5together represent =0; or RD9and RD1° together represent =0; or RD11and RD12together represent =0;preferably whereinmDand nDindependently of one another are 0, 1, 2 or 3; preferably with the proviso that mD+ nD< 3;YD1is selected from -O-, -NRD8- and -CRD9RD1°- and YD2represents -CRD11RD12-; or YD1represents - CRD9RD1°- and YD2is selected from -O- and -NRD8-;RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD1°, RD11and RD12independently of one another represent -H, -F, -OH, -Ci-3-alkylene-OH, -C(=O)NH2, -CH2NH2, -CH2N(CH3)2, -NHCH2CF3, -CH3, or -CH2CF3: or RD2and RD3together represent =0; or RD4and RD5together represent =0; or RD9and RD1° together represent =0; or RD11and RD12together represent =0; preferably with the proviso that only 1, 2 or 3 of RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD1°, RD11and RD12represent a residue that is not -H; preferably with the proviso that at least one of RD1, RD2, RD3, RD4, RD5, RD6, RD7, RD8, RD9, RD1°, RD11and RD12represent a20308-WO-PCT / 30175-102410 39residue that is not -H.

[0113] In some embodiments, R3, R10, R10’, and / or R10” independently represent a residue selected from the group consisting of:20308-WO-PCT / 30175-102410 40

[0114] In some embodiments, R6and R7independently of one another represent -H;-F, -Cl, -Br, -I, -OH, -SH, -SF5, -CN, -NO2, -C(=O)OH, -NH2;-Ci-e-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-O-Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-NHCi-e-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-N(Ci-6-alkyl)2, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-C(=O)OCi-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -OC(=O)Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -Ci-6-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0115] In some embodiments, R8independently at each occurrence represents -F, -Cl, -Br, -I, -OH, -SH, -SF5, -CN, -NO2, -C(=O)OH, -NH2;-Ci-e-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-O-Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-NHCi-e-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -N(Ci-6-alkyl)2, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -C(=O)OCi-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted;-OC(=O)Ci-6-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted; -Ci-6-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted.

[0116] In some embodiments, R6and R7independently of one another represent -H, -F, -Cl, -Br, -I, -OH, -SH, -SF5, -CN, -NO2, -C(=O)OH, -NH2,20308-WO-PCT / 30175-102410 41-Ci-e-alkyl, -CF3, -CHF2, -CH2F,-O-Ci-6-alkyl, -OCF3, -OCHF2, -OCH2F,-NHCi-e-alkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2;-N(Ci-6-alkyl)2unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2;-C(=0)0Ci-6-alkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2;-0C(=0)Ci-6-alkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2; or-Ci-6-heteroalkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2.

[0117] In some embodiments, R8independently at each occurrence represents-F, -Cl, -Br, -I, -OH, -SH, -SF5, -CN, -NO2, -C(=O)OH, -NH2,-Ci-e-alkyl, -CF3, -CHF2, -CH2F,-O-Ci-6-alkyl, -OCF3, -OCHF2, -OCH2F,-NHCi-e-alkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2;-N(Ci-6-alkyl)2unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2;-C(=0)0Ci-6-alkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=0)NH2;-0C(=0)Ci-6-alkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=0)NH2; or-Ci-6-heteroalkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=0)NH2.

[0118] In some embodiments, R6and R7independently of one another represents a residue selected from the group consisting of -H, -F, -Cl, -Br, -I, -CN, Ci-3-alkyl, -CF3, -CF2H, and -CFH2; preferably -H or -F.

[0119] In some embodiments, R7represents -H, -F, -Cl, -CN, or -Ci-Ce-alkyl.

[0120] In some embodiments, R7does not represent -H.20308-WO-PCT / 30175-102410 42

[0121] In some embodiments, R7represents a residue selected from the group consisting of -H, -F, -Cl, -CN or -CH3; preferably -H, -F, -CN or -CH3.

[0122] In some embodiments, R6represents -H, -F, -Cl, -CN, or -Ci-Ce-alkyl.

[0123] In some embodiments, R6does not represent -H.

[0124] In some embodiments, R6represents a residue selected from the group consisting of -H, -F, -Cl, -CN or CH3; preferably -H, or -F.

[0125] In some embodiments, R6represents a residue selected from the group consisting of -H or(i) R6and R7each represent -H; or(ii) one of R6and R7represents -H and the other of R6and R7independently of one another represent -F, -Cl, - CN, or -CH3.

[0127] In some embodiments of the invention, the TRPM3 -modulating derivative is selected from the group consisting of:Cpd 001 - (S)-N-( l-amino-3 -hydroxy -2-methyl- 1 -oxopropan-2-yl)-2 -methylnaphtho [2, 1 -b]furan- 1 -carboxamide;Cpd 002 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-2,8,8-trimethyl-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxamide;Cpd 003 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2,8,8-trimethyl-8,9-dihydro-7H-furo[3,2-f] chromene- 1 -carboxamide;Cpd 004 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-5-fluoro-2,8,8-trimethyl-8,9-dihydro-7H-furo[3,2-f] chromene- 1 -carboxamide;Cpd 005 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-5-fluoro-2,8,8-trimethyl-8,9-dihydro-7H-furo [3,2-f] chromene- 1 -carboxamide;Cpd 006 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2'-methyl-7'H,9'H-spiro[cyclopropane-l,8'-furo [3,2-f] chromene] - 1 '-carboxamide;Cpd 007 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2-methyl-8,9-dihydro-7H-furo[3,2-f] chromene- 1 -carboxamide;Cpd 008 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7-(methoxymethyl)-2-methyl-7,8-dihydro-6H-indeno [5,4-b]furan- 1 -carboxamide;Cpd 009 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-7-(methoxymethyl)-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan- 1 -carboxamide;Cpd 010 - (S)-N-( l-amino-3 -hydroxy -2-methyl- 1 -oxopropan-2-yl)-2-(2 -metho xyethyl)-7-methyl-2H-furo [3,2-e]indazole-8-carboxamide;Cpd 011 - (S)-N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-8,8-difluoro-2-methyl-8,9-dihydro-7H-furo [3,2-f] chromene- 1 -carboxamide;Cpd 012 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7-(methoxymethyl)-2-methyl-6, 7,8,9-tetrahydronaphtho [2, 1 -b]furan- 1-carboxamide;Cpd 013 - N-( 1,3 -dihydroxy-2-methylpropan-2-yl)-7-(methoxymethyl)-2-methyl-6,7,8,9-tetrahydronaphtho [2,1-b]furan- 1 -carboxamide;20308-WO-PCT / 30175-102410 43Cpd 014 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2,6,8,8-tetramethyl-6,7,8,9-tetrahy drofuro [3,2-f] quinoline- 1 -carboxamide;Cpd 015 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2'-methyl-8',9'-dihydro-7'H-spiro [cyclopropane- 1,6'-naphtho [2, 1 -b]furan] - 1 '-carboxamide;Cpd 016 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-6,6-difluoro-2-methyl-6, 7,8,9-tetrahydronaphtho [2, 1 -b]furan- 1-carboxamide;Cpd 017 - (S)-N-( l-amino-3 -hydro xy-2-methyl- 1 -oxopropan-2-yl)-3 -(2-methoxyethyl)-7-methyl-3H-furo [3,2-e]indazole-8-carboxamide;Cpd 018 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7,7-difluoro-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxamide;Cpd 019 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-7,7-difluoro-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxamide;Cpd 020 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7 -hydroxy-2 -methyl-7, 8-dihydro-6H-indeno[5,4-b]furan-l-carboxamide;Cpd 021 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7-methoxy-2 -methyl-7, 8-dihydro-6H-indeno[5,4-b]furan-l-carboxamide;Cpd 022 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7-(cyclopropylmethoxy)-2 -methyl-7, 8-dihy dro-6H-indeno [5,4-b]furan- 1 -carboxamide;Cpd 023 - 7-(cyclopropylmethoxy)-N-(l,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxamide;Cpd 024 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-6,6-difluoro-2-methyl-6H-indeno[5,4-b]furan- 1 -carboxamide;Cpd 025 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7-(2-methoxyethoxy)-2-methyl-7,8-dihydro-6H-indeno [5,4-b]furan- 1 -carboxamide;Cpd 026 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-7-(2-methoxyethoxy)-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan- 1 -carboxamide;Cpd 027 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-6,6-difluoro-2 -methyl-7, 8-dihydro-6H-indeno[5,4-b]furan-l-carboxamide;Cpd 028 - N-( 1,3 -dihydroxy -2 -methylpropan-2-yl)-6,6-difluoro-2-methyl-7,8-dihydro-6H-indeno [5,4-b]furan- 1-carboxamide;Cpd 029 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-6,6-difluoro-2-methyl-6,6a,7,7a-tetrahydrocyclopropa[2,3]indeno[5,4-b]furan-l-carboxamide;and physiologically acceptable salts thereof.

[0128] In some embodiments, the TRPM3 -modulating derivatives according to the invention are for use in the treatment of pain which is preferably selected from nociceptive pain, inflammatory pain, and neuropathic pain. More preferably, the pain is post-operative pain or migraine pain. In further embodiments, the TRPM3 -modulating derivatives according to the invention are for use in the treatment of neurological disorders, including epilepsy. In further embodiments, TRPM3 -modulating derivatives are for use in the treatment of other TRPM3 -associated disorders.

[0129] All definitions, embodiments and meanings of R1, R3, R6, R7, R8, R9(including R9’ and R9”), R1020308-WO-PCT / 30175-102410 44(including R10’ and R10”), R11, Q, X1, X2, Z, A1, A2, A3, A4, E, m, n, RQ, Rx, Rw, RY, and Rzincluding the disclosed substituents also analogously apply to all TRPM3 -modulating derivatives according to the invention, which are not necessarily restricted for use in the treatment of pain or epilepsy. Moreover, the meanings of R1, R3, R6, R7, R8, R9(including R9’ and R9”), R10(including R10’ and R10”), R11, Q, X1, X2, Z, A1, A2, A3, A4, E, m, n, RQ, RX, RW, RY, and Rzare also expressly considered to incorporate any exemplified groups in the exemplified compounds at these positions according to Formula I, Formula II, Formula III (including Formulae Ill-a and III-b), Formula IV (including Formulae IV-a to IV-h), Formula V-a (including Formulae V-a-i to V-a-iv), and / or Formula V-b (including Formulae V-b-i to V-b-iv). These Formulae may be referred to in the collective as Formulae I-V. Thus, this aspect of the invention relates to the TRPM3 -modulating derivatives as such, compositions comprising the TRPM3 -modulating derivatives, medicaments comprising the TRPM3 -modulating derivatives, and the TRPM3 -modulating derivatives for use in the prevention and / or treatment of TRPM3 mediated disorders such as pain and / or inflammatory hypersensitivity; and / or for treating or preventing epilepsy or epileptic seizures; and / or for counteracting pain and / or inflammatory hypersensitivity. Preferably, the pain is selected from nociceptive pain, inflammatory pain, and neuropathic pain. More preferably, the pain is post-operative pain.

[0130] In preferred embodiments of the invention, the TRPM3 -modulating derivative is selected from the group consisting of Cpd 1 to Cpd 29 as mentioned above and the physiologically acceptable salts thereof.

[0131] Another aspect of the invention relates to a pharmaceutical composition or a medicament comprising a compound according to the invention as described above.

[0132] Reference throughout this specification to "one embodiment" or "an embodiment" or “some embodiments” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Thus, appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment, but may refer to various embodiments compatible with the elements following the phrase(s). Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to one of ordinary skill in the art from this disclosure, in one or more embodiments. Also, embodiments described for an aspect of the invention may be used for another aspect of the invention and can be combined. Where an indefinite or definite article is used when referring to a singular noun e.g., "a" or "an", "the", this includes a plural of that noun unless something else is specifically stated.

[0133] Similarly, it should be appreciated that in the description of exemplary embodiments of the invention, various features of the invention are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in the understanding of one or more of the various inventive aspects.

[0134] In various descriptions, a variable representing chemical moieties may take on various chemical moieties at “each occurrence” of the variable, or in “each case,” particularly where the variable is present at two or more positions in a given formula. Unless expressly stated otherwise in the context, a variable is not required to, but may, represent the same chemical moiety at two or more positions in a given formula.

[0135] In each of the following definitions, the number of carbon atoms represents the maximum number of carbon atoms generally optimally present in the substituent or linker; it is understood that where otherwise indicated in the present application, the number of carbon atoms represents the optimal maximum number of carbon atoms for that particular substituent or linker.20308-WO-PCT / 30175-102410 45

[0136] The term “leaving group” or “LG” as used herein means a chemical group which is susceptible to be displaced by a nucleophile or cleaved off or hydrolyzed in basic or acidic conditions. In a particular embodiment, a leaving group is selected from a halogen atom (e.g., Cl, Br, I) or a sulfonate (e.g., mesylate, tosylate, triflate).

[0137] The term "protecting group" refers to a moiety of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. The chemical substructure of a protecting group varies widely. One function of a protecting group is to serve as intermediates in the synthesis of the parental drug substance. Chemical protecting groups and strategies for protection / deprotection are well known in the art. See: " Protective Groups in Organic Chemistry", Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991. Protecting groups are often utilized to mask the reactivity of certain functional groups, to assist in the efficiency of desired chemical reactions, e.g., making and breaking chemical bonds in an ordered and planned fashion. Protection of functional groups of a compound alters other physical properties besides the reactivity of the protected functional group, such as the polarity, lipophilicity (hydrophobicity), and other properties which can be measured by common analytical tools. Chemically protected intermediates may themselves be biologically active or inactive.

[0138] Protected compounds may also exhibit altered, and in some cases, optimized properties in vitro and in vivo, such as passage through cellular membranes and resistance to enzymatic degradation or sequestration. In this role, protected compounds with intended therapeutic effects may be referred to as prodrugs. Another function of a protecting group is to convert the parental drug into a prodrug, whereby the parental drug is released upon conversion of the prodrug in vivo. Because active prodrugs may be absorbed more effectively than the parental drug, prodmgs may possess greater potency in vivo than the parental drug. Protecting groups are removed either in vitro, in the instance of chemical intermediates, or in vivo, in the case of prodmgs. With chemical intermediates, it is not particularly important that the resulting products after deprotection, e.g., alcohols, be physiologically acceptable, although in general it is more desirable if the products are pharmacologically innocuous.

[0139] The term “heteroatom(s)” as used herein means an atom selected from nitrogen, which can be quatemized; oxygen; sulfur, including sulfoxide and sulfone; and phosphorous, including phosphorates.

[0140] The term “alkyl, saturated or unsaturated” as used herein encompasses saturated alkyl as well as unsaturated alkyl such as alkenyl, alkynyl, and the like, which may be linear or branched. The term “alkyl” as used herein means normal, secondary, or tertiary, linear or branched hydrocarbon with no site of unsaturation. However, it is generally contemplated that in various embodiments reciting “alkyl,” further corresponding embodiments with “alkyl, saturated or unsaturated” are contemplated, and vice versa. Examples are methyl, ethyl, 1-propyl (n-propyl), 2-propyl (iPr), 1-butyl, 2-methyl-l-propyl(i-Bu), 2-butyl (s-Bu), 2-dimethyl-2-propyl (t-Bu), 1-pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3 -methyl- 1-butyl, 2-methyl- 1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3 -methy 1-3 -pentyl, 2-methyl-3-pentyl, 2,3 -dimethyl-2 -butyl, and 3,3-dimethyl-2-butyl. The term “alkenyl” as used herein means normal, secondary or tertiary, linear or branched hydrocarbon with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp2 double bond. Examples include, but are not limited to: ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), and 5-hexenyl (-CH2CH2CH2CH2CH=CH2). The double bond may be in the cis or trans configuration. The term “alkynyl” as used herein means normal, secondary, tertiary, linear or branched hydrocarbon with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple bond. Examples include, but are not limited to: ethynyl (-C=CH). and 1-propynyl (propargyl, -CJLCACH).20308-WO-PCT / 30175-102410 46

[0141] The term “alkylene, saturated or unsaturated” as used herein encompasses saturated alkylene as well as unsaturated alkylene such as alkenylene, alkynylene, alkenynylene and the like. The term "alkylene" as used herein means saturated, linear or branched chain hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to: methylene (-CH2-), 1,2-ethyl (-CH2CH2-), 1,3 -propyl (-CH2CH2CH2-), 1,4-butyl (-CH2CH2CH2CH2-), and the like. The term "alkenylene" as used herein means linear or branched chain hydrocarbon radical with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp2 double bond, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkene. The term "alkynylene" as used herein means linear or branched chain hydrocarbon radical with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple bond, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkyne.

[0142] The term “heteroalkyl, saturated or unsaturated” as used herein encompasses saturated heteroalkyl as well as unsaturated heteroalkyl such as heteroalkenyl, heteroalky nyl, heteroalkenynyl and the like. The term “heteroalkyl” as used herein means linear or branched chain alkyl wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by a heteroatom, i.e., an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. This means that one or more -CH3 of said alkyl can be replaced by -NH2 and / or that one or more -CH2- of said alkyl can be replaced by -NH-, -O- or -S-. The S atoms in said chains may be optionally oxidized with one or two oxygen atoms, to afford sulfoxides and sulfones, respectively. Furthermore, the heteroalkyl groups in the TRPM3 -modulating derivatives of the invention can contain an oxo or thio group at any carbon or heteroatom that will result in a stable compound. Exemplary heteroalkyl groups include, but are not limited to, alcohols, alkyl ethers (such as for example -methoxy, -ethoxy, -butoxy...), primary, secondary, and tertiary alkyl amines, amides, ketones, esters, alkyl sulfides, and alkyl sulfones. The term “heteroalkenyl” means linear or branched chain alkenyl wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term heteroalkenyl thus comprises imines, -O-alkenyl, -NH-alkenyl, -N(alkenyl)2, -N(alkyl)(alkenyl), and -S-alkenyl. The term “heteroalkynyl” as used herein means linear or branched chain alky nyl wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term heteroalkynyl thus comprises -cyano, -O-alkynyl, -NH-alkynyl, -N(alkynyl)2, -N(alkyl)(alkynyl), -N(alkenyl)(alkynyl), and -S-alkynyl.

[0143] The term “heteroalkylene, saturated or unsaturated” as used herein encompasses saturated heteroalkylene as well as unsaturated heteroalkylene such as heteroalkenylene, heteroalkynylene, heteroalkenynylene and the like. The term “heteroalkylene” as used herein means linear or branched chain alkylene wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by a heteroatom, i.e., an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term “heteroalkenylene” as used herein means linear or branched chain alkenylene wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term “heteroalkynylene” as used herein means linear or branched chain alkynylene wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur20308-WO-PCT / 30175-102410 47atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms.

[0144] The term “cycloalkyl, saturated or unsaturated” as used herein encompasses saturated cycloalkyl as well as unsaturated cycloalkyl such as cycloalkenyl, cycloalky nyl and the like. The term “cycloalkyl” as used herein and unless otherwise stated means a saturated cyclic hydrocarbon radical, such as for instance cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbomyl, fenchyl, decalinyl, adamantyl and the like. The term “cycloalkenyl” as used herein means a non-aromatic cyclic hydrocarbon radical with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp2 double bond. Examples include, but are not limited to cyclopentenyl and cyclohexenyl. The double bond may be in the cis or trans configuration. The term “cycloalkynyl” as used herein means a non-aromatic cyclic hydrocarbon radical with at least one site (usually 1 to 3, preferably 1) of unsaturation, namely a carbon-carbon, sp triple bond. An example is cyclohept- 1-yne. Fused (two shared ring atoms) and spiro (one shared ring atom) systems of two cycloalkyl rings are contemplated under the term “cycloalkyl.” When represented by variables herein (e.g., Rw, RQ, etc.), fused systems of a cycloalkyl ring with a heterocycloalkyl ring are considered as heterocycloalkyl irrespective of the ring that is bound to the core structure. When represented by variables herein (e.g., Rw, RQ, etc.), fused systems of a cycloalkyl ring with an aryl ring are considered as aryl irrespective of the ring that is bound to the core structure. When represented by variables herein (e.g., Rw, RQ, etc.), fused systems of a cycloalkyl ring with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure.

[0145] The term “heterocycloalkyl, saturated or unsaturated” as used herein encompasses saturated heterocycloalkyl as well as unsaturated non-aromatic heterocycloalkyl including at least one heteroatom, i.e., an N, O, or S as ring member. The term “heterocycloalkyl” as used herein and unless otherwise stated means "cycloalkyl" wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term “heterocycloalkenyl” as used herein and unless otherwise stated means “cycloalkenyl” wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. The term “heterocycloalkynyl” as used herein and unless otherwise stated means “cycloalkynyl” wherein one or more carbon atoms (usually 1, 2 or 3) are replaced by an oxygen, nitrogen or sulfur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms. Examples of saturated and unsaturated heterocycloalkyl include but are not limited to azepane, 1,4-oxazepane, azetane, azetidine, aziridine, azocane, diazepane, dioxane, dioxolane, dithiane, dithiolane, imidazolidine, isothiazolidine, isoxalidine, morpholine, oxazolidine, oxepane, oxetane, oxirane, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiopyran, thiazolidine, thietane, thiirane, thiolane, thiomorpholine, indoline, dihydrobenzofuran, dihydrobenzothiophene, 1,1 -dioxothiacyclohexane, 2-azaspiro[3.3]heptane, 2-oxaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 8-azabicyclo[3.2.1]octane, 9-azabicyclo[3.3.1]nonane, hexahydro- IH-pyrrolizine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, and octahydropyrrolo[l,2-a]pyrazine. Further heterocycloalkyls in the meaning of the invention are described in Paquette, Leo A. " Principles of Modem Heterocyclic Chemistry" (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; " The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; Katritzky, AlanR., Rees, C. W. and Scriven, E. " Comprehensive Heterocyclic Chemistry" (Pergamon Press, 1996); and J. Am. Chem. Soc. (1960) 82:5566. When the heterocycloalkyl contains no nitrogen as ring member, it is20308-WO-PCT / 30175-102410 48typically bonded through carbon. When the heterocycloalkyl contains nitrogen as ring member, it may be bonded through nitrogen or carbon. When represented by variables herein (e.g., Rw, RQ, etc.), fused systems of heterocycloalkyl ring with a cycloalkyl ring are considered as heterocycloalkyl irrespective of the ring that is bound to the core structure. When represented by variables herein (e.g., Rw, RQ, etc.), fused systems of a heterocycloalkyl ring with an aryl ring are considered as heterocycloalkyl irrespective of the ring that is bound to the core structure. When represented by variables herein (e.g., Rw, RQ, etc.), fused systems of a heterocycloalkyl ring with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure.

[0146] The term “aryl” as used herein means an aromatic hydrocarbon. Typical aryl groups include, but are not limited to 1 ring (such as phenyl or others), or 2 or 3 rings fused together, radicals derived from benzene, naphthalene, anthracene, biphenyl, and the like. Fused systems of an aryl ring with a cycloalkyl ring are considered as aryl irrespective of the ring that is bound to the core structure. When represented by variables herein (e.g., Rw, RQ, etc.), fused systems of an aryl ring with a heterocycloalkyl ring are considered as heterocycloalkyl irrespective of the ring that is bound to the core structure. Thus, when represented by variables herein (e.g., Rw, RQ, etc.), indoline, dihydrobenzofuran, dihydrobenzothiophene and the like are considered as heterocycloalkyl according to the invention. When represented by variables herein (e.g., Rw, RQ, etc.), fused systems of an aryl ring with a heteroaryl ring are considered as heteroaryl irrespective of the ring that is bound to the core structure.

[0147] The term “heteroaryl” as used herein means an aromatic ring system including at least one heteroatom, i.e., N, O, or S as ring member of the aromatic ring system. Examples of heteroaryl include but are not limited to benzimidazole, benzisoxazole, benzoazole, benzodioxole, benzofuran, benzothiadiazole, benzothiazole, benzothiophene, carbazole, cinnoline, dibenzofuran, furane, furazane, imidazole, imidazopyridine, indazole, indole, indolizine, isobenzofuran, isoindole, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, oxindole, phthalazine, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinazoline, quinoline, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazine, triazole, and [l,2,4]triazolo[4,3-a]pyrimidine.

[0148] By further way of example, carbon bonded heterocyclic rings are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline.

[0149] Preferred carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl. By way of example, nitrogen bonded heterocyclic rings are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3 -imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, IH-indazole, position 2 of an isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or B-carbolinc. Preferred nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1 -pyrrolyl, 1 -imidazolyl, 1-pyrazolyl, and 1-piperidinyl. Further heteroaryls in the meaning of the invention are described in Paquette, Leo A. " Principles of Modem Heterocyclic Chemistry" (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9;20308-WO-PCT / 30175-102410 49" The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; Katritzky, Alan R., Rees, C. W. and Scriven, E. " Comprehensive Heterocyclic Chemistry" (Pergamon Press, 1996); and J. Am. Chem. Soc. (1960) 82:5566.

[0150] As used herein with respect to a substituting group, and unless otherwise stated, the terms “monosubstituted”, "disubstituted", "trisubstituted", "polysubstituted" and the like means chemical structures defined herein, wherein the respective moiety is substituted with one or more substituents, meaning that one or more hydrogen atoms of said moiety are each independently replaced with a substituent. For example, -Ci-e-alkyl that may be polysubstituted with -F covers -CH2F, -CHF2, -CF3, -CH2CF3, CF2CF3, and the like. Likewise, -Ci-e-alkyl that may be polysubstituted with substituents independently of one another selected from -F and -Cl covers -CH2F, -CHF2, -CF3, -CH2CF3, CF2CF3, -CH2CI, -CHCI2, -CCI3, -CH2CCI3, CCI2CCI3, -CHC1F, -CCIF2, -CCI2CF3, -CF2CCI3, -CCIFCCI2F, and the like. Any substituent designation that is found in more than one site in a compound of this invention shall be independently selected.

[0151] As used herein and unless otherwise stated, the term “solvate” includes any combination which may be formed by a derivative of this invention with a suitable inorganic solvent (e.g., hydrates) or organic solvent, such as but not limited to alcohols, ketones, esters, ethers, nitriles and the like.

[0152] In various embodiments, sulfate, sulfonate, sulfonyl, phosphate, phosphonate, orphosphonyl substituents may be present. Sulfate, sulfonate, phosphate, and phosphonate may generally be present in an acid (i.e., protonated) or esterified form, including but not limited to with C1-C3 alkyl. Sulfonate, phosphonate, sulfonyl, and phosphonyl are generally coordinated by their S or P atom to a described compound or formula. Sulfonyl and phosphonyl are generally further coordinated, at their S or P atom, to Ci-Ce alkyl, Ci-Ce heteroalkyl, halogen, Ci-Ce haloalkyl, Ci-Ce alkoxy, Cs-Cs cycloalkyl, Cs-Cs heterocycloalkyl, Ce-Cio aryl, or C5-C10 heteroaryl, each optionally substituted with R11as per its definitions herein.

[0153] The term “subject” as used herein, refers to an animal including humans, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

[0154] The term “therapeutically effective amount” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation or partial alleviation of the symptoms of the disease or disorder being treated.

[0155] The term “composition” as used herein is intended to encompass a product comprising the specified ingredients in the therapeutically effective amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

[0156] The term “antagonist” or “inhibitor” as used herein refers to a compound capable of producing, depending on the circumstance, a functional antagonism of the TRPM3 ion channel, including competitive antagonists, noncompetitive antagonists, desensitizing agonists, and partial agonists.

[0157] For purposes of the invention, the term “TRPM3 -modulated” is used to refer to the condition of being affected by the modulation of the TRPM3 ion channel, including the state of being mediated by the TRPM3 ion channel.

[0158] The term “TRPM3 mediated disorder” as used herein refers to disorders or diseases for which the use of an antagonist of TRPM3 would prevent, treat, (partially) alleviate or improve the symptoms and consist of pain and inflammatory hypersensitivity condition. According to the International Association for the Study of Pain and20308-WO-PCT / 30175-102410 50for the purpose of the invention, pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Preferably, the TRPM3 mediated disorder is pain which is preferably selected from nociceptive pain, inflammatory pain, and neuropathic pain. More preferably, the pain is post-operative pain or migraine pain. For the purpose of the invention, the term "inflammatory hypersensitivity" is used to refer to a condition that is characterized by one or more hallmarks of inflammation, including edema, erythema, hyperthermia, and pain, and / or by an exaggerated physiologic or pathophysiologic response to one or more than one type of stimulation, including thermal, mechanical and / or chemical stimulation.

[0159] The TRPM3 -modulating derivatives of the invention have been shown to be antagonists of TRPM3 and the invention therefore provides the compounds as such, the compounds for use as a medicine, more specifically for use as a medicine in the prevention or treatment of TRPM3 mediated disorders in a subject with a therapeutically effective amount of a TRPM3 -modulating derivative of the invention.

[0160] In a preferred embodiment of the invention, the TRPM3 -modulating derivative of the invention is the sole pharmacologically active compound to be administered for therapy. In another preferred embodiment of the invention, the TRPM3 -modulating derivative of the invention may be employed in combination with other therapeutic agents for the treatment or prophylaxis of TRPM3 mediated disorders. The invention therefore also relates to the use of a composition comprising:- one or more compounds of the formulae and embodiments herein, and- one or more further therapeutic or preventive agents that are used for the prevention or treatment of TRPM3 mediated disorders as biologically active agents in the form of a combined preparation for simultaneous, separate or sequential use.

[0161] The pharmaceutical composition or combined preparation according to this invention may contain TRPM3 -modulating derivatives of the invention over a broad content range depending on the contemplated use and the expected effect of the preparation. Generally, the content of the TRPM3 -modulating derivatives of the invention of the combined preparation is within the range of 0.1 to 99.9% by weight, preferably from 1 to 99% by weight, more preferably from 5 to 95% by weight.

[0162] In view of the fact that, when several active ingredients are used in combination, they do not necessarily bring out their joint therapeutic effect directly at the same time in the mammal to be treated, the corresponding composition may also be in the form of a medical kit or package containing the two ingredients in separate but adjacent repositories or compartments. In the latter context, each active ingredient may therefore be formulated in a way suitable for an administration route different from that of the other ingredient, e.g., one of them may be in the form of an oral or parenteral formulation whereas the other is in the form of an ampoule for intravenous injection or an aerosol.

[0163] Those of skill in the art will also recognize that the TRPM3 -modulating derivatives of the invention may exist in many different protonation states, depending on, among other things, the pH of their environment. While the structural formulae provided herein depict the compounds in only one of several possible protonation states, it will be understood that these structures are illustrative only, and that the invention is not limited to any particular protonation state - any and all protonated forms of the compounds are intended to fall within the scope of the invention.

[0164] The term "pharmaceutically acceptable salts" as used herein means the therapeutically active non-toxic salt forms which the compounds of formulae herein are able to form. Therefore, the compounds of this invention20308-WO-PCT / 30175-102410 51optionally comprise salts of the compounds herein, especially pharmaceutically acceptable non-toxic salts containing, for example, Na+, Li+, K+, Ca2+and Mg2+. Such salts may include those derived by combination of appropriate cations such as alkali and alkaline earth metal ions or ammonium and quaternary amino ions with an acid anion moiety, typically a carboxylic acid. The TRPM3 -modulating derivatives of the invention may bear multiple positive or negative charges. The net charge of the TRPM3 -modulating derivatives of the invention may be either positive or negative. Any associated counter ions are typically dictated by the synthesis and / or isolation methods by which the compounds are obtained. Typical counter ions include, but are not limited to ammonium, sodium, potassium, lithium, halides, acetate, trifluoroacetate, etc., and mixtures thereof. It will be understood that the identity of any associated counter ion is not a critical feature of the invention, and that the invention encompasses the compounds in association with any type of counter ion. Moreover, as the compounds can exist in a variety of different forms, the invention is intended to encompass not only forms of the compounds that are in association with counter ions (e.g., dry salts), but also forms that are not in association with counter ions (e.g., aqueous or organic solutions). Metal salts typically are prepared by reacting the metal hydroxide with a compound of this invention. Examples of metal salts which are prepared in this way are salts containing Li+, Na+, and K+. A less soluble metal salt can be precipitated from the solution of a more soluble salt by addition of the suitable metal compound. In addition, salts may be formed from acid addition of certain organic and inorganic acids to basic centers, typically amines, or to acidic groups. Examples of such appropriate acids include, for instance, inorganic acids such as hydrohalogen acids, e.g. hydrochloric or hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic (i.e. 2-hydroxybenzoic), p-aminosalicylic and the like. Furthermore, this term also includes the solvates which the compounds of formulae herein as well as their salts are able to form, such as for example hydrates, alcoholates and the like. Finally, it is to be understood that the compositions herein comprise TRPM3 -modulating derivatives of the invention in their unionized, as well as zwitterionic form, and combinations with stoichiometric amounts of water as in hydrates.

[0165] Also included within the scope of this invention are the salts of the parental compounds with one or more amino acids, especially the naturally -occurring amino acids found as protein components. The amino acid typically is one bearing a side chain with a basic or acidic group, e.g., lysine, arginine or glutamic acid, or a neutral group such as glycine, serine, threonine, alanine, isoleucine, or leucine.

[0166] The TRPM3 -modulating derivatives of the invention also include physiologically acceptable salts thereof. Examples of physiologically acceptable salts of the TRPM3 -modulating derivatives of the invention include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth (for example, magnesium), ammonium and NX4+(wherein X is -Ci-e-alkyl). Physiologically acceptable salts of a hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, benzoic, lactic, fumaric, tartaric, maleic, malonic, malic, isethionic, lactobionic and succinic acids; organic sulfonic acids, such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-toluenesulfonic acids; and inorganic acids, such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Physiologically acceptable salts of a compound containing a hydroxy group include the anion of said compound in combination with a suitable cation such as Na+and NX4+(wherein X typically is independently selected from -H or a -Ci-4-alkyl group). However, salts of acids or bases which are not20308-WO-PCT / 30175-102410 52physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived form a physiologically acceptable acid or base, are within the scope of the invention.

[0167] As used herein and unless otherwise stated, the term "enantiomer" means each individual optically active form of a TRPM3 -modulating derivative of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e., at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.

[0168] The term "isomers" as used herein means all possible isomeric forms, including tautomeric and stereochemical forms, which the compounds of formulae herein may possess, but not including position isomers. Typically, the structures shown herein exemplify only one tautomeric or resonance form of the compounds, but the corresponding alternative configurations are contemplated as well. Unless otherwise stated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers (since the compounds of formulae herein may have at least one chiral center) of the basic molecular structure, as well as the stereochemically pure or enriched compounds. More particularly, stereogenic centers may have either the R- or S-configuration, and multiple bonds may have either cis- or trans-configuration.

[0169] Pure isomeric forms of the said compounds are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure. In particular, the term "stereoisomerically pure" or “chirally pure" relates to compounds having a stereoisomeric excess of at least about 80% (i.e., at least 90% of one isomer and at most 10% of the other possible isomers), preferably at least 90%, more preferably at least 94% and most preferably at least 97%. The terms "enantiomerically pure" and "diastereomerically pure" should be understood in a similar way, having regard to the enantiomeric excess, respectively the diastereomeric excess, of the mixture in question.

[0170] Separation of stereoisomers is accomplished by standard methods known to those in the art. One enantiomer of a TRPM3 -modulating derivative of the invention can be separated substantially free of its opposing enantiomer by a method such as formation of diastereomers using optically active resolving agents (" Stereochemistry of Carbon Compounds," (1962) by E. L. Eliel, McGraw Hill; Lochmuller, C. H., (1975) J. Chromatogr., 113: (3) 283-302). Separation of isomers in a mixture can be accomplished by any suitable method, including: (1) formation of ionic, diastereomeric salts with chiral compounds and separation by fractional crystallization or other methods, (2) formation of diastereomeric compounds with chiral derivatizing reagents, separation of the diastereomers, and conversion to the pure enantiomers, or (3) enantiomers can be separated directly under chiral conditions. Under method (1), diastereomeric salts can be formed by reaction of enantiomerically pure chiral bases such as bmcine, quinine, ephedrine, strychnine, a-methyl-b-phenylethylamine (amphetamine), and the like with asymmetric compounds bearing acidic functionality, such as carboxylic acid and sulfonic acid. The diastereomeric salts may be induced to separate by fractional crystallization or ionic chromatography. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts. Alternatively, by method (2), the substrate to be resolved may be reacted with one enantiomer of a chiral compound to form a diastereomeric pair (Eliel, E. and Wilen, S. (1994) Stereochemistry of Organic Compounds, John Wiley & Sons, Inc., p. 322). Diastereomeric compounds can be formed by reacting20308-WO-PCT / 30175-102410 53asymmetric compounds with enantiomerically pure chiral derivatizing reagents, such as menthyl derivatives, followed by separation of the diastereomers and hydrolysis to yield the free, enantiomerically enriched compound. A method of determining optical purity involves making chiral esters, such as a menthyl ester or Mosher ester, a-methoxy-a-(trifluoromethyl)phenyl acetate (Jacob III. (1982) J. Org. Chem. 47:4165), of the racemic mixture, and analyzing the NMR spectrum for the presence of the two atropisomeric diastereomers. Stable diastereomers can be separated and isolated by normal- and reverse-phase chromatography following methods for separation of atropisomeric naphthyl-isoquinolines (Hoye, T., WO 96 / 151 ll). Under method (3), a racemic mixture of two asymmetric enantiomers is separated by chromatography using a chiral stationary phase. Suitable chiral stationary phases are, for example, polysaccharides, in particular cellulose or amylose derivatives. Commercially available polysaccharide based chiral stationary phases are ChiralCel® CA, OA, OB5, OC5, OD, OF, OG, OJ and OK, and Chiralpak® AD, AS, OP(+) and OT(+). Appropriate eluents or mobile phases for use in combination with said polysaccharide chiral stationary phases are hexane and the like, modified with an alcohol such as ethanol, isopropanol and the like. (" Chiral Liquid Chromatography" (1989) W. J. Lough, Ed. Chapman and Hall, New York; Okamoto, (1990) " Optical resolution of dihydropyridine enantiomers by High-performance liquid chromatography using phenylcarbamates of polysaccharides as a chiral stationary phase", J. of Chromatogr.513:375-378).

[0171] The terms cis and trans are used herein in accordance with Chemical Abstracts nomenclature and include reference to the position of the substituents on a ring moiety. The absolute stereochemical configuration of the compounds of the formulae described herein may easily be determined by those skilled in the art while using well-known methods such as, for example, X-ray diffraction.

[0172] When a compound is crystallized from a solution or slurry, it can be crystallized in a different arrangement lattice of spaces (this property is called "polymorphism") to form crystals with different crystalline forms, each of which is known as "polymorphs". The term “Polymorph” as used herein, therefore, refers to a crystal form of a compound of a compound of any of Formulae (I-V), where the molecules are localized in the three-dimensional lattice sites. Different polymorphs of the compound may be different from each other in one or more physical properties, such as solubility and dissolution rate, true specific gravity, crystal form, accumulation mode, flowability and / or solid state stability. Etc.

[0173] TRPM3 -modulating derivatives of the invention and their physiologically acceptable salts (hereafter collectively referred to as the active ingredients) may be administered by any route appropriate to the condition to be treated, suitable routes including oral, rectal, nasal, topical (including ocular, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intranasal, intravenous, intraarterial, intradermal, intrathecal and epidural). The preferred route of administration may vary with for example the condition of the recipient.

[0174] The therapeutically effective amount of the preparation of the compound(s), especially for the treatment of TRPM3 mediated disorders in humans and other mammals or in animals, preferably is a TRPM3 ion channel inhibiting amount of the compounds as defined herein and corresponds to an amount which ensures a plasma level of between 1µg / ml and 100 mg / ml, optionally of 10 mg / ml.

[0175] Suitable dosages of the compounds or compositions of the invention should be used to treat or prevent the TRPM3 mediated disorders in a subject. Depending upon the pathologic condition to be treated and the patient’s condition, the said effective amount may be divided into several sub-units per day or may be administered20308-WO-PCT / 30175-102410 54at more than one day intervals.

[0176] The invention further provides (pharmaceutical) compositions comprising one or more TRPM3-modulating derivatives of the invention, more in particular of all the Formula (I) and Formula (II) and other formulas and embodiments described herein and the more particular aspects or embodiments thereof. Furthermore, the invention provides the compounds or (pharmaceutical) compositions of the invention, more in particular of all the Formula (I) and other formulas and embodiments described herein and the more particular aspects or embodiments thereof, for use as a medicine, more in particular for use in the treatment of pain. The TRPM3 mediated disorders are selected from pain and an inflammatory hypersensitivity condition.

[0177] The TRPM3 -modulating derivatives of the invention may be formulated with conventional carriers and excipients, which will be selected in accord with ordinary practice. Tablets will contain excipients, glidants, fillers, binders and the like. Aqueous formulations are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. Formulations optionally contain excipients such as those set forth in the " Handbook of Pharmaceutical Excipients" (1986).

[0178] Subsequently, the term "pharmaceutically acceptable carrier" as used herein means any material or substance with which the active ingredient is formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and / or to facilitate its storage, transport or handling without impairing its effectiveness. The pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e., the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, suspensions, ointments, creams, tablets, pellets or powders.

[0179] Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art, and there is no particular restriction to their selection within the invention. They may also include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying agents, surface-active agents, solvents, coatings, antibacterial and antifungal agents, isotonic agents and the like, provided the same are consistent with pharmaceutical practice, i.e., carriers and additives which do not create permanent damage to mammals. The pharmaceutical compositions of the invention may be prepared in any known manner, for instance by homogeneously mixing, coating and / or grinding the active ingredients, in a one-step or multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents, may also be prepared by micronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 gm, namely for the manufacture of microcapsules for controlled or sustained release of the active ingredients.

[0180] While it is possible for the TRPM3 -modulating derivatives to be administered alone it is preferable to present them as pharmaceutical formulations. The formulations, both for veterinary and for human use, of the invention comprise at least one active ingredient, as above described, together with one or more pharmaceutically acceptable carriers therefore and optionally other therapeutic ingredients. The carrier(s) optimally are "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the20308-WO-PCT / 30175-102410 55active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0181] Formulations of the invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

[0182] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. For infections of the eye or other external tissues e.g., mouth and skin, the formulations are optionally applied as a topical ointment or cream containing the active ingredient(s) in an amount of, for example, 0.075 to 20% w / w (including active ingredient(s) in a range between 0.1% and 20% in increments of 0.1% w / w such as 0.6% w / w, 0.7% w / w, etc.), preferably 0.2 to 15% w / w and most preferably 0.5 to 10% w / w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example, at least 30% w / w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane 1,3 -diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG400) and mixtures thereof. The topical formulations may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs.

[0183] The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Optionally, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.

[0184] The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should optionally be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft20308-WO-PCT / 30175-102410 56paraffin and / or liquid paraffin or other mineral oils can be used.

[0185] Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is optionally present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% particularly about 1.5% w / w. Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

[0186] Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate. Formulations suitable for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns (including particle sizes in a range between 20 and 500 microns in increments of 5 microns such as 30 microns, 35 microns, etc.), which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as for example a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol administration may be prepared according to conventional methods and may be delivered with other therapeutic agents.

[0187] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[0188] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

[0189] Preferred unit dosage formulations are those containing a daily dose or unit daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.

[0190] It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

[0191] TRPM3 -modulating derivatives of the invention can be used to provide controlled release pharmaceutical formulations containing as active ingredient one or more TRPM3 -modulating derivatives of the invention ("controlled release formulations") in which the release of the active ingredient can be controlled and regulated to allow less frequency dosing or to improve the pharmacokinetic or toxicity profile of a given invention compound. Controlled release formulations adapted for oral administration in which discrete units comprising one or more TRPM3 -modulating derivatives of the invention can be prepared according to conventional methods.

[0192] Another embodiment of this invention relates to various precursor or “prodrug” forms of the TRPM3-20308-WO-PCT / 30175-102410 57modulating derivatives of the invention. It may be desirable to formulate the TRPM3 -modulating derivatives of the invention in the form of a chemical species which itself is not significantly biologically -active, but which when delivered to the animal, mammal or human will undergo a chemical reaction catalyzed by the normal function of the body, inter alia, enzymes present in the stomach or in blood serum, said chemical reaction having the effect of releasing a compound as defined herein. The term “prodrug” thus relates to these species which are converted in vivo into the active pharmaceutical ingredient.

[0193] The prodrugs of the TRPM3 -modulating derivatives of the invention can have any form suitable to the formulator, for example, esters are non-limiting common pro-drug forms. In the present case, however, the prodrug may necessarily exist in a form wherein a covalent bond is cleaved by the action of an enzyme present at the target locus. For example, a C-C covalent bond may be selectively cleaved by one or more enzymes at said target locus and, therefore, a pro-drug in a form other than an easily hydrolysable precursor, inter alia an ester, an amide, and the like, may be used. The counterpart of the active pharmaceutical ingredient in the pro-drug can have different structures such as an amino acid or peptide structure, alkyl chains, sugar moieties and others as known in the art.

[0194] For the purpose of the invention the term “therapeutically suitable pro-drug” is defined herein as “a compound modified in such a way as to be transformed in vivo to the therapeutically active form, whether by way of a single or by multiple biological transformations, when in contact with the tissues of the animal, mammal or human to which the pro-drug has been administered, and without undue toxicity, irritation, or allergic response, and achieving the intended therapeutic outcome ”.

[0195] More specifically the term “prodrug”, as used herein, relates to a derivative of a compound such as represented by the structural formulae herein described, which undergoes spontaneous or enzymatic transformation within the body in order to release the pharmacologically active form of the compound. For a comprehensive review, reference is made to Rautio J. et al. (“Prodrugs: design and clinical applications” Nature Reviews Drug Discovery, 2008, doi: 10.1038 / nrd2468).

[0196] Representative TRPM3 -modulating derivatives of the invention can be synthesized in accordance with the general synthetic methods described below and illustrated in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the specific chemical reaction and specific conditions described in the schemes and examples. The various starting material used in the schemes are commercially available or may be prepared by methods well within the skill persons versed in the art. The variables are as defined herein and within the skill of persons verses in the art.EXAMPLES

[0197] The following examples are provided for the purpose of illustrating the invention and by no means should be interpreted to limit the scope of the invention.

[0198] Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and illustrated in the schemes that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the specific chemical reaction and specific conditions described in the schemes and examples. The various starting material used in the schemes are commercially available or may be prepared by methods well within the skill of persons versed in the art. The variables are as defined herein and within the skill of persons versed in the art.20308-WO-PCT / 30175-102410 58

[0199] Abbreviations used in the instant specification, particularly in the schemes and examples, are as follows: ABC - Aqueous solution of Ammonium Bicarbonate, ACN - acetonitrile, AcOH - Acetic acid, ADDP - 1,1'-(Azodicarbonyl)dipiperidide, aq. - Aqueous, AIBN - Azobisisobutyronitrile, Boc - tert-butoxycarbonyl, BOC2O -Di-tert-butyl dicarbonate, BrettPhos - 2-(Dicyclohexylphosphino)3,6-dimethoxy-2',4',6'-triisopropyl-l,l'-biphenyl, CAN - Ceric ammonium nitrate, COMU - (l-Cyano-2 -ethoxy -2 -oxoethylidenaminooxy)dimethylamino-morpholino-carbenium, hexafluorophosphate, DABCO - l,4-diazabicyclo[2.2.2]octane, DAST -Diethylaminosulfur trifluoride, DBDMH - l,3-Dibromo-5,5-dimethylhydantoin, DBU - 1,8- Diazabicyclo[5.4.0]undec-7-ene, DCC - N, N’ -dicyclohexylcarbodiimide, DCM - Dichloromethane, DEAD -Diethyl azodicarboxylate, DIA - Diastereomer, DIAD - Diisopropyl azodicarboxylate, DEA - Diethylamine, DIPEA - Diisopropyl-ethyl amine, DMAP -4-Dimethylaminopyridine, DME - 1,2-Dimethoxy ethane, DMEDA -1,2-Dimethylethylenediamine, DMF - N, N-Dimethylformamide, DMSO - Dimethylsulfoxide, DPPA -Diphenylphosphoryl azide, 2,4-DNPH - 2,4-Dinitrophenylhydrazine, DTBAD - tert-Butylazodicarboxylate, EDCI or EDC - 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, En - Enantiomer, Et2O - Diethyl ether, EtOH -Ethanol, EtOAc - Ethyl acetate, Eq. - Equivalent, FA - Formic acid, FCC - Flash column chromatography, h -Hour, HATU - O-(7-Azabenzotriazol-l-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate, HPLC - High performance liquid chromatography, IPA - isopropyl alcohol, LAH - Lithiumaluminiumhydride, LG - Leaving group, mCPBA - meta-Chloroperoxybenzoic acid, MeOH - methanol, min. - Minute, Ms - Methanesulfonyl, NBS - N-Bromosuccinimide, nBuLi - n-Butyl lithium, NMP - l-Methyl-2-pyrrolidinone, Pd(PPh3)4 - Tetrakis-(triphenylphosphine)-palladium(O), NMU - N-Nitroso-N-methylurea, PdC12(dppf). DCM - [1,1'- Bis(diphenylphosphino)ferrocene]dichloropalladium(II), Pd2(dba)3- Tris(dibenzylideneacetone)dipalladium, Pet ether - Petroleum ether, PPh3 - Triphenylphospine, PS-DIEA - Diisopropyl-ethyl amine supported on PolyStyrene, PS-PPh3 - Triphenylphospine supported on PolyStyrene, PyBop - Benzotriazol- 1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, Pyr. - Pyridine, PTSA - p-Toluenesulfonic acid, RBF -Round-bottom flask, RF: ratio of frontiers, RM - Reaction mixture, RP - Reverse phase, RT - Room temperature, sat. - Saturated, SEM - [2-(Trimethylsilyl)ethoxy]methyl acetal, SFC - Supercritical fluid chromatography, SPE -Solid Phase Extraction, TBDMS - Tert-Butyldimethylsilyl ether, TBAF - Tetrabutylammonium fluoride hydrate, TBAI - Tetrabutylammonium iodide, TEA - Triethylamine, Tf - Trifluoromethanesulfonate, THF -Tetrahydrofurane, TFA - Trifluoroacetic acid, TLC - thin layer chromatography, TPP - triphenyl phosphine, IPA - isopropyl alcohol, TMS - trimethyl silyl, T3P - Propylphosphonic anhydride, XPhos Pd G3 - (2-Dicyclohexylphosphino-2',4',6'-triisopropyl-l,r-biphenyl)[2-(2'-amino-l,r-biphenyl)]palladium(II) methanesulfonate.

[0200] In a more particular embodiment, the compounds of the present invention may be synthesized as depicted in scheme 1.Scheme 1: all R1, R3, R6, R7, R8, Z, X1, X2, m and n are as described for the compounds of the present invention.20308-WO-PCT / 30175-102410 59

[0201] Phenol derivatives of formula 1 (commercially available or synthesized by procedures known to people skilled in the art or as set forth in the examples below) may be condensed on derivatives of general formula 2, wherein R’ is an ester protecting group (e.g. methyl, ethyl, t-Bu and the like), (commercially available or synthesized by procedures known to people skilled in the art or as set forth in the examples below) via a 1,4-addition mediated by a base (e.g., DABCO, DBU, and the like) in a polar aprotic solvent (e.g., ACN, THF and the like) at a temperature ranging from RT to 100°C to provide the desired compounds of formula 10. Benzofuran derivatives 4 may be obtained via a cyclisation of derivatives 3 in presence of a metal catalyst (e.g., Harmann-Beller catalyst, and the like) and a base (e.g., K2CO3, K3PO4 and the like) in a polar aprotic solvent (e.g., Dioxane, THF and the like) at a temperature ranging from RT to 120°C. Ester derivatives 4 may then be converted into the desired compounds of formula 6, via standard saponification reactions, followed by a reaction with amine derivatives of formula 5 (commercially available or synthesized by procedures known in the art or as set forth in the examples below) under standard peptide coupling conditions (e.g. DCC, EDCI, HATU, PyBop and the like) in a polar aprotic solvent (e.g. DCM, DMF and the like).

[0202] In a more particular embodiment, the compounds of the present invention may be synthesized as depicted in scheme 2.Scheme 2: all R1, R3, R6, R7, R8, Z, X1, X2, m and n are as described for the compounds of the present invention.

[0203] 5-Hydroxy-Benzofuran derivatives of formula 7, wherein R’ is an ester protecting group (e.g. methyl, ethyl, t-Bu and the like), (commercially available or synthesized by procedures known to people skilled in the art or as set forth in the examples below) may be converted into the intermediates of formula 9 via nucleophilic substitution using ester derivatives of formula 8 (commercially available or synthesized), wherein LG is a leaving group, in the presence of a base (e.g., DIPEA, DBU, triethylamine, Cs2CO3, and the like) in a polar solvent (e.g., acetonitrile, DMF, NMP, and the like), with or without a chelating agent (e.g., 18-crown-6, cis-anti-cis-dicyclohexano-18-crown-6, and the like) at a temperature ranging from 0 to 100°C. Ester derivatives 9 may then be converted into acids derivatives of formula 10, via standard saponification reactions, followed by a cyclisation mediated by a Bronsted acid (e.g., TFA and the like) in a polar aprotic solvent (e.g. DCM and the like). Ketone derivatives 10 may be reduced, in intermediates of formula 11, by a metal (e.g. Znh and the like) and a reducing agent (e.g. Sodium cyanoborohydride and the like) in a polar solvent ( e.g. DCM; 1,2-dichloroethane and the like) Acid derivatives 11 may then be converted into the desired compounds of formula 12, via a reaction with amine derivatives of formula 5 (commercially available or synthesized by procedures known in the art or as set forth in the examples below) under standard peptide coupling conditions (e.g. DCC, EDCI, HATU, PyBop and the like)20308-WO-PCT / 30175-102410 60in a polar aprotic solvent (e.g. DCM, DMF and the like).

[0204] In a more particular embodiment, the compounds of the present invention may be synthesized as depicted in schemeScheme 3: all R1, R3, R6, R7, R8, Z, X1, X2, m and n are as described for the compounds of the present invention.

[0205] 5-Bromo-Benzofuran derivatives of formula 13, wherein R’ is an ester protecting group (e.g. methyl, ethyl, t-Bu and the like), (commercially available or synthesized by procedures known to people skilled in the art or as set forth in the examples below) may be converted into the intermediates of formula 15 via Buchwald-Hartwig amination using amines derivatives of formula 14 (commercially available or synthesized by procedures known to people skilled in the art or as set forth in the examples below). More detailed information can be found in the following reference (J. Organometallic Chem. 2018, 861, 17-104) Intermediates of formula 15 may then be converted into the desired compounds of formula via nucleophilic substitution using intermediates of formula 16 (commercially available or synthesized), wherein LG is a leaving group, in the presence of a base (e.g., DIPEA, DBU, triethylamine, Cs2CO3, and the like) in a polar solvent (e.g., acetonitrile, DMF, NMP, and the like). Ester derivatives 17 may then be converted into the desired acid of formula 18, via standard saponification reactions, followed by a cyclisation mediated by a Bronsted acid (e.g., TFA and the like) in a polar aprotic solvent (e.g. DCM and the like). Ketone derivatives 18 may be reduced in intermediates of formula 19 with a metal (e.g. ZnI2and the like) and a reducing agent (e.g. Sodium cyanoborohydride and the like) in a polar solvent ( e.g. DCM; 1,2-dichloroethane and the like) Acid derivatives 19 may then be converted into the desired compounds of formula 20, via a reaction with amine derivatives of formula 5 (commercially available or synthesized by procedures known in the art or as set forth in the examples below) under standard peptide coupling conditions (e.g. DCC, EDCI, HATU, PyBop and the like) in a polar aprotic solvent (e.g. DCM, DMF and the likeTable 1: Exemplary Compounds20308-WO-PCT / 30175-102410 6120308-WO-PCT / 30175-102410 62

[0206] The following examples are provided for the purpose of illustrating the present invention and by no means should be interpreted to limit the scope of the present invention.

[0207] Part A represent the preparation of the compounds whereas Part B represents the pharmacological examples.Part A

[0208] All starting materials which are not explicitly described were either commercially available (the details of suppliers such as for example ABCR, Apollo Scientific Combi-Blocks, Enamine, FluoroChem, MatrixScientific, Maybridge, Merck, TCI etc. can be found in the SciFinder® Database for example) or the synthesis thereof has already been described precisely in the specialist literature (experimental guidelines can be found in the Reaxys® Database or the SciFinder® Database respectively, for example) or can be prepared using the conventional methods known to the person skilled in the art. CAS (Chemical Abstract Service) registry number was reported for some starting materials.

[0209] The reactions were, if necessary, carried out under an inert amosphere (mostly argon and N2). The number of equivalents of reagents and the amounts of solvents employed as well as the reaction temperatures and times can vary slightly between different reactions carried out by analogous methods. The work-up and purification methods were adapted according to the characteristic properties of each compound and can vary slightly for analogous methods. The yields of the compounds prepared are not optimized.

[0210] The indication „equivalents“ ("eq." or “eq” or “equiv.”) means molar equivalents, “RT” or “rt” means room temperature T (23 ± 7 °C), “M” are indications of concentration in mol / 1, “sol.” means solution, "cone." means concentrated. The mixing ratios of solvents are usually stated in the volume / volume ratio.

[0211] Key analytical characterization was carried out by means of 'H-NMR spectroscopy and / or mass spectrometry (MS, m / z for [M+H]+and / or [M-H | ) for all the exemplary compounds and selected intermediate products. In certain cases, where e.g. regioisomers and / or diastereomers could be / were formed during the reaction, additional analytics, such as, e.g.13C NMR and NOE (nuclear Overhauser effect) NMR experiments were in some cases performed.

[0212] Analytical instruments employed were e.g. for NMR analysis a BRUKER 400MHz or a BRUKER 500MHz machine (Software Topspin), alternatively a BRUKER AVANCE 300MHz and 400Mhz was employed. For LC / MS analysis e.g. an Agilent 1290 infinity, Mass:6150 SQD(ESI / APCI) or an Agilent 1200 SERIES, Mass:6130 SQD(ESI / APCI) (Software Chemistation) was employed. Analytical HPLCs were measured e.g. on Waters (Software Empower), an Agilent-1200-ELSD (Software Chemistation) or an Agilent-1260 (Software OpenLAB). Analytical SFC were performed e.g. on a PIC solution (Software: SFC PICLAB ONLINE), a WATERS-X5 (Software MASSLYNX) or a WATERS-UPC2 (Empower).

[0213] Preparative HPLC were performed e.g. on a Waters 2998 (Software Empower) or a YMC (Software K-Prep). Preparative SFC were performed e.g. on a Waters, SFC-200 (Software Chromscope or Super chrome), a Waters, SFC-80 (Super chrome) or a PIC, PIC-175 (Software S10-100).

[0214] Structures of example compounds that contain stereocenters are drawn and named with absolute stereochemistry, if known. In case of unknown absolute stereochemistry the compounds can be either racemic, a20308-WO-PCT / 30175-102410 63mixture of diastereomers, a pure diastereomer of unknown stereochemistry, or a pure enantiomer of unknown stereochemistry. Dia 1 and Dia 2 means that diastereoisomers were separated but the stereochemistry is unknown.En 1 and En 2 means that both enantiomers were separated but the absolute configuration is unknown. No suffix given after the compound code means that a compound containing stereocenters was obtained as a racemic mixture or a mixture of diastereomers, respectively, unless the chemical name of the compound specifies the exact stereochemistry.EXAMPLES OF THE PREPARATION OF BUILDING BLOCKSSynthesis of 4-bromo-2-(methoxymethyl)-2,3-dihvdro-lH-inden-5-ol (BB-001)

[0215] Step 1: To a stirred solution of ethyl 4-bromo-5-hydroxy-2,3-dihydro-lH-indene-2-carboxylate [CAS: 2713993-56-5] (2.8 g, 9.824 mmol) in DMF (30 mL) were added Imidazole (1.337 g, 19.65 mmol) and TBDMS-Cl (1.554 g, 10.315 mmol) at 0 °C. The RM was stirred at RT for 5 h. The RM was diluted with EtOAc (50 mL) and washed with chilled water (25 mL). The organic layer was dried over Na2SO4and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-10% EtOAc in PE to afford the desired compound (2.2 g, 61%).1H NMR (400 MHz, CDCl3) δ ppm: 6.98 (d, 1 H), 6.69 (d, 1 H), 4.23 - 4.18 (m, 2 H), 3.37-3.33 (m, 1 H), 3.30 - 3.25 (m, 4 H), 1.31 (t, 3 H), 1.06 (s, 9 H), 0.25 (s, 6 H).

[0216] Step 2: To a stirred solution of ethyl 4-bromo-5-((tert-butyldimethylsilyl) oxy)-2,3 -dihydro- IH-indene-2 -carboxylate (2.2 g, 5.508 mmol) in MeOH (10 mL) and THF (10 mL), was added Lithium borohydride, 2 M solution in THF (27.54 mL, 55.082 mmol) at 0 °C dropwise. The RM was stirred at RT for 16 h. The RM was cooled to 0 °C and added chilled water (30 mL) then extracted with EtOAc (2 x 50 mL). The organic layer was dried over Na2SO4and concentrated under reduced pressure to afford the desired compound (1.5 g) as a pale yellow gummy. The compound was used for the next step without further purification. 'H NMR (400 MHz, CDCl3) δ ppm: 6.95 (d, 1 H), 6.66 (d, 1 H), 3.66 (s, 2 H), 3.12 - 3.05 (m, 2 H), 2.81 - 2.70 (m, 3 H), 1.04 (s, 9 H), 0.24 (s, 6 H).

[0217] Step 3: To a stirred solution of (4-bromo-5-((tert-butyldimethylsilyl)oxy)-2,3-dihydro-lH-inden-2-yl)methanol (1.7 g, 4.757 mmol) in THF (20 mL) was added NaH, 60% dispersion in mineral oil (0.381 g, 9.514 mmol) portion wise at 0 °C. The RM was stirred at RT for 10 min. Then Mel (0.888 mL, 14.271 mmol) was added. The RM was stirred at RT for 2 h. The RM was added to a saturated aq. NH4CI solution (25 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layer was dried over Na2SO4and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-5% EtOAc in PE to afford ((4-bromo-2-(methoxymethyl)-2,3-dihydro-lH-inden-5-yl) oxy) (tert-butyl) dimethyl silane (BB-001) (1.4 g, 79.24%) as20308-WO-PCT / 30175-102410 64pale-yellow gummy. 'H NMR (400 MHz, CDCl3) δ ppm: 6.97-6.95 (d, 1 H), 6.68-6.64 (d, 1 H), 3.42-3.38 (m, 6 H), 3.13-3.07 (m, 2 H), 2.83-2.70 (m, 3 H), 1.06 (s, 9 H), 0.25 (s, 6 H).

[0218] Step 4: To a stirred solution of HF-pyr, 65-70% (3.396 mL, 37.696 mmol) in THF (2 mL) was added Pyr (3.043 mL, 37.696 mmol) in THF (2 mL) at 0 °C followed by addition of a solution of ((4-bromo-2-(methoxymethyl)-2,3-dihydro-lH-inden-5-yl)oxy)(tert-butyl)dimethylsilane (1.4 g, 3.770 mmol) in THF (6 mL) at RT. The RM was stirred at RT for 16 h. The RM was diluted with EtOAc (25 mL), washed with cold saturated aq. NaHCOi solution (pH~8) (2 x 10 mL), brine (10 mL) and dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-5% EtOAc in PE to afford 4-bromo-2-(metho xymethyl)-2, 3 -dihydro- lH-inden-5-ol (BB-001) (650 mg, 67 %). 'H NMR (400 MHz, CDCl3) δ ppm: 7.00 (d, 1 H), 6.80 (d, 1 H), 3.39 - 3.35 (m, 5 H), 3.10 - 3.04 (m, 2 H), 2.84 - 2.69 (m, 3 H).

[0219] The following building block was prepared in a manner similar to BB-001 (use of appropriate SM (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art):Table 2: Exemplary intermediateSynthesis of ethyl 5-bromo-6-hydroxy-1.2,3.4-tetrahydronaphthalene-2-carboxylate (BB-002)

[0220] Step 1: A stirred solution of ethyl 5-bromo-6-methoxy-l,2,3,4-tetrahydronaphthalene-2-carboxylate [CAS: 1985617-80-8] (6 g, 19.158 mmol) in DCM (120 mL) was treated with boron tribromide (IM in DCM, 38.315 mmol) at 0 °C and stirred for 1.5 h. The RM was quenched with ice cooled EtOH (20 mL) and concentrated. Cold water (50 mL) was added to the residue. The residue was extracted with DCM (2x30 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure to afford ethyl 5-bromo-6-hydroxy-l, 2, 3, 4-tetrahydronaphthalene-2 -carboxylate (BB-002) (5 g) as a pale brown solid. 'H NMR (400 MHz, CDCl3) δ ppm: 6.98 (d, 1 H), 6.84 (d, 1 H), 5.50 (s, 1 H), 4.20 - 4.15 (m, 1 H), 3.72 (s, 1 H), 2.96 - 2.90 (m, 2 H), 2.68 - 2.63 (m, 2 H), 2.26 - 2.22 (m, 1 H), 1.90 - 1,.83 (m, 1 H),l.30 - 1.24 (m, 2 H), 0.95 - 0.91 (m, 2 H).EXAMPLES OF THE PREPARATION OF INTERMEDIATES ASynthesis of (S)-2-amino-3-((tert-butyldimethylsilyl)oxy)-2-methylpropanamide (Int-AOOl - Enl),and (R)-2-amino-3-((tert-bntyldimethylsilyl)oxy)-2-methylpropanamide (Int-AOOl - En2),20308-WO-PCT / 30175-102410 65lnt-A001 lnt-A001 - En1 lnt-A001 - En2

[0221] Step 1: A solution of l-((tert-butyldimethylsilyl)oxy)propan-2-one (20 g, 106.19 mmol) in EtOH (100 mL) was treated with (4-methoxyphenyl)methanamine (15.3 mL, 116.81 mmol), TMSCN (15.94 mL, 127.42 mmol) and NH4CI (1.7 g, 31.8 mmol) at RT. The RM was stirred at 80 °C for 16 h. After completion of the reaction, volatiles were removed under reduced pressure. The residue was diluted with EtOAc (200 mL), washed with saturated NaHCO3(100 ml), brine solution (100 mL), dried over MgSO4, filtered and evaporated under reduced pressure. The residue was purified by FCC on silica gel using 10% EtOAc in pet ether as an eluent to afford 3-((tert-butyldimethylsilyl)oxy)-2-((4-methoxybenzyl)amino)-2-methylpropanenitrile as a pale yellow liquid (20 g, 56.30%). 'H NMR (400 MHz, DMSO-D6) δH ppm: 7.25 (d, 2 H), 6.88 (d, 2 H), 3.72 (s, 5 H), 3.65 -3.75 (m, 1 H), 3.45 - 3.51 (m, 1 H), 2.74 - 2.77 (m, 1 H), 1.36 (s, 3 H), 0.87 (s, 9 H), 0.77 (m, 6 H).

[0222] Step 2: A solution of 3-((tert-butyldimethylsilyl)oxy)-2-((4-methoxybenzyl)amino)-2-methylpropanenitrile (10 g, 29.940 mmol) in DMSO (70 mL) was treated with K2CO3 (28.966 g, 209.581 mmol) and H2O2 (14.041 mL, 598.802 mmol) at 0° C. The RM was stirred at RT for 16 h. After completion, the RM was cooled to RT and quenched with ice-cold water (100 mL). The aqueous layer was extracted with Et20 (3 x 100 mL). Combined organic phases was washed with brine (50 mL), dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by FCC on silica gel using 40-50% EtOAc in pet ether as an eluent to afford 3-((tert-butyldimethylsilyl)oxy)-2-((4-methoxybenzyl)amino)-2-methylpropanamide as a pale yellow liquid (3.8 g, 36%).1H NMR (400 MHz, DMSO-D6) δH ppm: 7.25 (d, 2 H), 7.24 (br s, 1 H), 7.07 (br s, 1 H), 6.86 (d, 2 H), 3.72 (s, 3 H), 3.68 - 3.71 (m, 1 H), 3.56 - 3.59 (m, 1 H), 3.51 (d, 2 H), 2.05 (br s, 1 H), 1.15 (s, 3 H), 0.85 (s, 9 H), 0.03 (s, 6 H). LCMS: Rt= 1.85 min (97.01%), m / z: 353.39 [M+H]+.

[0223] Step 3: A solution of 3-((tert-butyldimethylsilyl)oxy)-2-((4-methoxybenzyl)amino)-2-methylpropanamide (10 g, 28.365 mmol) in MeOH (200 mL) was treated with 10% palladium hydroxide (5.178 g, 36.874 mmol) at RT. The RM stirred at RT for 48 h under H2 pressure (70 psi). After completion, the reaction mixture was filtered through a celite pad, washed with 10% MeOH in DCM (200 mL), filtrate was concentrated under reduced pressure. The residue was purified by FCC on silica gel using 80% EtOAc in Pet. ether as an eluent to afford 2-amino-3-((tert-butyldimethylsilyl)oxy)-2-methylpropanamide as an off white solid (, 5.5 g). 'H NMR (400 MHz, DMSO) δH ppm: 7.25 (s, 1 H), 6.95 (s, 1 H), 3.76 (d, 1 H), 3.25 (d, 1 H), 1.77 (s, 2 H), 1.04 (s, 3 H), 0.85 (s, 9 H), 0.02 (s, 6 H).

[0224] Step 4: 5.5 g of Int-001 was separated by Prep. SFC. Column [Dimensions]: Lux. Cellulose-4 [250 x 30 x 5pm], % CO2: 75%, % solvent: 25% (0.5% Diethyl Amine in ACN), Total Flow: 90 g / min, Back Pressure: 120.020308-WO-PCT / 30175-102410 66bar, Temperature: 30°C, Wavelength: 215 nm, stack: 18.0 min, Loadability: 44.0 mg / injection, Solubility: 70 mL of ACN, No of Injection: 93, Instrument details: Make / Model: SFC-MASS. The collected fractions were concentrated and lyophilized to afford two isomers: First eluting (Int-AOOl - Enl), as a pale yellow gummy (1.7 g). 1H NMR (400 MHz, DMSO-D6) δ ppm: 7.24 (s, 1 H), 6.93 (s, 1 H), 3.76 (d, 1 H), 3.26 (d, 1 H), 1.77 (s, 2 H), 1.04 (s, 3 H), 0.85 (s, 9 H), 0.02 (s, 6H). SOR: -28.62 (1.0% in CHCh) and second eluting (Int-AOOl - En2), as a pale yellow gummy (1.5 g,). 'H NMR (400 MHz, DMSO-D6) δ ppm: 7.24 (s, 1 H), 6.93 (s,l H), 3.76 (d, 1 H), 3.26 (t, 1 H), 1.77 (s, 2 H), 1.04 (s, 3 H), 0.85 (s, 9 H), 0.02 (t, 6 H). SOR: +47.54 (1.0% in CHCh).Synthesis of ((S)-2-amino-3-hydroxy-2-methylpropanamide hydrochloride (Int-A002 - Enl),lnt-A001 - En1 lnt-A002 - En1

[0225] Step 1: A solution of (S)-2-amino-3-((tert-butyldimethylsilyl)oxy)-2-methylpropanamide (Int-AOOl-Enl) (500 mg, 2.151 mmol) in 1,4-Dioxane (2.5 mL) was cooled to 0 °C and treated with 4M HCl in 1,4-Dioxane (2.689 mL, 10.757 mmol). The RM was stirred at RT for 16 h. The RM was concentrated under reduced pressure. The residue was suspended in Et20 (10 mL) and concentrated under reduced pressure. The solid was triturated with Et20 (3 x io mL) and solvent was decantated and then, further triturated with n-Pentane (3 x 10 mL). The solid was isolated and dried under reduced pressure to afford (S)-2-amino-3-hydroxy-2-methylpropanamide hydrochloride (Int-A002-Enl) (220 mg, 66%). 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.01 (br s, 3 H), 7.73 (s, 1 H), 7.55 (s, 1 H), 5.64 (t, 1 H), 3.77 - 3.73 (m, 1 H), 3.58 - 3.55 (m, 1 H), 1.36 (s, 3 H).Synthesis of 2-amino-4.4-difluoro-2-methylbutan-l-ol (Int-A003),

[0226] Step 1: To a solution of t-BuOK (13.2 g, 117.83 mmol) in DMF (150 mL) was added ethyl 2-((diphenylmethylene)amino)acetate (30 g, 112.22 mmol) at 0 °C. After 30 min, 1,1-difluoro-2-iodoethane (24.9 g, 130.18 mmol) was added over 10 min at 0 °C. The RM was stirred at 0°C for 1 h. After completion of the reaction, the RM was diluted with 5% aq NH4C1 (100.0 mL), extracted with EtOAc (3 x 50.0 mL). Combined organic layer was washed with brine (100.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using 5% EtOAc in pet ether as an eluent to afford ethyl 2-((diphenylmethylene)amino)-4,4-difluorobutanoate as a pale yellow liquid (30 g, 80.67%). 1H NMR (400 MHz, CDCl3) δ ppm: 7.63 - 7.65 (m, 2 H), 7.39 - 7.48 (m, 4 H), 7.31 - 7.36 (m, 2 H), 7.18 - 7.20 (m, 2 H), 5.75 - 5.91 (m, 1 H), 4.27 - 4.30 (m, 1 H), 4.14 - 4.19 (m, 2 H), 2.45 - 2.53 (m, 2 H), 1.25 (t, 3 H).20308-WO-PCT / 30175-102410

[0227] Step 2: To a solution of t-BuOK (7.450 g, 112.21 mmol) in DMF (30 mL) was added Ethyl N-(diphenylmethylene)glycinate (20 g, 331.36 mmol) at 0 °C. After 30 min, iodomethane (42.83 g, 141.93 mmol) was added over 10 min at 0 °C. The RM was stirred at 0°C for 1 h. After completion of the reaction, the RM was diluted with 5% aq NH4CI (100 mL), extracted with EtOAc (3 x 50 mL). Combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using 10% EtOAc in pet ether as an eluent to afford ethyl 2-((diphenylmethylene)amino)-4,4-difluoro-2-methylbutanoate as a pale yellow liquid (16 g, 76.75%). 1H NMR (400 MHz, CDCl3) δ ppm: 7.50 - 7.59 (m, 2 H), 7.36 - 7.41 (m, 4 H), 7.28 - 7.32 (m, 2 H), 7.13 - 7.15 (m, 2 H), 6.16 - 6.49 (m, 1 H), 3.69 - 3.77 (m, 2 H), 2.31 - 2.57 (m, 2 H), 1.44 (s, 3 H), 1.11 (t, 3 H).

[0228] Step 3: To a solution of ethyl 2-((diphenylmethylene)amino)-4,4-difluoro-2-methylbutanoate (16 g, 46.32 mmol) in Pet. ether (75 mL) was added 1N HCl (150 mL) at RT. The RM was stirred at RT for 16 h. The RM was washed with EtOAc (2 x 50 mL). The aqueous solution was basified with NaHCO3(pH ~8), extracted with EtOAc (3 x 50 mL). The combined organic layer was dried over Na2SO4and concentrated under reduced pressure to afford ethyl 2-amino-4,4-difluoro-2-methylbutanoate as a pale yellow liquid (5.910 g, 70.42%). 1H NMR (400 MHz, CDCl3) δ ppm: 5.87 - 6.15 (m, 1 H), 4.17 - 4.12 (m, 2 H), 2.04 - 2.33 (m, 2 H), 1.39 (s, 3 H), 1.27 (t, 3 H).

[0229] Step 4: To a solution of ethyl 2-amino-4,4-difluoro-2-methylbutanoate (5.6 g, 30.90 mmol) in EtOH (50 mL) was added sodium borohydride (3.508 mg, 92.72 mmol) at 0 °C. The RM was stirred at RT for 7 h. The RM was quenched with water (10 mL), extracted with EtOAc (3 x 30 mL). The combined organic layer was dried over Na2SO4and concentrated under reduced pressure to afford 2-amino-4,4-difluoro-2-methylbutan-l-ol (Int-A003) as a colorless gum (2.3 g, 53%). 1H NMR (400 MHz, DMSO-De) δ ppm: 6.02 -6.33 (m, 1 H), 4.76 (t, 1 H), 3.09 - 3.19 (m, 2 H), 1.75 - 1.87 (m, 2 H), 1.48 (br, s, 2 H), 0.95 (s, 3 H).int-A004

[0230] Step 1: A stirred solution of 2-((tert-butoxycarbonyl) amino)-3-hydroxy-2-methylpropanoic acid (1 g, 4.56 mmol) in MeCN (50 mL) was treated with DIPEA (3.983 mL, 22.806 mmol) and methylamine hydrochloride (0.615 g, 9.123 mmol) followed by TBTU (1.904 mg, 5.930 mmol) at RT. The RM was stirred at RT for 6 h. The RM was concentrated under reduced pressure. The residue was purified by FCC on silica gel using 4% MeOH in DCM as a gradient to afford tert-butyl (3 -hydroxy-2-methyl-l -(methylamino)- l-oxopropan-2-yl)carbamate (1 g, 94.38%) as a pale yellow gummy.1H NMR (400 MHz, DMSO-d6) δ ppm: 7.95 (d, 1 H), 7.53-7.51 (m, 1 H), 4.87 (t, 1 H), 3.17 - 3.12 (m, 2 H), 2.56 (d, 3 H), 1.36 (s, 9 H), 1.26-1.23 (m, 3 H).

[0231] Step 2: A solution of tert-butyl (3-hydroxy-2-methyl-l-(methylamino)-l-oxopropan-2-yl)carbamate (1 g, 4.3 mmol) in 4M Dioxane. HCl (10 mL) at 0 °C. The RM was stirred at RT for 16 h. The RM was concentrated under reduced pressure to afford 2-amino-3-hydroxy-N,2-dimethylpropanamide hydrochloride (Int-A004) (725 mg, 99.87%) as a pale brown gummy. This crude compound was proceeded to next step without further20308-WO-PCT / 30175-102410 68purification. 1H NMR (400 MHz, DMSO-d6) δ ppm: 8.98 (br s, 2 H), 8.19 (br s, 1 H), 3.60 - 3.56 (m, 1 H), 3.15 - 3.09 (m, 1 H), 2.69 (s, 3 H), 1.34 (s, 3 H).Synthesis of 3 -Amino-3-(hvdroxymethyl)pyrro lidin-2 -one (Int-A005 - Enl) and (Int-A005 - En2),int-A005 - En2

[0232] Step 1: To a stirred solution of diethyl 2-(2-(l,3-dioxoisoindolin-2-yl)ethyl)malonate (60 g, 179.99 mmol) in 1,4-Dioxane (600 mL) was added TEA (49.90 mL, 359.99 mmol) at 0 °C. After 15 minutes, formaldehyde (29.18 g, 359.99 mmol) was added at 0 °C. The RM was warmed to RT and stirred at 80 °C for 16 h. The RM was diluted with ice-cold water (200 mL) and extracted with EtOAc (2 * 300 mL). The combined organic layers were washed with brine (150 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0 to 40% EtOAc in pet ether to afford diethyl 2-(2-(l,3-dioxoisoindolin-2-yl)ethyl)-2-(hydroxymethyl)malonate (59 g, 90%) as pale yellow gummy. 'H NMR (400 MHz, CDCl3) δ ppm: 7.86-7.82 (m, 2 H), 7.74-7.69 (m, 2 H), 4.25-4.18 (m, 4 H), 4.07 (d, 2 H), 3.83-3.79 (m, 2 H), 2.79 (t, 1 H), 2.33-2.30 (m, 2 H), 1.28 (t, 6 H).

[0233] Step 2: To a stirred solution of diethyl 2-(2-(l,3-dioxoisoindolin-2-yl)ethyl)-2-(hydroxymethyl)malonate (68 g, 187.13 mmol) in DCM (700 mL) was added Imidazole (25.48 g, 374.27 mmol) at 0 °C. After 15 min., tert-Butyldimethylsilyl chloride (33.84 g, 224.56 mmol) at 0 °C was added. The RM was stirred for 16 h at RT. The RM was diluted with ice cold water (300 mL) and extracted with DCM (2 x 500 mL). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 10% EtOAc in pet ether to afford diethyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-2-(2-(l,3-dioxoisoindolin-2-yl)ethyl)malonate (68 g, 77%) as an off-white solid.1H NMR (400 MHz, CDCl3) δ ppm: 7.84-7.82 (m, 2 H), 7.71-7.69 (m, 2 H), 4.18–4.11 (m, 6 H), 3.76-3.72 (m, 2 H), 2.41-2.37 (m, 2 H), 1.26 (t, 6 H), 0.89 (s, 9 H), 0.08 (s, 6 H).

[0234] Step 3: To a stirred solution of diethyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-2-(2-(l,3-dioxoisoindolin-2-yl)ethyl)malonate (68 g, 142.37 mmol) in Ethanol (700 mL) was added Hydrazine hydrate (10.69 g, 213.55 mmol) at 0 °C. The RM was stirred for 16 h at RT. The RM was diluted with ice cold water (300 mL) and extracted with EtOAc (2 x 500 mL). The combined organic layers were washed with brine solution (200 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on20308-WO-PCT / 30175-102410 69silica gel using a gradient of 0-30% EtOAc in Pet. ether to afford ethyl 3-(((tert-butyldimethylsilyl)oxy)methyl)-2 -oxopyrrolidine-3 -carboxylate (30.7 g, 71%) as an off white solid.1H NMR (400 MHz, CDCl3) δ ppm: 5.76 (s, 1 H), 4.22-4.17 (m, 2 H), 4.06 (d, 1 H), 3.94 (d, 1 H), 3.46-3.42 (m, 1 H), 3.36-3.35 (m, 1 H), 2.59-2.55 (m, 1 H), 2.49-2.43 (m, 1 H), 1.27 (t, 3 H), 0.87 (d, 9 H), 0.06 (d, 6 H).

[0235] Step 4: To a solution of ethyl 3-(((tert-butyldimethylsilyl)oxy)methyl)-2-oxopyrrolidine-3-carboxylate (29 g, 96.19 mmol) in EtOH (120 mL), THF (60 mL) and H2O (30 mL) was added LiOH.H2O (20.18 g, 480.99 mmol) at 0 °C. The RM was stirred for 16 h at RT. The volatiles were removed under reduced pressure. The residue was diluted with cold water (20 mL) and then acidified with saturated aqueous Citric acid solution (pH~4). The solid was filtered, washed with water (10 mL) followed by water (10 mL), dried under vacuum to afford 3-(((tert-butyldimethylsilyl)oxy)methyl)-2-oxopyrrolidine-3-carboxylic acid (16.7 g, 63%) as a white solid.1H NMR (400 MHz, DMSO-de) δ ppm: 7.82 (s, 1 H), 3.88 (d, 1 H), 3.70 (d, 1 H), 3.27-3.21 (m, 1 H), 3.17-3.12 (m, 1 H), 2.34-2.32 (m, 1 H), 2.24-2.22 (m, 1 H), 0.84 (s, 9 H), 0.01 (d, 6 H).

[0236] Step 5: To a stirred solution of 3-(((tert-butyldimethylsilyl)oxy)methyl)-2-oxopyrrolidine-3-carboxylic acid (9.5 g, 34.74 mmol) in THF (40 mL) and benzene (120 mL) were added TEA (14.65 mL, 104.24 mmol) followed by DPPA (19.12 g, 69.49 mmol) at RT. The RM was stirred at RT for 2 h. The RM was quenched with ice cold water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate (2 x 50 mL), brine solution (50 mL), then dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF (40 mL) and benzene (120 mL). Then, Benzyl alcohol (7.51 g, 69.49 mmol) was added at RT. The RM was stirred at 55 °C for 16 h. The RM was diluted with ice-cold water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layers were washed with brine solution (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-40% EtOAc in Pet. ether to afford benzyl (3-(((tert-butyldimethylsilyl)oxy)methyl)-2-oxopyrrolidin-3-yl)carbamate (9 g, 68%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.37-7.29 (m, 5 H), 5.84 (br s, 1 H), 5.42 (br s, 1 H), 5.07 (s, 2 H), 3.85 (d, 1 H), 3.67 (d, 1 H), 3.39-3.33 (m, 2 H), 2.63-2.62 (m, 1 H), 2.53-2.51 (m, 1 H), 0.88 (s, 9 H), 0.05 (d, 6 H).

[0237] Step 6: To a stirred solution of benzyl (3-(((tert-butyldimethylsilyl)oxy)methyl)-2-oxopyrrolidin-3-yl)carbamate (11 g, 29.05 mmol) in MeOH (150 mL) was added PTSA monohydrate (2.21 g, 11.62 mmol) in MeOH (50 mL) over 2 h at 0 °C. The RM was stirred for 16 h at RT. The RM was concentrated under reduced pressure. The residue was quenched with ice-cold water (50 mL) and extracted with 10% MeOH in DCM (3 x 50 mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was triturated with n-pentane (3 x 15 mL) followed by diethyl ether (15 mL), filtered and dried under vacuum to afford benzyl (3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)carbamate (7 g, 91%) as an off white solid. 'H NMR (400 MHz, DMSO-de) δ ppm: 7.66 (s, 1 H), 7.38-7.29 (m, 5 H), 7.08 (s, 1 H), 4.98-4.95 (m, 3 H), 3.46-3.38 (m, 2 H), 3.18-3.15 (m, 1 H), 3.13-3.07 (m, 1 H), 2.28-2.25 (m, 2 H). 3.5 g of benzyl (3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)carbamate was purified by chiral SFC prep.[ Preparative SFC Conditions: Column: Chiral peak IF (250 x 30 x 5pm), %CO2: 65%, %Co-solvent: 35% (100% Methanol), Total Flow: 90 g / min, Back Pressure: 100.0 bar, Temperature: 30 °C, Wavelength: 215 nm, Stack time: 7.2 min, Solubility: 100 ml of MeOH.] The collected pure fractions were concentrated under reduced pressure to afford two isomers Enl (the first eluting)20308-WO-PCT / 30175-102410 70and En2 (the second eluting).

[0238] Step 7: To a stirred solution of benzyl (3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)carbamate Enl (1.4 g, 5.297 mmol) in Ethanol (30 mL) was added Pd / C (450 mg) at RT. The RM was stirred under H2(70 psi) at RT for 16 h. The RM was filtered through a pad of Celite, and washed with MeOH (50 mL). The filtrate concentrated under reduced pressure. The residue was triturated with diethyl ether (2 x 5 mL) and dried under high vacuum to afford 3-amino-3-(hydroxymethyl)pyrrolidin-2-one (Int-A005 - Enl) (610 mg, 88%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm: 7.54 (s, 1 H), 4.73 (t, 1 H), 3.36-3.34 (m, 1 H), 3.18-3.12 (m, 2 H), 3.10-3.04 (m, 1 H), 2.22-2.15 (m, 1 H), 1.76-1.72 (m, 1 H), 1.56 (s, 2 H). UPLC: Rt = 2.29 min (98%).

[0239] Step 8: To a stirred solution of benzyl (3-(hydroxymethyl)-2-oxopyrrolidin-3-yl)carbamate En2 (1.2 g, 4.54 mmol) in Ethanol (30 mL) was added Pd / C (350 mg) at RT. The RM was stirred under H2(70 psi) at RT for 16 h. The RM was filtered through a pad of Celite, and washed with MeOH (50 mL). The filtrate was concentrated under reduced pressure. The residue was triturated with diethyl ether (2 x 5 L) and dried under high vacuum to afford 3 -amino-3-(hydroxymethyl)pyrro lidin-2 -one (Int-A005 - En2) (550 mg, 93%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm: 7.54 (s, 1 H), 4.73 (brs, 1 H), 3.36-3.32 (m, 1 H), 3.18-3.12 (m, 2 H), 3.10-3.04 (m, 1 H), 2.22-2.15 (m, 1 H), 1.76-1.71 (m, 1 H), 1.57 (s, 2 H).EXAMPLES OF THE PREPARATION OF INTERMEDIATES BSynthesis of 2-methylnaphtho[2.1-b]furan-l-carboxylic acid (Int-BOOl)

[0240] Step 1: To a stirred solution of ethyl 2 -methylnaphtho [2, l-b]furan-l -carboxylate [CAS: 2375352-83-1] (280 mg, 1.1 mmol) in THF (2 mL), MeOH (2 mL) and water (2 mL) was added NaOH (220 mg, 5.50 mmol) at RT. The RM was stirred at RT for 16 h. The RM was concentrated under reduced pressure. The residue was acidified with citric acid solution (pH~l). The solid was filtered and washed with water (10 mL). The collected precipitate fraction was dried using high vacuum to afford 2 -methylnaphtho [2, l-b]furan-l -carboxylic acid (Int-BOOl) (210 mg, 84%). 'H NMR (400 MHz, DMSO-de) δ ppm: 13.26 (bs, 1 H), 9.22 (d, 1 H), 8.04 (d, 1 H), 7.87 (d, 1 H), 7.78 (d, 1 H), 7.62 - 7.58 (m, 1 H), 7.54 - 7.75 (m, 1 H), 2.77 (s, 3 H).Synthesis of 2.8.8-trimethyl-9-oxo-8.9-dihvdro-7H-furo[3,2-f| chromene-l-carboxylic acid (Int-B002)

[0241] Step 1: A stirred solution of ethyl 5-hydroxy-2-methylbenzofuran-3-carboxylate [CAS: 7287-40-3] (2.5 g, 11.35 mmol) in DMF (25 mL) was added methyl 2, 2-dimethy 1-3 -(tosyloxy) propanoate [CAS: 25255-56-5] (3.9 g, 13.62 mmol), K2CO3 (3.9 g, 28.38 mmol) and KI (188 mg, 1.135 mmol) at RT. The RM was stirred at 120 °C for 16 h. The RM was dilute with water (200 mL) and extracted with EtOAc (2 x 50 mL). The combined organic20308-WO-PCT / 30175-102410 71layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-3% EtOAc in PE to afford ethyl 5-(3-methoxy-2,2-dimethyl-3-oxopropoxy)-2-methylbenzofuran-3-carboxylate (950 mg, 25%).1H NMR (400 MHz, CDCl3) δ ppm: 7.45 (d, 1 H), 7.28 (d, 1 H), 6.85 (dd, 1 H), 4.41 (q, 2 H), 4.01 (s, 2 H), 3.70 (s, 3 H), 2.73 (s, 3 H), 1.44 (t, 3 H), 1.41 (s, 6 H).

[0242] Step 2: A solution of ethyl 5-(3-methoxy-2,2-dimethyl-3-oxopropoxy)-2-methylbenzofuran-3-carboxylate (1 g, 2.991 mmol) inTHF (10 mL), MeOH (3 mL) and Water (3 mL) was treated with LiOH.H2O (1.2 g, 29.90 mmol) at RT. The RM was stirred at RT for 16 h. The RM was concentrated under reduced pressure. The residue was diluted with water (20 mL) and acidified with aq. Citric acid solution (pH, ~l-2). The solid was fdtered and washed with water (25 mL) and PE (25 mL) and dried under high vacuum to afford 5-(2-carboxy-2-methylpropoxy)-2-methylbenzofuran-3-carboxylic acid (750 mg, 86%).1H NMR (400 MHz, MeOD-d4) δ ppm: 7.44 (d, 1 H), 7.32 (d, 1 H), 6.87 (dd, 1 H), 4.00 (s, 2 H), 2.71 (s, 3 H), 1.32 (s, 6 H).

[0243] Step 3: A stirred solution of 5-(2 -carboxy -2 -methylpropoxy)-2-methylbenzofuran-3-carboxylic acid (900 mg, 3.079 mmol) in DCM (30 mL) was treated with TFA (2.1 mL, 24.633 mmol) at RT and stirred at 45 °C for 16 h. The RM was concentrated under reduced pressure. The residue was diluted with ice cold water (100 mL). The solid was filtered and dried under vacuum to afford mixture of two isomers (720 mg, LCMS: 50% & 38%) as an off-white solid. The crude compound was purified twice by reverse phase flash column chromatography (Combi-Flash) on C18 column and using 0-100% ACN in water as a gradient. The collected pure fraction of Peak-1 (first to elute) was concentrated under reduced pressure to afford 2,8,8-trimethyl-9-oxo-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxylic acid (Int-B002) (250 mg, 29%).1H NMR (400 MHz, MeOD-d4) δ ppm: 7.56 (d, 1 H), 6.86 (d, 1 H), 4.19 (s, 2 H), 2.51 (s, 3 H), 1.18 (s, 6 H).

[0244] The following Int. were prepared in a manner similar to Int-B002 (use of appropriate SM (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art):Table 3: Exemplary intermediateSynthesis of 2.6.8.8-tetramethyl-9-oxo-6.7.8.9-tetrahvdrofuro[3.2-f|quinoline-l-carboxylic acid (Int-B020)20308-WO-PCT / 30175-102410 72

[0245] Step 1: A stirred solution of ethyl 5-bromo-2-methylbenzofuran-3-carboxylate [CAS: 945907-49-3] (3.5 g, 12.362 mmol) in toluene (50 mL) were treated with ethyl 3-amino-2,2-dimethylpropanoate. HCl [CAS: 80253-38-9] (3.359 g, 18.543 mmol), Cs2CO3(12.084 g, 37.087 mmol) at RT and degassed with N2 for 10 min. Then, the RM was treated with XPhos (0.589 g, 1.236 mmol) and Pd2(dba)3(0.566 g, 0.618 mmol) at RT. The RM was stirred at 100 °C for 16 h. The RM was filtered through a celite pad and washed with EtOAc (250 mL). The filtrate was concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-15% EtOAc in PE to afford ethyl 5-((3-ethoxy-2,2-dimethyl-3-oxopropyl)amino)-2-methylbenzofuran-3-carboxylate (2.50 g, 58%).1H NMR (400 MHz, CDCl3) δ ppm: 7.20 - 7.18 (m, 2 H), 6.59 (dd, 1 H), 4.39 (q, 2 H), 4.14 (q, 2 H), 3.98 (bs, 1 H), 3.27 (s, 2 H), 2.71 (s, 3 H), 1.44 (s, 3 H), 1.29 (s, 6 H), 1.25 (t, 3 H).

[0246] Step 2: A stirred solution of ethyl 5-((3-ethoxy-2,2-dimethyl-3-oxopropyl)amino)-2-methylbenzofuran-3-carboxylate (2.50 g, 7.196 mmol) in FA (15 mL) was treated with formaldehyde (37% in water, 15 mL) at RT. The RM was stirred at 60 °C for 16 h. The RM was concentrated under reduced pressure. The residue was diluted with water (100 mL), with sat. NaHCO3solution (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with water (25 mL), brine (25 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-5% EtOAc in PE to afford ethyl 5-((3-ethoxy-2,2-dimethyl-3-oxopropyl)(methyl)amino)-2-methylbenzofuran-3-carboxylate (1.8 g, 69%).1H NMR (400 MHz, CDCl3) δ ppm: 7.32 (d, 1 H), 7.24 (d, 1 H), 6.76 (dd, 1 H), 4.37 (q, 2 H), 4.07 (q, 2 H), 3.57 (s, 2 H), 2.96 (s, 3 H), 2.72 (s, 3 H), 1.44 (t, 3 H), 1.23 - 1.20 (m, 9 H).

[0247] Step 3: A stirred solution of ethyl 5-((3-ethoxy-2,2-dimethyl-3-oxopropyl)(methyl)amino)-2-methylbenzofuran-3 -carboxylate (1.6 g, 4.427 mmol) in THF (5 mL), MeOH (5 mL) and H2O (5 mL) was treated with LiOH.H2O (1.115 g, 26.561 mmol) at 0 °C. The RM was stirred at RT for 16 h. The RM was concentrated under reduced pressure. The residue was diluted with water (25 mL), acidified with aq. citric acid solution (pH ~ 3) and extracted with EtOAc (3 x 25 mL). The combined organic extracts were washed with water (5 mL), brine (5 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-25% EtOAc in PE to afford 5-((2-carboxy-2-methylpropyl)(methyl)amino)-2-methylbenzofuran-3 -carboxylic acid (750 mg, 55%).1H NMR (400 MHz, CDCl3) δ ppm: 7.62 (d, 1 H), 7.27 (s, 1 H), 6.71 (dd, 1 H), 3.67 (s, 2 H), 3.09 (s, 3 H), 2.51 (s, 3 H), 1.32 (s, 6 H).

[0248] Step 4: A stirred solution of 5-((2-carboxy-2-methylpropyl)(methyl)amino)-2-methylbenzofuran-3-carboxylic acid (800 mg, 2.62 mmol) in DCM (40 mL) was treated with a solution of TFA (0.734 mL, 5.240 mmol) in DCM (5 mL) at RT. The RM was stirred at 45 °C for 16 h. The RM was concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-30% EtOAc in pet ether as a gradient. The collected pure fractions were concentrated under reduced pressure to afford 2,6,8,8-tetramethyl-9-oxo-6,7,8,9-tetrahydrofuro[3,2-f]quinoline-l-carboxylic acid (Int-B020)(180 mg, 23.9%).1H NMR (400 MHz, CDCl3) δ ppm: 7.52 (d, 1 H), 6.68 (d, 1 H), 3.25 (s, 2 H), 3.16 (s, 3 H), 2.70 (s, 3 H), 1.18 (s, 6 H).Synthesis of 2,8,8-trimethyl-8,9-dihvdro-7H-furo[3,2-f|chromene-l-carboxylic acid (Int-B003)20308-WO-PCT / 30175-102410 73

[0249] Step 1: A stirred solution of 2,8,8-trimethyl-9-oxo-8,9-dihydro-7H-furo[3,2-f]chromene-1-carboxylic acid (Int-B002) (420 mg, 1.531 mmol) in 1,2-dichloroethane (20 mL) was treated with Znl 2 (1.4 g, 4.594 mmol) followed by Sodium cyanoborohydride (1.45 g, 22.970 mmol) at 0 °C. The RM was stirred at RT for 6 h. The RM was quenched with Sat. NH4CI solution and extracted with DCM (2 x 20 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-50% EtOAc in PE 0 afford 2,8,8-trimethyl-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxylic acid (Int-B003) (180 mg, 45%).1H NMR (400 MHz, DMSO-d6) δ ppm: 12.84 (br s, 1 H), 7.28 (d, 1 H), 6.76 (d, 1 H), 3.71 (s, 2 H), 2.82 (s, 2 H), 2.59 (s, 3 H), 0.96 (s, 6 H).

[0250] The following Int. were prepared in a manner similar to Int-B003 (use of appropriate SM (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art):Table 4: Exemplary intermediateSynthesis of ethyl 2-methyl-8.9-dihvdro-7H-furo[3.2-f|chromene-l-carboxylate (Int-B008)

[0251] Step 1: A stirred solution of 5-bromochroman-6-ol [CAS: 32337-88-5] (1.1 g, 4.802 mmol) and ethyl but-2-ynoate [CAS: 4341-76-8] (0.841 mL, 7.203 mmol) in ACN (15 mL) was treated with DAB CO (538.684 mg, 4.802 mmol) at RT. The RM was stirred at 70 °C for 16 h. The RM was quenched with saturated aq. NH4CI solution (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-1% of EtOAc in PE to afford ethyl (E)-3-((5-bromochroman-6-yl)oxy)but-2-enoate (1.1 g).1H NMR (400 MHz, CDCl3) δ ppm: 6.83 (d, 1 H), 6.78 (d, 1 H), 4.76 (s, 1 H), 4.15 - 4.06 (m, 4 H), 2.77 (t, 2 H), 2.50 (s, 3 H), 2.05 - 2.03 (m, 2 H), 1.24 (t, 3 H).

[0252] Step 2: A solution of ethyl (E)-3-((5-bromochroman-6-yl)oxy)but-2 -enoate (200 mg, 0.586 mmol) in 1,4-dioxane (20 mL) was treated with Cesium carbonate (572.953 mg, 1.758 mmol), and degassed with N2 for 5 min. Then, the RM was treated with Pd(PPh3)4 (67.702 mg, 0.059 mmol) and stirred at 110 °C for 16 h. The RM was diluted with ice-cold water (30 mL), and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-2% EtOAc in PE to afford ethyl 2-methyl-8,9-dihydro-7H-furo[3,2-f]chromene-1-carboxylate (Int-B008) (120 mg, 78%).1H NMR (400 MHz, CDCl3) δ ppm: 7.14 (d, 1 H),20308-WO-PCT / 30175-102410 746.75 (d, 1 H), 4.36 (q, 2 H), 4.18 (t, 2 H), 3.12 (t, 2 H), 2.64 (s, 3 H), 2.02 - 1.99 (m, 2 H), 1.40 (t, 3 H).Synthesis of ethyl 7-(methoxymethyl)-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (Int-BOlO)

[0253] Step 1: To a stirred solution of 4-bromo-2-(methoxymethyl)-2,3-dihydro-lH-inden-5-ol (BB-001) (650 mg, 2.528 mmol) in ACN (10 mL) were treated with DABCO (283.584 mg, 2.528 mmol) and ethyl but-2-ynoate [CAS: 4341-76-8] (0.295 mL, 2.528 mmol) at RT. The RM was stirred at 70 °C for 16 h. The RM was directly concentrated under reduced pressure and then diluted with cold water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (50 mL), brine (50 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-5% EtOAc in PE to afford ethyl (E)-3-((4-bromo-2-(methoxymethyl)-2,3-dihydro-lH-inden-5-yl)oxy)but-2-enoate (800 mg, 85 %) as a pale-yellow gummy.1H NMR (400 MHz, CDCl3) δ ppm: 7.10 (d, 1 H), 6.84 (d, 1 H), 4.76 (s, 1 H), 4.12 - 4.06 (m, 2 H), 3.42 - 3.37 (m, 5 H), 3.15 - 3.08 (m, 2 H), 2.85 - 2.75 (m, 3 H), 2.51 (s, 2 H), 1.22 (t, 3 H).

[0254] Step 2: A stirred solution of ethyl (E)-3-((4-bromo-2-(methoxymethyl)-2,3-dihydro-lH-inden-5-yl)oxy)but-2-enoate (750 mg, 2.031 mmol) in ACN (10 mL) was treated with TEA (0.849 mL, 6.093 mmol) at RT. The RM was degassed with N2 gas for 10 min and then PdC12(dppf). DCM (165.869 mg, 0.203 mmol) was added. The RM was stirred at 85 °C for 20 h. The RM was cooled to RT, filtered through a celite pad, and washed with EtOAc (100 mL). Filtrate was concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-10% EtOAc in PE to afford ethyl 7-(methoxymethyl)-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (Int-BOlO) (320 mg, 54%).1H NMR (400 MHz, CDCl3) δ ppm: 7.21 (d, 1 H), 7.10 (d, 1 H), 4.41 - 4.35 (m, 2 H), 3.41 - 3.37 (m, 5 H), 3.13 - 3.08 (m, 3 H), 2.84 - 2.78 (m, 3 H), 2.72 (s, 3 H), 1.42 (t, 3 H).

[0255] The following Int. were prepared in a manner similar to Int-BOlO (use of appropriate SM (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art):Table 5: Exemplary intermediateSynthesis of ethyl 3-(2-methoxyethyl)-7-methyl-3H-furo[3,2-e]indazole-8-carboxylate (Int-B012) & ethyl 2-(2-methoxyethyl)-7-methyl-2H-furo[3,2-e]indazole-8-carboxylate (Int-B013)20308-WO-PCT / 30175-102410 75

[0256] Step l: A solution of 4-bromo-lH-indazol-5-ol [CAS: 705927-37-3] (18 g, 84.494 mmol) in THF (300 mL) was treated with DMAP (2.064 g, 16.899 mmol) and BOC2O (38.823 mL, 168.987 mmol) drop wise at 0 °C. The RM was stirred at RT for 16 h. The RM was concentrated under reduced pressure, and the residue was diluted with water (250 mL) and extracted with 50% EtOAc in PE (3 x 100 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to afford tert-butyl 4-bromo-5-((tert-butoxycarbonyl)oxy)-lH-indazole-l-carboxylate (19 g). The compound was used in the next step without further purification.1H NMR (400 MHz, CDCl3) δ ppm: 8.19 - 8.18 (m, 1 H), 8.14 (d, 1 H), 7.36 (d, 1 H), 1.72 (s, 9 H), 1.58 (s, 9 H).

[0257] Step 2: A stirred solution of tert-butyl 4-bromo-5-((tert-butoxycarbonyl)oxy)-lH-indazole-l-carboxylate (19 g, 45.975 mmol) in THF (200 mL) and H2O (200 mL) was treated with NaOH (4.964 g, 124.13 mmol) at 0 °C. Then, the RM was stirred for 40 h at RT. The RM was concentrated under reduced pressure and the residue was diluted with water (200 mL), acidified with 0.5 N HCl (pH ~5) at 0 °C and extracted with EtOAc (3 x 200 mL). The combined organic layers were washed with water (2 x 50 mL), brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-20% of EtOAc in PE to afford tert-butyl 4-bromo-5-hydroxy-lH-indazole-l-carboxylate (10.5 g, 55%) as an off-white solid.1H NMR (400 MHz, CDCl3) δ ppm: 8.06 (s, 1 H), 8.04 (d, 1 H), 7.24 (d, 1 H), 5.56 (s, 1 H), 1.72 (s, 9 H).

[0258] Step 3: A solution of tert-butyl 4-bromo-5-hydroxy-lH-indazole-l -carboxylate (5 g, 15.967 mmol) in ACN (100.0 mL) was treated with DAB CO (1.790 g, 15.967 mmol) and ethyl but-2-ynoate (1.790 g, 15.967 mmol) at RT. The RM was stirred at 70 °C for 16 h. The RM was concentrated under reduced pressure and diluted with water (100 mL), extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water (100 mL), brine (100 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-10% of EtOAc in PE to afford tert-butyl (E)-4-bromo-5-((4-ethoxy-4-oxobut-2-en-2-yl)oxy)-1H-indazole-1-carboxylate (4 g, 59%) as an off-white solid.1H NMR (400 MHz, CDCl3) 5ppm: 8.19 - 8.16 (m, 2 H), 7.26 - 7.24 (m, 1 H), 4.69 (s, 1 H), 4.07 (q, 2 H), 2.56 (s, 3 H), 1.73 (s, 9 H), 1.19 (t, 3 H).

[0259] Step 4: A stirred solution of tert-butyl (E)-4-bromo-5-((4-ethoxy-4-oxobut-2-en-2-yl)oxy)-lH-indazole-1-carboxylate (1.9 g, 4.468 mmol) in 1,4-dioxane (80 mL) was treated with Cs2CO3(2.183 g, 6.701 mmol) and degassed with N2 for 5 min. Then, the RM was treated with PPh3(0.469 g, 1.787 mmol) and Palladium(II) acetate (0.100 g, 0.447 mmol) in sealed tube and stirred at 100 °C for 16 h. The same reaction was performed on 1.9 g scale in parallel. Both RM were filtered through a small pad of Celite and washed with EtOAc (100 mL). The20308-WO-PCT / 30175-102410 76filtrate was concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-10% EtOAc in PE to afford 3 -(tert-butyl) 8-ethyl 7-methyl-3H-furo[3,2-e]indazole-3,8-dicarboxylate (1.6 g, 52%) as a pale-yellow gummy.1H NMR (400 MHz, CDCl3) δ ppm: 8.88 (s, 1 H), 8.22 (d, 1 H), 7.62 (d, 1 H), 4.50 (q, 2 H), 2.84 (s, 3 H), 1.74 (s, 9 H), 1.50 (t, 3 H).

[0260] Step 5: A solution of 3 -(tert-butyl) 8-ethyl 7-methyl-3H-furo[3,2-e]indazole-3,8-dicarboxylate (1.5 g, 4.356 mmol) in DCM (25 mL) was treated with TFA (1.667 mL, 21.779 mmol) drop wise at 0 °C. The RM was stirred at RT for 16 h. The RM was concentrated under reduced pressure and the residue was diluted with DCM (100 mL), washed with aq. NaHCO3solution (2 x 10 mL), brine (10 mL), dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was triturated with n-pentane (2 x io mL), filtered, and dried under high vacuum suction to afford ethyl 7-methyl-3H-furo[3,2-e]indazole-8-carboxylate (800 mg, 75%) as an off-white solid.1H NMR (400 MHz, CDCl3) δ ppm: 8.71 (s, 1 H), 7.52 (d, 1 H), 7.40 - 7.38 (m, 1 H), 4.53 (q, 2 H), 2.83 (s, 3 H), 1.52 (t, 3 H).

[0261] Step 6: A solution of ethyl 7-methyl-3H-furo[3,2-e]indazole-8-carboxylate (800 mg, 3.275 mmol) in DMF (10 mL) was treated with K2CO3 (1.358 g, 9.826 mmol). The RM was stirred for 10 min at RT. Then, the RM was treated with l-bromo-2 -methoxy ethane (0.976 mL, 9.826 mmol, 3 eq) and stirred at 60 °C for 16 h. The RM was diluted with ice-cold water (50 mL), extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with ice-cold water (2 x 10 mL), brine (10 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-15% of EtOAc in PE to afford two isomers ethyl 3-(2-methoxyethyl)-7-methyl-3H-furo[3,2-e]indazole-8-carboxylate (350 mg) (Int-B012) and ethyl 2-(2-methoxyethyl)-7-methyl-2H-furo[3,2-e]indazole-8-carboxylate (380 mg) (Int-B013). Int-B012:1H NMR (400 MHz, CDCl3) δ ppm: 8.62 (s, 1 H), 7.49 (d, 1 H), 7.37 (dd, 1 H), 4.60 (t, 2 H), 4.51 (q, 2 H), 3.86 (t, 2 H), 3.28 (s, 3 H), 2.82 (s, 3 H), 1.52 (t, 3 H) and Int-B013:1H NMR (400 MHz, CDCl3) δ ppm: 8.63 (s, 1 H), 7.60 (dd, 1 H), 7.45 (d, 1 H), 4.64 (t, 2 H), 4.47 (q, 2 H), 3.91 (t, 2 H), 3.34 (s, 3 H), 2.79 (s, 3 H), 1.50 (t, 3 H).Svnthesis of ethvl 8,8-difluoro-2-methvl-8,9-dihvdro-7H-furo[3,2-l:-l-carboxvlate (Int-B016)

[0262] Step 1: A solution of ethyl 6-bromo-5-hydroxy -2 -methylbenzofuran-3 -carboxylate [CAS: 7287-41-4] (8 g, 26.8 mmol) and K2CO3 (14.841 g, 107.390 mmol) in acetone (240 mL) was treated with 3 -bromoprop- l-yne [CAS: 106-96-7] (2.777 mL, 32.217 mmol) at 0 °C. The RM was stirred at 50 °C for 16 h. The RM was cooled to RT, and filtered through filter paper, washed with EtOAc (50 mL). The filtrate was concentrated under reduced pressure. The residue was triturated with n-pentane (2 x 20 mL), fdtered and dried under high vacuum suction to afford ethyl 6-bromo-2-methyl-5-(prop-2-yn-l-yloxy)benzofuran-3-carboxylate (8.5 g, 94%).1H NMR (400 MHz, CDCI3) δ ppm: 7.69 (s, 1 H), 7.64 (s, 1 H), 4.81 (d, 2 H), 4.40 (q, 2 H), 2.73 (s, 3 H), 2.55 (t, 1 H), 1.45 (t, 3 H).20308-WO-PCT / 30175-102410 77

[0263] Step 2: A stirred solution of ethyl 6-bromo-2-methyl-5-(prop-2-yn-l-yloxy)benzofuran-3-carboxylate (5 g, 14.881 mmol) in toluene (20 mL) was treated with Indium(III) iodide (737.398 mg, 1.488 mmol) at 0 °C. Then RM was stirred at 100 °C for 30 min. The RM was poured into ice-cold water (100 mL) and organic parts were extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (2 x 100 mL), and brine (100 mL), dried over Na2SO4. filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-30% EtOAc in hexane to afford ethyl 5-bromo-2-methyl-7H-furo[3,2-f]chromene-l-carboxylate (3 g, 60%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.56 - 7.52 (m, 1 H), 7.45 (s, 1 H), 5.90 - 5.88 (m, 1 H), 4.85 - 4.84 (m, 2 H), 4.41 - 4.36 (m, 2 H), 2.67 (s, 3 H), 1.41 (t, 3 H).

[0264] Step 3: A stirred solution of ethyl 5-bromo-2-methyl-7H-furo[3,2-f]chromene-l-carboxylate (3 g, 8.898 mmol) in THF (30 mL) was treated with Borane dimethyl sulfide complex (8.898 mL, 17.795 mmol) at 0 °C. The RM was stirred for 2 h at RT. Then, the RM was treated with aq. 3M NaOH (5.932 mL, 17.795 mmol) at 0 °C and stirred for 5 min and treated with Hydrogen Peroxide (30% in water, 2.017 mL, 17.795 mmol, 2 equiv.) at 0 °C and stirred for 45 min. The RM was diluted with EtOAc (15 mL) and stirred for 10 minutes. The organic layer was separated, and the aqueous layer was extracted with EtOAc (2 x 40 mL). The combined organic layer was dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-20% EtOAc inPE to afford ethyl 5-bromo-8-hydroxy-2-methyl-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxylate (1.7 g, 54%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.50 (s, 1 H), 4.40 - 4.30 (m, 2 H), 4.25 (bs, 1 H), 4.23 - 4.20 (m, 2 H), 3.51 - 3.45 (m, 1 H), 3.25 - 3.20 (m, 1 H), 2.64 (s, 3 H), 2.01 (d, 1 H), 1.39 (t, 3 H).

[0265] Step 4: A stirred solution of ethyl 5-bromo-8-hydroxy-2-methyl-8,9-dihydro-7H-furo[3,2-f]chromene-1-carboxylate (2 g, 5.631 mmol) in acetone (10 mL) at 0 °C, was treated with Jones reagent (19.708 mL, 39.416 mmol). The RM was stirred for 2 h at RT. The RM was quenched with ice-cold water (10 mL) and saturated sodium bicarbonate (20 mL) and organic parts were extracted with EtOAc (2 x 30 mL). The combined organic layer was washed with water (2 x 20 mL), brine (20 mL) dried over Na2SO4. filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-10% EtOAc in PE to afford ethyl 5-bromo-2-methyl-8-oxo-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxylate (400 mg, 40%).1H NMR (400 MHz, CDCl3) δ ppm: 7.59 (s, 1 H), 4.48 (s, 2 H), 4.42 - 4.37 (m, 2 H), 4.27 (s, 2 H), 2.69 (s, 3 H), 1.42 (t, 3 H).

[0266] Step 5: A stirred solution of ethyl 5-bromo-2-methyl-8-oxo-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxylate (400 mg, 1.136 mmol) in MeOH (20 mL) was treated with 10% Pd / C (200 mg, 1.136 mmol) at RT and stirred for 2 h under Hi atmosphere (balloon pressure). The RM was filtered through a celite bed and washed with MeOH (20 mL). The filtrate was concentrated under reduced pressure to afford ethyl 2-methyl-8-oxo-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxylate (340 mg). 1H NMR (400 MHz, CDC13) δ ppm: 7.27 (d, 1 H), 7.02 (d, 1 H), 4.42 - 4.37 (m, 4 H), 4.22 (s, 2 H), 2.74 (s, 3 H), 1.43 (t, 3 H).

[0267] Step 6: A stirred solution of ethyl 2-methyl-8-oxo-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxylate (340 mg, 1.240 mmol) in DCM (5 mL) was treated with DAST (0.819 mL, 6.198 mmol) at 0 °C. The RM was stirred for 3 h at RT. The RM was quenched with ice-cold water (10 mL) and organic parts were extracted with DCM (2 x 10 mL). The combined organic layers were washed with water (2 x 5 mL), and brine (5 mL) was dried over Na2SO4. fdtered and concentrated under reduced pressure to afford ethyl 8,8-difluoro-2-methyl-8,9-dihydro-20308-WO-PCT / 30175-102410 787H-furo[3,2-f]chromene-l-carboxylate (Int-B016) (260 mg, 71%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.24 (d, 1 H), 6.89 (d, 1 H), 4.41 - 4.36 (m, 2 H), 4.17 - 4.11 (m, 2 H), 3.76 - 3.64 (m, 2 H), 2.68 (s, 3 H), 1.43 (t, 3 H).Synthesis of ethyl 2-methyl-6-methylene-6,7,8,9-tetrahvdronaphtho[2,l-b]furan-l-carboxylate (Int-B023) and ethyl 2'-methyl-8',9'-dihydro-7'H-spiro|cyclopropane-l,6'-naphtho[2,l-blluranl-r-carboxylate (Int-B024)

[0268] Step 1: To a stirred solution of Nysted reagent [CAS: 41114-59-4] (20%inTHF, 34.05 mL, 17.62 mmol) in THF (40 mL) was treated with TiCl4(1M in DCM, 14.69 mL, 14.69 mmol) at 0 °C and stirred for 10 min. Then, the RM was treated with a solution of ethyl 2-methyl-6-oxo-6,7,8,9-tetrahydronaphtho[2,l-b]furan-l-carboxylate (Int-B022) (2.0 g, 7.34 mmol) in THF (10 mL) at 0 °C. The RM was stirred at RT for 16 h. The RM was quenched with ice cooled saturated aq. NaHCO3solution, filtered through a celite pad and washed with EtOAc (100 mL). The aqueous layer from the filtrate was extracted with EtOAc (2 x 100 mL). The combined organic extracts were washed with brine solution (100 mL) and dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 5% EtOAc in PE to afford ethyl 2-methyl-6-methylene-6,7,8,9-tetrahydronaphtho[2,1-b]furan-1-carboxylate (Int-B023) (800 mg, 40%).1H NMR (400 MHz, CDCl3) δ ppm: 7.61 (d, 1 H), 7.22 (d, 1 H), 5.41 (s, 1 H), 4.92 (s, 1 H), 4.39 (q, 2 H), 3.17 (t, 2 H), 2.63 (s, 3 H), 2.56 - 2.53 (m, 2 H), 1.92 - 1.88 (m, 2 H), 1.41 (t, 3 H).

[0269] Step 2: A stirred solution of Et2Zn (1 M in hexane, 3.69 mL, 3.69 mmol) in DCM (7 mL) was treated with diiodomethane (0.597 mL, 7.39 mmol) at -78 °C. The RM was stirred at 0 °C for 15 min. The RM was treated with TFA (0.283 mL, 3.69 mmol) in DCM (1 mL) at 0 °C and stirred for 15 min. A solution of ethyl 2-methyl-6-methylene-6,7,8,9-tetrahydronaphtho[2,l-b]furan-l-carboxylate (Int-B023) (500 mg, 1.85 mmol) in DCM (2 mL) was added and stirred at RT for 16 h. The RM was quenched with cold water and extracted with DCM (2 x 20 mL). The combined organic layer was washed with brine (20 mL) and dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 5% EtOAc in PE to afford ethyl 2'-methyl-8',9'-dihydro-7'H-spiro[cyclopropane-l,6'-naphtho[2, l-b]furan]-l'-carboxylate (Int-B024) (200 mg, 38%).1H NMR (400 MHz, CDCl3) δ ppm: 7.15 (d, 1 H), 6.58 (d, 1 H), 4.38 (q, 2 H), 3.16 (t, 2 H), 2.61 (s, 3 H), 1.94 - 1.88 (m, 2 H), 1.69 - 1.66 (m, 2 H), 1.41 (t, 3 H), 0.97 - 0.95 (m, 2 H), 0.92 - 0.88 (m, 2 H).Synthesis of ethyl 6.6-difluoro-2-methyl-6.7.8.9-tetrahydronaphtho[2.1-b]furan-l-carboxylate (Int-B026)

[0270] Step 1: A stirred solution of ethyl 2-methyl-6-oxo-6,7,8,9-tetrahydronaphtho[2,l-b]furan-l-carboxylate (Int-B022) (900 mg, 3.30 mmol) in toluene (10 mL) were treated with ethane- 1,2-dithiol (0.55 mL, 6.61 mmol) and PTSA (62 mg, 0.331 mmol) at RT. The RM was stirred at 100 °C for 3 h. The RM was quenched with water (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine (20 mL), dried over Na2SO4and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-3% EtOAc in PE to afford ethyl 2-methyl-8,9-dihydro-7H-spiro[naphtho[2,l-b]furan-6,2'-20308-WO-PCT / 30175-102410 79[l,3]dithiolane]-l-carboxylate (900 mg, 78%). 1H NMR (400 MHz, CDCl3) δ ppm: 7.94 (d, J = 8.8 Hz, 1H), 7.26 - 7.23 (m, 1 H), 4.37 (q, 2 H), 3.63 - 3.57 (m, 2 H), 3.49 - 3.45 (m, 2 H), 3.08 (t, 2 H), 2.61 (s, 3 H), 2.44 - 2.41 (m, 2 H), 2.02 - 1.99 (m, 2 H), 1.40 (t, 3 H).

[0271] Step 2: A stirred solution of NIS (1.16 g, 5.16 mmol) inDCM (15 mL) was treated with HF-pyr (65% in pyridine, 1.43 mL, 10.33 mmol) at -78 °C and stirred for 10 min. The RM was treated with a solution of ethyl 2-methyl-8,9-dihydro-7H-spiro[naphtho[2,l-b] furan-6,2'-[l,3]dithiolane]-l-carboxylate (900 mg, 2.58 mmol) in DCM (5 mL) at -78 °C and stirred for 1 h. The RM was quenched with ice cooled sat. sodium thiosulfate solution and extracted with DCM (2 x 20 mL). The combined organic extracts were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-5% EtOAc in PE to afford ethyl 6,6-difluoro-2-methyl-6,7,8,9-tetrahydronaphtho[2,l-b]furan-l-carboxylate (Int-B026) (300 mg, 39%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.65 (d, 1 H), 7.37 (d, 1 H), 4.39 (q, 2 H), 3.22 - 1.90 (m, 2H), 2.67 (s, 3 H), 2.36 - 2.26 (m, 2 H), 2.05 - 1.98 (m, 2 H), 1.41 (t, 3 H).Synthesis of ethyl 6-hvdroxy-2-methyl-7.8-dihvdro-6H-indeno[5.4-b]furan-l-carboxylate (Int-B028)

[0272] Step 1: A stirred solution of 4-bromo-5-hydroxy-2,3-dihydro-lH-inden-l-one [CAS: 896132-97-1] (4.2 g, 18.587 mmol) andDABCO (2.502 g, 22.305 mmol) in ACN (70 mL) was treated with ethyl but-2-ynoate (2.171 mL, 18.587 mmol) at RT. The RM was heated at 70 °C and stirred for 16 h. The RM was diluted with EtOAc (100 mL) and washed with water (2 x 30 mL), brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure, to obtain the crude product (3.5 g) as a brown liquid. The residue was purified by FCC on silica gel using a gradient of 0-30% of EtOAc in PE to afford ethyl (E)-3-((4-bromo-l-oxo-2,3-dihydro-lH-inden-5-yl)oxy)but-2-enoate (1.8 g, 28%) as pale-yellow solid1H NMR (400 MHz, CDCl3) δ ppm: 7.74 (d, 1 H), 7.12 (d, 1 H), 4.79 (s, 1 H), 4.11 (q, 2 H), 3.13 - 3.10 (m, 2 H), 2.79 - 2.76 (m, 2 H), 2.55 (t, 3 H), 1.21 (t, 3 H).

[0273] Step 2: A stirred solution of ethyl (E)-3-((4-bromo-l-oxo-2,3-dihydro-lH-inden-5-yl)oxy)but-2-enoate (1.8 g, 5.307 mmol) in MeOH (15 mL) and THF (15 mL) was treated with Sodium Borohydride (1.405 g, 37.148 mmol) at -40 °C. The RM was stirred at -15 °C for 2 h. The RM was quenched with saturated aq. NH4Cl solution (30 mL) and extracted with EtOAc (40 mL) and water (20 mL) dried over Na2SO4, filtered and concentrated under reduced pressure to afford (E)-3-((4-bromo-l-hydroxy-2,3-dihydro-lH-inden-5-yl)oxy)but-2 -enoate (1.8 g, 99%) as an off-white solid. The compound was used in the next step without further purification.1H NMR (400 MHz, CDCl3) δ ppm: 7.35 (d, 1 H), 6.96 (d, 1 H), 5.33 - 5.31 (m, 1 H), 4.75 (s, 1 H), 4.11 - 4.06 (m, 2 H), 3.09 - 3.05 (m, 1 H), 2.88 - 2.82 (m, 1 H), 2.58 – 2.752 (m, 1 H), 2.51 (s, 3 H), 2.04 - 2.01 (m, 1 H), 1.92 (d, 1 H), 1.21 (t, 3 H).

[0274] Step 3: A stirred solution of ethyl (E)-3-((4-bromo-l-hydroxy-2,3-dihydro-lH-inden-5-yl)oxy)but-2-enoate (1.8 g, 5.275 mmol) in ACN (23 mL) was treated TEA (3.707 mL, 26.377 mmol) at RT. The RM was degassed with N2 for 15 min and then treated with PdC12(dppf). DCM (0.862 g, 1.055 mmol) at RT. The RM was stirred at 85 °C for 36 h. The RM was cooled to RT, filtered through a Celite pad, and washed with EtOAc (40 mL). The filtrate was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic20308-WO-PCT / 30175-102410 80layer was washed with water (30 mL), and brine (30 mL), dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-20% EtOAc in PE to afford ethyl 6-hydroxy-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-1-carboxylate (Int-B028) (1 g, 73%).1H NMR (400 MHz, CDCl3) δ ppm: 7.35 - 7.30 (m, 2 H), 5.30 - 5.29 (m, 1 H), 4.42 - 4.36 (m, 2 H), 3.54 - 3.48 (m, 1 H), 3.28 - 3.20 (m, 1 H), 2.74 (s, 3 H), 2.57 - 2.52 (m, 1 H), 2.06 - 1.99 (m, 1 H), 1.71 (d, 1 H), 1.43 (t, 3 H).Synthesis of ethyl 7-hvdroxy-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-1-carboxylate (Int-B029)

[0275] Step 1: A stirred solution of ethyl 6-hydroxy-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (Int-B028) (1 g, 3.842 mmol) in DCE (30 mL) was treated with Pyridinium p-Toluenesulfonate (1.931 g, 7.684 mmol) at RT. The RM was stirred at 60 °C for 16 h. The RM was quenched with water (20 mL) and organic parts were extracted with EtOAc (2 x 20 mL). The combined organic layer was washed with water (2 x 10 mL), brine (10 mL) dried over Na2SO4. filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0 - 20% EtOAc in PE to afford ethyl 2-methyl-8H-indeno[5,4-b]furan-1-carboxylate (770 mg, 82%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.35 - 7.32 (m, 2 H), 6.93 - 6.92 (m, 1 H), 6.59 - 6.58 (m, 1 H), 4.46 - 4.41 (m, 2 H), 3.82 (s, 2 H), 2.76 (s, 3 H), 1.47 (t, 3 H).

[0276] Step 2: A stirred solution of ethyl 5-bromo-2-methyl-7H-furo[3,2-f]chromene-l-carboxylate (0.770 g, 2.284 mmol) in THF (15 mL) was treated with Borane dimethyl sulfide complex (2.284 mL, 4.567 mmol) at 0 °C. The RM was stirred at RT for 2 h. Then, the RM was treated with 3M NaOH (1.522 mL, 4.567 mmol) at 0 °C and stirred for 5 min. The RM was further treated with Hydrogen Peroxide (30% in water, 0.518 mL, 4.567 mmol) at 0 °C and stirred for 45 min. The RM was diluted with EtOAc (20 mL) and stirred for 10 min. The layers were separated, and the aqueous layer was again extracted with EtOAc (2 x 10 mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-20% EtOAc in PE to afford ethyl 7-hydroxy-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-1-carboxylate (Int-B029) (570 mg, 70%).1H NMR (400 MHz, CDCl3) δ ppm: 7.26 (t, 1 H), 7.15 (d, 1 H), 4.76 - 4.74 (m, 1 H), 4.43 - 4.35 (m, 2 H), 3.64 - 3.58 (m, 1 H), 3.45 - 3.40 (m, 1 H), 3.30 - 3.24 (m, 1 H), 2.99 - 2.95 (m, 1 H), 2.74 - 2.71 (m, 4 H), 1.42 (t, 3 H).Synthesis of ethyl 2-methyl-7-oxo-7.8-dihydro-6H-indeno[5,4-b]furan-1-carboxylate (Int-B030) and ethyl 7,7-difluoro-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-1-carboxylate (Int-B031)

[0277] Step 1: A stirred solution ethyl 7-hydroxy-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (Int-B029) (100 mg, 0.192 mmol) in DCM (3 mL) was treated with Dess-Martin periodinane (325.9 mg, 0.384 mmol) at 0 °C. The RM was stirred at RT for 2 h. The RM was quenched with ice-cold sodium bicarbonate solution (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layer was washed with water (20 mL), and20308-WO-PCT / 30175-102410 81brine (20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-20% EtOAc in PE to afford ethyl 2-methyl-7-oxo-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (Int-B030) (40 mg, 60%).1H NMR (400 MHz, CDCl3) δ ppm: 7.36 (d, 1 H), 7.21 (d, 1 H), 4.39 (q, 2 H), 3.99 (s, 2 H), 3.62 (s, 2 H),2.76 (s, 3 H), 1.43 (t, 3 H).

[0278] Step 2: A stirred solution of ethyl 2-methyl-7-oxo-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (Int-B030) (40 mg, 0.155 mmol) in DCM (2 mL) was treated with DAST (0.307 mL, 2.323 mmol) at 0 °C. The RM was stirred at RT for 16 h. The RM was quenched with ice-cold sodium bicarbonate solution (20 mL) and extracted with DCM (2 x 20mL). The combined organic layer was washed with water (20 mL), and brine (20 mL), dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0 -10% EtOAc in PE to afford ethyl 7,7-difluoro-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-1-carboxylate (Int-B031) (30 mg, 69%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.31 (d, 1 H), 7.11 (d, 1 H), 4.40 (q, 2 H), 3.88 (t, 2 H), 3.48 (t, 2 H), 2.74 (s, 3 H), 1.43 (t, 3 H).Synthesis of ethyl 7-methoxy-2-methyl-7.8-dihydro-6H-indeno[5.4-b] furan- 1 -carboxylate (Int-B034)

[0279] Step 1: A stirred solution of ethyl 7-hydroxy-2-methyl-7,8-dihydro-6H-indeno[5,4-b] furan-1-carboxylate (Int-B029) (700 mg, 2.689 mmol) in THF (40 mL) was treated with methyl iodide (16.742 mL, 268.932 mmol) at 0 °C and stirred for 15 min. Then the RM was treated with NaH (60%, 309.272 mg, 8.068 mmol) at 0 °C. The RM was stirred for 16 h at RT. The RM was quenched with NH4CI solution (20 mL) and organic parts were extracted with EtOAc (2 x 20 mL). The combined organic layer was washed with water (2 x 10 mL), brine (10 mL) dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-20% EtOAc in PE to afford ethyl 7-methoxy-2-methyl-7,8-dihydro-6H-indeno[5,4-b] furan- 1 -carboxylate (Int-B034) (520 mg, 70%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.31 - 7.22 (m, 1 H), 7.14 (d, 1 H), 4.40 - 4.36 (m, 2 H), 4.28 (t, 1 H), 3.61 - 3.55 (m, 1 H), 3.47 - 3.40 m, 4 H), 3.23 - 3.18 (m, 1 H), 3.06 - 3.01 (m, 1 H) 2.72 (s, 3 H), 1.45 - 1.40 (m, 3 H).Synthesis of ethyl 7-(allyloxy)-2-methyl-7.8-dihvdro-6H-indeno[5.4-b] furan- 1 -carboxylate (Int-B036) and ethyl 7-(cvclopropylmethoxy)-2-methyl-7.8-dihvdro-6H-indeno [5,4-b]furan- 1 -carboxylate (Int-B037)

[0280] Step 1: A stirred solution of ethyl 7-hydroxy-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (Int-B029) (1 g, 3.842 mmol) in THF (15 mL) at 0 °C was treated with 3 -iodoprop- 1-ene (3.227 g, 19.209 mmol) and stirred for 10 min. Then, the RM was treated with NaOH (0.461 gm, 11.526 mmol) at 0 °C. The RM was stirred at RT for 16 h. The RM was quenched with ice-cold solution of ammonium chloride (50 mL) and organic parts were extracted with EtOAc (2 x 100 mL). The combined organic layer was washed with water (2 x 50 mL), brine (50 mL) dried over Na2SO4and concentrated under reduced pressure. The residue was purified20308-WO-PCT / 30175-102410 82by FCC on silica gel using a gradient of 0-10% EtOAc in PE to afford ethyl 7-(allyloxy)-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate(Int-B036) (550 mg, 50%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.23 (d, 1 H), 7.11 (d, 1 H), 5.96 - 5.92 (m, 1 H), 5.23 - 5.27 (m, 1 H), 5.19 - 5.15 (m, 1 H), 4.45 - 4.36 (m, 3 H), 4.09 -4.06 (m, 2 H), 3.65 - 3.59 (m, 1 H), 3.46- 3.41 (m, 1 H), 3.24 - 3.19 (m, 1 H), 3.08 - 3.03 (m, 1 H), 2.72 (s, 3 H), 1.45 - 1.41 (m, 3 H).

[0281] Step 2: To a stirred solution of NMU (5.663 g, 54.935 mmol) in Et2O (5 mL) was treated with 75% KOH solution (10 mL, 1.831 mmol) dropwise at 0 °C and stirred for 15 min. Then, the organic layer was separated and dried over Na2SO4. In another RBF, a stirred solution of ethyl 7-(allyloxy)-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l -carboxylate (550 mg, 1.831 mmol) in Et20 (5 mL) was treated with Palladium(II) 2,4-pentanedionate (55.785 mg, 0.183 mmol) at 0 °C followed by the above freshly prepared diazomethane solution. The RM was stirred at 0 °C for 1 h. The RM was filtered through a Celite pad, washed with EtOAc (50 mL). The filtrate was diluted with water (10 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-5% EtOAc in PE to afford ethyl 7-(cyclopropylmethoxy)-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l -carboxylate (Int-B037) (440 mg).1H NMR (400 MHz, CDCl3) 5ppm: 7.22 (d, 1 H), 7.11 (d, 1 H), 4.41 - 4.36 (m, 3 H), 3.61 - 3.60 (m, 1 H), 3.42 - 3.35 (m, 3 H), 3.24 - 3.20 (m, 1 H), 3.07 - 3.06 (m, 1 H), 2.73 (s, 3 H), 1.44 - 1.42 (m, 3 H), 1.08 - 1.07 (m, 1 H), 0.55 - 0.51 (m, 2 H), 0.24 - 0.20 (m. 2 H).Synthesis of ethyl 6.6-difluoro-2-methyl-6H-indeno[5.4-b]furan-l-carboxylate (Int-B039)

[0282] Step 1: A solution of ethyl 6-hydroxy-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (Int-B028) (4 g, 15.368 mmol) in DCM (100 mL) was treated with MnO2(26.718 g, 307.351 mmol). The RM was stirred at RT for 3 h. The RM was filtered through a Celite pad, and washed with DCM (250 mL). The combined organic layer was concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-5% EtOAc in hexane to afford ethyl 2-methyl-6-oxo-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (3.5 g, 88%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.72 (d, 1 H), 7.43 (d, 1 H), 4.43 (q, 2 H), 3.59 -3.56 (m, 2 H), 2.79 (s, 3 H), 2.78 - 2.73 (m, 2 H), 1.45 (t, 3 H).

[0283] Step 2: A solution of ethyl 2-methyl-6-oxo-7,8-dihydro-6H-indeno[5,4-b]furan-l -carboxylate (1.5 g, 5.808 mmol) in Toluene (50 mL) was treated with ethane- 1,2-dithiol (0.977 mL, 11.616 mmol), and PTSA monohydrate (110.476 mg, 0.581 mmol) atRT. The RM was stirred at 100 °C for 3 h using Dean-Stark condenser. The RM was poured into water (250 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with brine (25 mL), dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-3% EtOAc in hexane to afford ethyl 2-methyl-7,8-dihydrospiro[indeno[5,4-b]furan-6,2'-[l,3]dithiolane]-l-carboxylate (1.2 g, 61%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.52 (d, 1 H), 7.32 (d, 1 H), 4.40 (q, 2 H), 3.56 - 3.42 (m, 4 H), 3.40 (t, 2 H), 2.76 (t, 2 H), 2.73 (s, 3 H), 1.4220308-WO-PCT / 30175-102410 83(t, 3 H).

[0284] Step 3: A solution of DBDMH (2.394 g, 8.372 mmol) in DCM (10 mL) was treated with HF•pyr (65-70%, 0.830 g, 8.372 mmol) at -78 °C and stirred for 10 min. The RM was treated with a solution of ethyl 2-methyl-7,8-dihydrospiro[indeno[5,4-b]furan-6,2'-[l,3]dithiolane]-l-carboxylate (700 mg, 2.093 mmol) in DCM (10 mL). The RM was stirred at -78 °C for 2 h. Then, the RM was stirred for 16 h at RT. The RM was diluted with water (50 mL), acidified with 1N HCl (pH ~ 4), and extracted with EtOAc (3 x 25 mL). The combined organic layer was washed with water (20 mL), brine (20 mL), dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-3% EtOAc in hexane to afford ethyl 7-bromo-6,6-difluoro-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (600 mg). The compound was used in the next step without further purification.

[0285] Step 4: A solution of ethyl 7-bromo-6,6-difluoro-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (1.2 g, 3.341 mmol), in DCM (50 mL) was treated with DBU (2.543 g, 16.705 mmol) and stirred at RT for 16 h. The RM was diluted with DCM (25 mL), washed with 1N HCl (5 mL), water (5 mL), brine (5 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-3% EtOAc in hexane to afford ethyl 6,6-difluoro-2-methyl-6H-indeno[5,4-b]furan-l-carboxylate (Int-B039) (650 mg, 69%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.72 (d, 1 H), 7.40 (d, 1 H), 7.27 (d, 1 H), 6.21 (d, 1 H), 4.42 (q, 2 H), 2.76 (s, 3 H), 1.44 (t, 3 H).Synthesis of ethyl 7-(2-methoxyethoxy)-2-methyl-7.8-dihvdro-6H-indeno[5.4-b] furan- 1 -carboxylate (Int-B041)

[0286] Step 1: A solution of ethyl 7-(allyloxy)-2-methyl-7,8-dihydro-6H-indeno[5,4-b] furan- 1 -carboxylate (Int-B036) (1.4 g, 4.664 mmol) in THF (15 mL) and water (15 mL) was treated with Osmium Tetroxide ((4% in Water), 1.186 mL, 0.187 mmol) at 0 °C for 5 min. Then, the RM was treated with sodium metaperiodate (1.995 g, 9.329 mmol) at 0 °C. The RM was stirred at RT for 1 h. The RM was quenched with water (30 mL) and organic parts were extracted with EtOAc (2 x 20 mL). The combined organic layer was washed with brine (20 mL), dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-50% EtOAc in PE to afford ethyl 2-methyl-7-(2-oxoethoxy)-7,8-dihydro-6H-indeno[5,4-b] furan- 1 -carboxylate (815 mg, 58%).

[0287] Step 2: A solution of ethyl 2-methyl-7-(2-oxoethoxy)-7,8-dihydro-6H-indeno[5,4-b] furan- 1 -carboxylate (815 mg, 2.698 mmol) in MeOH (10 mL) was treated with Sodium Borohydride (204 mg, 5.395 mmol) at 0 °C. The RM was stirred at RT for 10 min. The RM was quenched with saturated ammonium chloride solution (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layer was washed with water (2 x 10 mL), brine solution (20 mL) and dried over Na2SO4. filtered and concentrated under reduced pressure to afford ethyl 7-(2-hydroxyethoxy)-2-methyl-7,8-dihydro-6H-indeno[5,4-b] furan- 1 -carboxylate (730 mg, 89%). The crude compound was used in the next step without further purification. 'H NMR (400 MHz, CDC13) δ ppm: 7.24 (d, 1 H), 7.12 (d, 1 H), 4.44 - 4.37 (m, 3 H), 3.75 - 3.71 (m, 2 H), 3.66 - 3.60 (m, 3 H), 3.51 - 3.48 (m, 1 H), 3.28 -3.22 (m, 1 H), 3.10 - 3.07 (m, 1 H), 2.73 (s, 3 H), 1.99 (t, 1 H), 1.43 (t, 3 H)20308-WO-PCT / 30175-102410 84

[0288] Step 3: A stirred solution of ethyl 7-(2-hydroxyethoxy)-2-methyl-7,8-dihydro-6H-indeno[5,4-b] furan-1-carboxylate (730 mg, 2.399 mmol) in THF (10 mL) was treated with methyl iodide (2.986 mL, 47.972 mmol) at 0 °C and stirred for 5 min. Then, the RM was treated with NaH (60%, 275.841 mg, 7.196 mmol) at 0 °C. The RM was stirred for 16 h at RT. The RM was quenched with saturated ammonium chloride solution (1 x 20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layer was washed water (2 x 10 mL) with brine (10 mL), dried over Na2SO4. filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-20% EtOAc in PE to afford ethyl 7-(2-methoxyethoxy)-2-methyl-7,8-dihydro-6H-indeno[5,4-b] furan-1 -carboxylate (Int-B041)(640 mg, 84%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.22 (d, 1 H), 7.11 (d, 1 H), 4.44 - 4.36 (m, 1 H), 4.38 (q, 2 H), 3.71 - 3.65 (m, 3 H), 3.57 (t, 2 H), 3.46 (d, 1 H), 3.39 (s, 3 H), 3.26 - 3.20 (m, 1 H), 3.10 - 3.05 (m, 1 H), 2.72 (s, 3 H), 1.43 (t, 3 H).Synthesis of ethyl 6,6-difluoro-2-methyl-7,8-dihvdro-6H-indeno[5,4-b]furan-l-carboxylate (Int-B043)

[0289] Step 1: A solution of ethyl 6,6-difluoro-2-methyl-6H-indeno[5,4-b]furan-l-carboxylate (Int-B039) (250 mg, 0.898 mmol) in EtOH (10 mL) was treated with 10% Pd / C (100 mg) and stirred at RT under H2 balloon pressure for 6 h. The RM was filtered through a Celite pad and washed with EtOH (25 mL). The filtrate was concentrated under reduced pressure. The residue was triturated with 10% Et2O / n-pentane. The solid was filtrated and dried under high vacuum to afford ethyl 6,6-difluoro-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylate (Int-B043) (180 mg, 71%) as an off white solid. 'H NMR (400 MHz, CDCl3) δ ppm: 7.47 (d, 1 H), 7.41 (d, 1 H), 4.40 (q, 2 H), 3.50 - 3.46 (m, 2 H), 2.76 (s, 3 H), 2.70 - 2.60 (m, 2 H), 1.43 (t, 3 H).19F NMR (376 MHz, CDCl3) δ ppm: -83.33 (t).Synthesis of ethyl 6.6-diflnoro-2-methyl-6.6a,7.7a-tetrahydrocvclopropa [2,3] indeno [5,4-b] furan-1 -carboxylate(Int-B045)

[0290] Step 1: To a stirred solution of KOH (75% in water) (20 mL) in Et2O (25 mL) was added NMU (4.6 g, 44.923 mmol) at 0 °C. After 15 min, the organic layer was separated and dried over Na2SO4. In another RBF, a stirred solution of ethyl 6,6-difluoro-2-methyl-6H-indeno[5,4-b] furan-1 -carboxylate (0.5 g, 1.797 mmol) and Pd(Acac)2 (0.27 g, 0.898 mmol) in Et20 (25 mL) at 0 °C was treated with freshly prepared Diazomethane in Et20. The RM was stirred for 16 h at RT. The RM was diluted with water (25 mL) and extracted with Et20 (3 x 20 mL). The combined organic layer was dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-3% EtOAc in PE to afford ethyl 6,6-difluoro-2-methyl-6,6a,7,7a-tetrahydrocyclopropa [2,3] indeno[5,4-b] furan-1 -carboxylate (Int-B045) (0.52 g, 99%). 'H NMR (400 MHz, CDCl3) δ ppm: 7.37 - 7.32 (m, 2 H), 4.47 - 4.38 (m, 2 H), 3.49 - 3.39 (m, 1 H), 2.76 (s, 3 H), 2.37 - 2.31 (m, 1 H), 1.45 - 1.35 (m, 4 H), 0.90 - 0.98 (m, 1 H).Synthesis of 2-methyl-8,9-dihydro-7H-luro[3,2-f|chromene-l-carboxylic acid (Int-B009)20308-WO-PCT / 30175-102410Int-B008 Int-B009

[0291] Step 1: A stirred solution of ethyl 2-methyl-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxylate (Int-B008) (120 mg, 0.461 mmol) in THF (2 mL), MeOH (1 mL), and Water (1 mL) was treated with LiOH. H2O (110.402 mg, 4.610 mmol) at RT. The RM was stirred at 50 °C 16 h. The RM was concentrated under reduced pressure. The residue was acidified with saturated Citric acid (pH ~3). The solid was filtered, washed with water (10 mL) and dried under high vacuum suction to afford 2-methyl-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxylic acid (Int-B009) (90 mg, 84%).1H NMR (400 MHz, MeOD) δ ppm: 7.13 (d, 1 H), 6.72 (d, 1 H), 4.14- 4.12 (m, 2 H), 3.12 (t, 2 H), 2.62 (s, 3 H), 2.00 - 1.94 (m, 2 H).

[0292] The following Int. were prepared in a manner similar to Int-B009 (use of appropriate SM (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art):Table 6: Exemplary intermediateSynthesis of 7-(methoxymethyl)-2-methyl-7,8-dihvdro-6H-indeno[5,4-b]furan-l-carboxylic acid (Int-BOll)20308-WO-PCT / 30175-102410 86o oInt-B010 Int-B011

[0293] Step 1: To a stirred solution of ethyl 7-(methoxymethyl)-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-1-carboxylate (Int-BOlO) (320 mg, 1.110 mmol) ina mixture of THF (5 mL), MeOH (2.5 mL) and H2O (2.5 mL) was added NaOH (443.916 mg, 11.098 mmol) at RT. The RM was stirred at 70 °C for 16 h. The RM was concentrated under reduced pressure. The residue was acidified (pH~2-3) with citric acid solution and extracted with EtOAc (2 x 25 mL). The combined organic layer was dried over Na2SO4and concentrated under reduced pressure to afford the desired compound (200 mg) as a pale-yellow gummy. The compound was used directly for the next step without further purification.1H NMR (400 MHz, DMSO-de) δ ppm: 12.74 (br s, 1 H), 7.31 (d, 1 H), 7.13 (d, 1 H), 3.40 - 3.34 (m, 1 H), 3.29 - 3.24 (m, 4 H), 3.04 - 2.98 (m, 3 H), 2.71 - 2.67 (m, 6 H).

[0294] The following Int. was prepared in a manner similar to Int-BOll (use of appropriate SM (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art):Table 7: Exemplary intermediateSynthesis of potassium 6.6-difluoro-2-methyl-6.7.8.9-tetrahvdronaphtho[2.1-b]furan-l-carboxylate (Int-B027)Int-B026 Int-B027

[0295] Step 1: A stirred solution of ethyl 6,6-difluoro-2-methyl-6,7,8,9-tetrahydronaphtho[2,l-b]furan-l-carboxylate (Int-B026) (100 mg, 0.340 mmol) in THF (3.0 mL) was treated with potassium trimethylsilanolate (130 mg, 1.01 mmol) at RT. The RM was stirred at 90 °C for 3 h. The RM was concentrated under reduced pressure. The residue was triturated with n-pentane (2 x 5 mL) and dried under reduced pressure to afford potassium 6,6-difluoro-2-methyl-6,7,8,9-tetrahydronaphtho[2,l-b]furan-l-carboxylate (Int-B027) (100 mg, 96%).19F NMR (376 MHz, DMSO-d6) δ ppm: -78.32 (t).

[0296] The following Int. were prepared in a manner similar to Int-B027 (use of appropriate SM (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art):Table 8: Exemplary intermediate20308-WO-PCT / 30175-102410 87EXAMPLE OF THE PREPARATION OF COMPOUNDS OF THE INVENTIONExample 1 - Synthesis of (S)-N-(l-amino-3-hvdroxy-2-methyl-l-oxopropan-2-yl)-2-methylnaphtho[2,l-b]furan- 1-carboxamide (Cpd 001)

[0297] Step 1: A solution of 2-methylnaphtho[2,l-b]furan-l-carboxylic acid (Int-BOOl) (150 mg, 0.663 mmol) in DMF (3 mL) was treated with HATU (378 mg, 0.995 mmol), DIPEA (0.578 mL, 3.31 mmol) at RT and stirred for 10 min. (S)-2-amino-3-((tert-butyldimethylsilyl)oxy)-2-methylpropanamide (Int-AOOl-Enl) (169 mg, 0.729 mmol) was added and stirred at RT for 16 h. The RM was diluted with cold water (50 mL), extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with sat. NaHCO3 solution (20 mL), brine (20 mL), dried over Na2SO4. filtered and concentrated under reduced pressure to afford (S)-N-(l-amino-3-((tert-butyldimethylsilyl)oxy)-2 -methyl- 1 -oxopropan-2-yl)-2 -methylnaphtho [2, 1 -b]furan- 1 -carboxamide (210 mg, 71%). Tl NMR (400 MHz, DMSO-de) δ ppm: 8.52 - 8.49 (m, 1 H), 8.08 (bs, 1 H), 8.01 - 7.99 (m, 1 H), 7.81 (d, 1 H), 7.74 (d, 1 H), 7.51 - 7.48 (m, 2 H), 7.29 (bs, 2 H), 4.12 (s, 2 H), 2.65 (s, 3 H), 1.53 (s, 3 H), 0.86 (s, 9 H), 0.06 (s, 6 H).

[0298] Step 2: A solution of HF-Pyr. (65%) (0.66 mL, 4.76 mmol) in THF (5 mL) was treated withPyr (0.384 mL, 4.76 mmol) at 0 °C and stirred for 10 min. A solution of (S)-N-(l-amino-3-((tert-butyldimethylsilyl)oxy)-2-methyl-l-oxopropan-2-yl)-2-methylnaphtho[2,l-b]furan-l-carboxamide (210 mg, 0.477 mmol) in THF (3.0 mL) was added at 0 °C and stirred at RT for 16 h. The RM was concentrated and the resulting crude residue was basified with sat. NaHCOi solution. The solid was filtered and washed with n-pentane. The collected pure precipitate fraction was dried using high vacuum to afford (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2-methylnaphtho [2, l-b]furan- 1-carboxamide (Cpd 001) (115 mg, 73%).

[0299] The following compounds were prepared in a manner similar to compound Cpd 001 (by use of appropriate benzofuran-3 -carboxylic derivative (chiral or racemic) and appropriate amine (chiral or racemic) in step-1 and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art). The reagents are commercially available or synthesized by procedures known in the art or synthesized as described above.Table 9: Examples preparation20308-WO-PCT / 30175-102410 88Example 2 - Synthesis of N-(l,3-dihvdroxy-2-methylpropan-2-yl)-2,8,8-trimethyl-8,9-dihvdro-7H-furo[3,2-f|chromene-l-carboxamide (Cpd 002)

[0300] Step 1: A stirred solution of 2,8, 8-trimethyl-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxylic acid (Int-B003) (90 mg, 0.346 mmol) and 2-amino-2-methylpropane- 1,3 -diol [CAS: 115-69-5] (45.5 mg, 0.432 mmol) in DMF (5 mL) was treated with DIPEA (0.3 mL, 1.729 mmol) followed by HATU (197 mg, 0.519 mmol) at RT. The RM was stirred at RT for 16 h. The RM was diluted with water (25 mL) and extracted with EtOAc (2 x 30 mL). The combined organic extracts were washed with water (20 mL) and brine (20 mL), dried over Na2SO4. filtered and concentrated under reduced pressure. The residue was purified by FCC on silica gel using a gradient of 0-100% EtOAc in PE to afford the desired compound (100 mg, LCMS: 78%) as an off-white solid. The residue was purified by Prep. HPLC [Prep. HPLC conditions: Mobile phase: lOmM ABC in Water, Mobile phase B: ACN; Column: YMC TRIART (25 x 150) x 10 pm; FLOW: 18 ml / min; Method: (T in min. / % of B): 0 / 35, 2 / 35, 10 / 60, 11.8 / 60, 12 / 98, 13.8 / 98, 14 / 35, 17 / 35; Temperature: RT.]. The desired fractions were evaporated and lyophilized to afford N-(l,3-dihydroxy-2-methylpropan-2-yl)-2,8,8-trimethyl-8,9-dihydro-7H-furo[3,2-f]chromene-l-carboxamide (Cpd 002) (48 mg, 40%).

[0301] The following compounds were prepared in a manner similar to compound Cpd 002 (by use of appropriate benzofuran-3 -carboxylic derivative (chiral or racemic) and appropriate amine (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art). The reagents are commercially available or synthesized by procedures known in the art or synthesized as described above.Table 10: Examples preparation20308-WO-PCT / 30175-102410 89Example 3 - Synthesis of (S)-N-(l-amino-3-hvdroxy-2-methyl-l-oxopropan-2-yl)-7,7-difluoro-2-methyl-7,8-dihvdro-6H-indeno[5,4-b]furan-l-carboxamide (Cpd 018)

[0302] Step 1: A stirred solution of 7, 7-difluoro-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l-carboxylic acid (Int-B032) (30 mg, 0.119 mmol) in DMF (3 mL), was treated with HATU (81.408 mg, 0.214 mmol), DIPEA (0.104 mL, 0.595 mmol) at 0°Cand stirred for 10 min. Then, the RM was treated with (S)-2-amino-3 -hydroxy -2-methylpropanamide-HCl (Int-A002-Enl) (27.476 mg, 0.178 mmol) at 0°C. The RM was stirred for 16 h at RT. The RM was dilute with water (30 mL), extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine (30 mL), dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was purified by Prep. HPLC [Prep. HPLC conditions: Mobile phase: lOmM Ammonium Hydroxide in Water, Mobile phase B: ACN; Column: YMC TRIART ACTUS C18 (20 x 150) x 5 pm; FLOW: 14 ml / min: Method: (T in min. / % of B): 0 / 20, 2 / 20, 10 / 40, 14 / 40, 14.01 / 99, 17 / 99, 17.1 / 20, 19 / 20; Temperature: RT.]. The desired fractions were evaporated and lyophilized to afford (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7,7-difluoro-2-methyl-7,8-dihydro-6H-indeno[5,4-b]furan-l -carboxamide (Cpd 018) (16 mg, 38%).

[0303] The following compounds were prepared in a manner similar to compound Cpd 018 (by use of appropriate benzofuran-3 -carboxylic derivative (chiral or racemic) and appropriate amine (chiral or racemic) and purification methods (including chiral HPLC or chiral SFC) known to the person skilled in the art). The reagents are commercially available or synthesized by procedures known in the art or synthesized as described above.Table 11: Examples preparation

[0304]

[0305] Further incorporated by reference herein for their synthetic teachings are PCT / US2024 / 056806, filed Nov.21, 2024, and provisional application No. 63 / 790,784, filed April 18, 2025.

[0306] Table 12: Analytical data for exemplary compounds.20308-WO-PCT / 30175-102410 9020308-WO-PCT / 30175-102410 9120308-WO-PCT / 30175-102410 92

[0307] Table 13: Chiral analytical data for exemplary compounds.20308-WO-PCT / 30175-102410 93Part B20308-WO-PCT / 30175-102410 94Example 4- Monitoring the TRPM3 ion channel driven Ca2+ uptake.

[0308] In order to monitor the inhibition of the mouse TRPM3a2 (mTRPM3) ion channel by the compounds of the invention, a cellular system making use of an mTRPM3alpha2 or hTRPM3 overexpressing cell line (flip-in HEK293) was used. The TRPM3 channel was stimulated / opened with Pregnenolone sulfate (PS) (50pM) which results in Ca2+influx.

[0309] For mTRPM3, the intracellular Ca2+was measured with a Calcium responsive dye, Fluor-4 AM ester (Invitrogen). Cells were cultured until a confluence of 80-90%, washed with Versene (Invitrogen) and detached from the surface by a short incubation with 0.05% Trypsin (Invitrogen). The trypsination process was stopped by the addition of complete cell culture medium (DMEM, glutamax, 10%FCS, NEAA, Pen-Strep). Cells were collected and resuspended in Krebs buffer without Calcium at RT.

[0310] Prior the cell seeding (±2000 cells / well into a black, 384 well plate (Greiner)) the diluted compound was added in the assay plate, together with the PS dissolved in Krebs buffer containing Calcium. This resulted in a 2.4mM Ca2+assay solution. Directly after cell addition the plates were read on an Envision fluorescence reader (Perkin Elmer) by an Excitation of 485nM and emission at 535nM.

[0311] Channel inhibition was calculated compared to a non-PS stimulated control versus a condition stimulated with PS (50pM) with vehicle. The ability of the compounds of the invention to inhibit this activity was determined as: Percentage inhibition = [1-((RFU determined for sample with test compound present - RFU determined for sample with positive control inhibitor) divided by (RFU determined in the presence of vehicle - RFU determined for sample with positive control inhibitor))] * 100.

[0312] The activities of the Example compounds Cpd 1 -29 tested are depicted in the table below. All tested compounds show an activity in the Fluo-4 AM assay. The activity ranges A, B and C refer to IC50 values in the Fluo-4 AM assay as follows: “A”: ICso <.05 pM; “B”:.05 pM < ICso < 0.5 pM and “C”: ICso > 0.5 pM.Table 14: Activities for exemplary compounds20308-WO-PCT / 30175-102410 95

[0313] Throughout this application, various publications are referenced by author name and date, or by patent number or patent publication number. The disclosures of these publications are hereby incorporated in their entireties by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein. However, the citation of a reference herein should not be construed as an acknowledgement that such reference is prior art to the present invention.

[0314] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims. For example, pharmaceutically acceptable salts other than those specifically disclosed in the description and Examples herein can be employed. Furthermore, it is intended that specific items within lists of items, or subset groups of items within larger groups of items, can be combined with other specific items, subset groups of items or larger groups of items whether or not there is a specific disclosure herein identifying such a combination.20308-WO-PCT / 30175-102410 96

Claims

CLAIMS1. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereofwherein:R1represents -F, -Cl, -Br, -I, -CN, -Rw, -ORW, -OC(=O)RW, -NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, - S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX,R3represents -OH or -RY;Q represents 5-8-membered cycloalkyl, saturated or unsaturated, 5-8-membered heterocycloalkyl, saturated or unsaturated, 6-8-membered aryl, or 5-8-membered heteroaryl;n is an integer ranging from 0 to 6;R6and R7independently of one another represent -F, -Cl, -Br, -I, -CN, -NO2, -SF5, -Rw, -ORW, -OC(=O)RW,- NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX;R8independently at each occurrence represents -F, -Cl, -Br, -I, -CN, -NO2, -SF5, =O, -RQ, -ORY, -OC(=O)RY,- NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ, optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11,or two occurrences of R8together form 3-6-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; 3-6-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; phenyl, unsubstituted, mono- or polysubstituted with R11; or 5-6- membered heteroaryl, unsubstituted, mono- or polysubstituted with R11;wherein Rwand Rxindependently of one another in each case independently represent-H,-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11,-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11,3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11, wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce- heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11, or 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11, wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce- heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RQin each case independently represents20308-WO-PCT / 30175-102410 97-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11, -Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11,3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11, wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11, 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11, wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11, 6-14-membered aryl, unsubstituted, mono- or polysubstituted with R11; wherein said 6-14-membered aryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11, or5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11, wherein said 5-14-membered heteroaryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RYand Rzindependently of one another in each case independently represent -H or -RQ, orRYand Rztogether form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted with R11;and wherein R11is independently selected from, at each occurrence, -F, -Cl, -Br, -I, -CN, -Ci-e-alkyl, -CFs, -CF2H, -CFH2, -CF2Cl, -CFCl2, -Ci-e-alkylene-CFs, -Ci-6-alkylene-CF2H, -Ci-e-alkylene-CFFF, -Ci-6-alkylene-O-CF3, -Ci-6-alkylene-O-CF2H, -Ci-e-alkylene-O-CFFF, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3,-Ci-6-alkylene-N(Ci-6-alkyl)-Ci-6-alkylene-CF3, -C(=O)-Ci-6-alkyl, -Ci-6-alkylene-C(=O)-Ci-6-alkyl, -C(=O)OH, -Ci-e-alkylene-C(=O)-OH, -C(=O)-OCi-6-alkyl, -Ci-6-alkylene-C(=O)-OCi-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3,-C(=O)-NH2, -Ci-6-alkylene-C(=O)-NH2, -C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-C(=O)-NH(Ci-6-alkyl),-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-C(=O)-N(Ci-6-alkyl)2, -C(=O)-NH(OH), -Ci-6-alkylene-C(=O)-NH(OH),-OH, -Ci-6-alkylene-OH, =0, -OCF3, -OCF2H, -OCFH2, -OCF2Cl, -OCFCl2, -O-Ci-6-alkyl, -Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-e-alkylene-NFF, -O-Ci-6-alkylene-NH-Ci-6-alkyl, -O-Ci-6-alkylene-N(Ci-6-alkyl)2, -O-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-O-C(=O)-Ci-6-alkyl, -0-C(=0)-0-Ci-6-alkyl, -Ci-6-alkylene-O-C(=O)-O-Ci-6-alkyl, -O-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-O-C(=O)-NH(Ci-6-alkyl), -O-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-C(=O)-N(Ci-6-alkyl)2, -O-S(=O)2-NH2, -Ci-6-alkylene-O-S(=O)2-NH2, -O-S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-O-S(=O)2-NH(Ci-6-alkyl), -O-S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-S(=O)2-N(Ci-6-alkyl)2, -NH2, -NO, -NO2, -Ci-6-alkylene-NH2, -NH(Ci-6-alkyl), -N(3-14-membered cycloalkyl)(Ci-6-alkyl), -N(Ci-6-alkyl)-Ci-6-alkylene-OH, -N(H)-Ci-6-alkylene-OH, -Ci-6-alkylene-NH(Ci-6-alkyl), -N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)2, -NH-C(=0)-Ci-6-alkyl, -Ci-e-alkylene-NH-C(=0)-Ci-6-alkyl, -NH-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-NH-C(=O)-O-Ci-6-alkyl, -NH-C(=O)-NH2, -Ci-e-alkylene-NH-C(=O)-NH2, -NH-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-NH-C(=O)-NH(Ci-6-alkyl), -NH-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-C(=O)-N(Ci-6-alkyl)2, -N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -Ci-e-alkylene-N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -N(Ci-6-alkyl)-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=0)-0-Ci-6-alkyl, -N(Ci-6-alkyl)-C(=O)-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH2, -N(Ci-6-alkyl)-C(=0)-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -NH-S(=O)2OH, -Ci-6-alkylene-NH-S(=O)2OH, -20308-WO-PCT / 30175-102410 98NH-S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-NH-S(=O)2-Ci-6-alkyl, -NH-S(=O)2-O-Ci-6-alkyl, -Ci-e-alkylene-NH- S(=O)2-O-Ci-6-alkyl, -NH-S(=O)2-NH2, -Ci-6-alkylene-NH-S(=O)2-NH2, -NH-S(=O)2-NH(Ci-6-alkyl), -Ci-e- alkylene-NH-S(=O)2-NH(Ci-6-alkyl), -NH-S(=O)2N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-S(=O)2N(Ci-6-alkyl)2, - N(Ci-6-alkyl)-S(=O)2-OH, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-OH, -N(Ci-6-alkyl)-S(=O)2-Ci-6-alkyl, -Ci-e- alkylene-N(Ci-6-alkyl)-S(=O)2-Ci-6-alkyl, -N(Ci-6-alkyl)-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)- S(=O)2-O-Ci-6-alkyl, -N(Ci-6-alkyl)-S(=O)2-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH2, -N(Ci-6-alkyl)- S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-S(=O)2-N(Ci-6- alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -SH, =S, -SF5, -SCF3, -SCF2H, -SCFH2, -S-Ci-e- alkyl, -Ci-6-alkylene-S-Ci-6-alkyl, -S(=0)-Ci-6-alkyl, -Ci-6-alkylene-S(=O)-Ci-6-alkyl, -S(=O)2-Ci-6-alkyl, -Ci- 6-alkylene-S(=O)2-Ci-6-alkyl, -S(=0)2-0H, -Ci-6-alkylene-S(=O)2-OH, -S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene- S(=O)2-O-Ci-6-alkyl, -S(=O)2-NH2, -Ci-6-alkylene-S(=O)2-NH2, -S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene- S(=O)2-NH(Ci-6-alkyl), -S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-S(=O)2-N(Ci-6-alkyl)2, 3-14-membered cycloalkyl, -Ci-6-alkylene-(3-14-membered cycloalkyl), 3 to 14-membered heterocycloalkyl, -Ci-6-alkylene- (3 to 14-membered heterocycloalkyl), -phenyl, -Ci-6-alkylene-phenyl, 5 to 14-membered heteroaryl, -Ci-e- alkylene-(5 to 14-membered heteroaryl), -O-(3- 14-membered cycloalkyl), -O-(3 to 14-membered heterocycloalkyl), -O-phenyl, -O-(5 to 14-membered heteroaryl), -C(=O)-(3-14-membered cycloalkyl), - C(=O)-(3 to 14-membered heterocycloalkyl), -C(=O)-phenyl, -C(=O)-(5 to 14-membered heteroaryl), - S(=O)2-(3-14-membered cycloalkyl), -S(=O)2-(3 to 14-membered heterocycloalkyl), -S(=O)2-phenyl, - S(=O)2-(5 to 14-membered heteroaryl).

2. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 1, wherein R1represents C1-3 alkyl.

3. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 2, wherein R1represents methyl.

4. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 3, wherein R3represents C-R9R9R9", where R9, R9', and R9" are independently RY, or Ci-ealkyl or Ci-eheteroalkyl optionally substituted with one or more RY5. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 3, wherein R3represents C-R9R9'R9", where one of R9, R9, and R9" is RY, or Ci-ealkyl or Ci-eheteroalkyl optionally substituted with one or more RY, and where two of R9, R9', and R9" together form a 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl, said 3-14-membered cycloalkyl, 3- 14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl optionally monosubstituted or poly substituted with one or more RY.20308-WO-PCT / 30175-102410 996. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 3, wherein R3represents C-R9R9R9", where R9, R9', and R9" are independently -H, -Ci-ealkyl, -Ci-ealkyl-OH, -Ci-ealkyl-O-CHs, -(C=0)-NH2, -(C=O)-NH- CH3, -(C=O)-N(CH3)2, -Ci-6alkyl-CF2H, and -C1-6alkyl-CF3.

7. A compound of Formula (I) a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 4 or claim 6, wherein one of R9, R9', and R9" is -H, and wherein the other two of R9, R9', and R9" are not -H.

8. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 7, wherein Q represents 5-membered cycloalkyl, 6-membered cycloalkyl, 5-membered heterocycloalkyl, 6-membered heterocycloalkyl, 6-membered aryl, 5 -membered heteroaryl, or 6 membered heteroaryl, wherein said heterocycloalkyl and heteroaryl comprise one, two, or three ring heteroatoms selected from O, S, and N.

9. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 8, wherein said heterocycloalkyl and heteroaryl comprise one or two ring heteroatoms selected from O and N.

10. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 3, 8, or 9, wherein R3represents -C-R10R10’R10”, and wherein R10, R10’, and R10” independently represent-H;-S(=O)2Ci-6-alkyl, saturated, unsubstituted, monosubstituted or poly substituted with -F;-S(=O)2(3-14-membered cycloalkyl), saturated, unsubstituted;-Ci-e-alkyl, saturated, unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -OH,, =0, -OCi-e-alkyl, -NH2, -NHCi-e-alkyl, -N(Ci-e- alkyl)2, -Ci-6-alkylene-NH2, -Ci-e-alkylene-NH-Ci-e-alkyl, -C(=O)NH2, -C(=O)-NH-Ci-3-alkyl, - C(=O)N(Ci-3-alkyl)2, -phenyl unsubstituted;3-14-membered cycloalkyl or -Ci-6-alkylene-(3- 14-membered cycloalkyl), wherein -Ci-6-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered cycloalkyl is saturated, unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -Ci-e-alkyl, -Ci-6-alkylene-NH2, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3, -Ci-e- alkylene-OH, -Ci-6-alkylene-NHC(=O)O-Ci-6-alkyl, -OH, -OCi-e-alkyl, -NH2, -N(Ci-6-alkyl)2, - NHC(=O)O-Ci-6-alkyl;3-14-membered heterocycloalkyl or -Ci-6-alkylene-(3- 14-membered heterocycloalkyl), wherein -Ci-e- alkylene- is unsubstituted or monosubstituted with -OH, wherein said 3-14-membered heterocycloalkyl in each case is selected from azetane, 1,4-oxazepane, pyrrolidine, piperidine, azepane, diazepane, tetrahydrofuran, tetrahydropyran, oxetane, morpholine, piperazine, hexahydrocyclopenta[c]pyrrole, octahydrocyclopenta[c]pyrrole, octahydropyrrolo[l,2-a]pyrazin, 8-azabicyclo[3.

2. l]octane, 9-azabicyclo-20308-WO-PCT / 30175-102410 100[3.3.1]nonane, quinuclidine, hexahydro- IH-pyrrolizine, 2-oxaspiro[3.3]heptane, 2-azaspiro[3.3]heptane, 7-azaspiro[3.5]nonane, 1,1 -dioxothiacyclohexane, in each case unsubstituted, mono- or polysubstituted with substituents independently of one another selected from the group consisting of -F, -OH, =0, -Ci-e- alkyl, -Ci-e-alkylene-CFs, -Ci-6-alkylene-OH, -Ci-6-alkylene-O-Ci-6-alkyl, -NH2, -N(Ci-6-alkyl)2, -Ci-e- alkylene-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)2, -C(=0)-Ci-6-alkyl, -C(=O)OH, -C(=0)0-Ci-6-alkyl, - C(=O)O-Ci-6-alkylene-CF3, -C(=0)NH2, -C(=0)NH(Ci-6-alkyl), -S(=O)2Ci-6-alkyl, oxetanyl, pyrimidinyl, -Ci-6-alkylene-phenyl;-phenyl unsubstituted;5-14-membered heteroaryl or -Ci-6-alkylene-(5-14-membered heteroaryl), wherein -Ci-6-alkylene- is unsubstituted or monosubstituted with -OH, wherein said 5-14-membered heteroaryl in each case is selected from the group consisting of pyridine, pyridazine, pyrazine, pyrazole, isoxazole, triazole, and [l,2,4]triazolo[4,3-a]pyrimidine, in each case unsubstituted, monosubstituted or disubstituted with substituents independently of one another selected from the group consisting of -Ci-e-alkyl, -OH.

11. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 10, wherein R8is RQ, and wherein RQis selected from halogen, Ci-Ce alkyl, Ci-Ce alkoxy, and Ci-ehaloalkyl.

12. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 11 wherein RQis selected from -F, methyl, -CH2-CH2-O-CH3, and -CH2-O-CH3.

13. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 10, wherein two R8combine to form a spiro cyclopropyl group.

14. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 13, wherein n is an integer ranging from 0 to 3.

15. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 14, wherein R6and R7independently of one another represent-H, -F, -Cl, -Br, -I, -OH, -SH, -SF5, -CN, -NO2, -C(=O)OH, -NH2,-Ci-e-alkyl, -CF3, -CHF2, -CH2F,-O-Ci-6-alkyl, -OCF3, -OCHF2, -OCH2F,-NHCi-e-alkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2;-N(Ci-6-alkyl)2 unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs,20308-WO-PCT / 30175-102410 101-N02, -C(=O)OH, -NH2, and -C(=O)NH2;-C(=0)0Ci-6-alkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2;-0C(=0)Ci-6-alkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2; or-Ci-6-heteroalkyl unsubstituted or substituted with one or more substituents independently of one another selected from -OH, =0, -F, -Cl, -Br, -I, -SH, =S, -CN, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, SFs, -NO2, -C(=O)OH, -NH2, and -C(=O)NH2.

16. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 15 wherein R6and R7represent -H.

17. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 15 wherein R6represents -H, -Cl, or -F.

18. A compound a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof selected from the group consisting ofCpd 001 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2-methylnaphtho[2,l-b]furan-l- carboxamide;Cpd 002 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-2,8,8-trimethyl-8,9-dihydro-7H-furo[3,2-f]chromene- 1 -carboxamide;Cpd 003 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2,8,8-trimethyl-8,9-dihydro-7H- furo[3,2-f]chromene-1-carboxamide;Cpd 004 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-5-fluoro-2,8,8-trimethyl-8,9-dihydro-7H-furo[3,2- f] chromene- 1 -carboxamide;Cpd 005 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-5-fluoro-2,8,8-trimethyl-8,9-dihydro- 7H-furo [3,2-f]chromene- 1 -carboxamide;Cpd 006 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2'-methyl-7'H,9'H-spiro[cyclopropane- 1,8'-furo [3,2-f]chromene] - 1 '-carboxamide;Cpd 007 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2-methyl-8,9-dihydro-7H-furo[3,2- f] chromene- 1 -carboxamide;Cpd 008 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7-(methoxymethyl)-2-methyl-7,8- dihydro-6H-indeno [5,4-b]furan- 1 -carboxamide;Cpd 009 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-7-(methoxymethyl)-2-methyl-7,8-dihydro-6H- indeno [5,4-b]furan- 1 -carboxamide;Cpd 010 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2-(2-methoxyethyl)-7-methyl-2H- furo [3,2-e] indazole-8-carboxamide;Cpd 011 - (S)-N-(1-amino-3-hydroxy-2-methyl-1-oxopropan-2-yl)-8,8-difluoro-2-methyl-8,9-dihydro-20308-WO-PCT / 30175-102410 1027H-furo [3,2-f]chromene- 1 -carboxamide;Cpd 012 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7-(methoxymethyl)-2-methyl-6, 7,8,9- tetrahy dronaphtho [2, 1 -b]furan- 1 -carboxamide;Cpd 013 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-7-(methoxymethyl)-2-methyl-6,7,8,9- tetrahy dronaphtho [2, 1 -b]furan- 1 -carboxamide;Cpd 014 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2, 6,8, 8-tetramethyl-6, 7,8,9- tetrahydrofuro [3,2-f]quinoline- 1 -carboxamide;Cpd 015 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-2'-methyl-8',9'-dihydro-7'H- spiro [cyclopropane- 1,6'-naphtho[2, l-b]furan] - l'-carboxamide;Cpd 016 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-6, 6-difluoro-2-methyl-6, 7,8,9- tetrahy dronaphtho [2, 1 -b]furan- 1 -carboxamide;Cpd 017 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-3-(2-methoxyethyl)-7-methyl-3H- furo [3,2-e] indazole-8-carboxamide;Cpd 018 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7,7-difluoro-2-methyl-7,8-dihydro- 6H-indeno [5,4-b]furan- 1 -carboxamide;Cpd 019 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-7,7-difluoro-2-methyl-7,8-dihydro-6H-indeno[5,4- b]furan- 1 -carboxamide;Cpd 020 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7 -hydroxy-2 -methyl-7,8-dihydro-6H- indeno [5,4-b]furan- 1 -carboxamide;Cpd 021 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7-methoxy-2-methyl-7,8-dihydro-6H- indeno [5,4-b]furan- 1 -carboxamide;Cpd 022 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7-(cyclopropyhnethoxy)-2 -methyl- 7, 8-dihydro-6H-indeno [5,4-b]furan- 1 -carboxamide;Cpd 023 - 7-(cyclopropylmethoxy)-N-(l,3-dihydroxy-2-methylpropan-2-yl)-2-methyl-7,8-dihydro-6H- indeno [5,4-b]furan- 1 -carboxamide;Cpd 024 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-6,6-difluoro-2-methyl-6H-indeno[5,4- b]furan- 1 -carboxamide;Cpd 025 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-7-(2-methoxyethoxy)-2-methyl-7,8- dihydro-6H-indeno [5,4-b]furan- 1 -carboxamide;Cpd 026 - N-(l,3-dihydroxy-2-methylpropan-2-yl)-7-(2-methoxyethoxy)-2-methyl-7,8-dihydro-6H- indeno [5,4-b]furan- 1 -carboxamide;Cpd 027 - (S)-N-(l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-6,6-difluoro-2-methyl-7,8-dihydro- 6H-indeno [5,4-b]furan- 1 -carboxamide;Cpd 028 - N-( 1,3 -dihydro xy-2-methylpropan-2-yl)-6,6-difluoro-2-methy 1-7, 8-dihydro-6H-indeno [5,4- b]furan-l-carboxamide; andCpd 029 - N-((S)-l-amino-3-hydroxy-2-methyl-l-oxopropan-2-yl)-6,6-difluoro-2-methyl-6,6a,7,7a- tetrahydrocyclopropa[2,3]indeno[5,4-b]furan-l-carboxamide.

19. A pharmaceutical composition comprising a compound according to any one of claims 1 to 18, and a pharmaceutically-acceptable carrier.20308-WO-PCT / 30175-102410 10320. A compound of Formula (I), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 1 to 18 or the pharmaceutical composition according to claim 19, for use in the treatment of pain or epilepsy.

21. The compound or pharmaceutical composition for use in the treatment of pain according to claim 20, wherein the pain is selected from nociceptive pain, inflammatory pain, and neuropathic pain; preferably post-operative pain or migraine pain.

22. A method of treating pain or epilepsy, comprising administering to a patient in need thereof a therapeutically effective amount of a compound as defined in any one of claims 1 to 18, or the pharmaceutical composition according to claim 19.

23. The method of claim 22, wherein the pain is selected from nociceptive pain, inflammatory pain, and neuropathic pain; preferably post-operative pain or migraine pain.

24. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / ordashed lines indicate the presence or absence of a double bond, wherein:R1represents -F, -Cl, -Br, -I, -CN, -Rw, -ORW, -OC(=O)RW, -NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, - S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX;R3is selected from -CR9R9R9", wherein R9, R9', and R9" are independently RY, or Ci-ealkyl or Ci-eheteroalkyl optionally substituted with one or more RY, optionally wherein two of R9, R9', and R9" together form a 3-14- membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl, said 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl optionally monosubstituted or polysubstituted with RY;R6, and R7independently of one another represent -F, -Cl, -Br, -I, -CN, -NO2, -SF5, -Rw, -ORW, -OC(=O)RW,- NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX;R8independently at each occurrence represents -F, -Cl, -Br, -I, -CN, -NO2, -SF5, =O, -RQ, -ORY, -OC(=O)RY,- NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ, optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted,or two occurrences of R8together form 3-6-membered cycloalkyl, saturated or unsaturated, unsubstituted,20308-WO-PCT / 30175-102410 104mono- or polysubstituted with R11; 3-6-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; phenyl, unsubstituted, mono- or polysubstituted with R11; or 5-6-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11;X1, X2and Z represent, independently of one another and in each case, an atom selected from C, N, O, and S; n is an integer ranging from 0 to 6;m is an integer ranging from 1 to 4;whereinRwand Rxindependently of one another in each case independently represent-H,-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted,-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted,3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted, wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted, or3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted, wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RQin each case independently represents-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted,-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted,3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted, wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted,3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted, wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted,6-14-membered aryl, unsubstituted, mono- or polysubstituted, wherein said 6-14-membered aryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted, or5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted, wherein said 5-14-membered heteroaryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RYand Rzindependently of one another in each case independently represent -H or -RQ,or RYand Rztogether form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted with R11;and wherein R11is independently selected from, at each occurrence, halogen, carbonyl, hydroxy, amino, cyano, nitro, sulfate, sulfonate, sulfonyl, phosphate, phosphonate, phosphonyl, Ci-Ce haloalkyl, Ci-Ce alkyl, Ci-Ce heteroalkyl, and Ci-Ce alkoxy.20308-WO-PCT / 30175-102410 10525. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 25, wherein R1is C1-C2 alkyl, C1-C2 haloalkyl, or cyclopropyl.

26. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 24 or 25, wherein R3represents C-R9R9R9", where R9, R9', and R9" are independently RY, or Ci-ealkyl or Ci-eheteroalkyl optionally substituted with one or more RY.

27. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 24 or 25, wherein R3represents C-R9R9'R9", where one of R9, R9', and R9" is RY, or Ci-ealkyl or Ci-eheteroalkyl optionally substituted with one or more RY, and where two of R9, R9', and R9" together form a 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14- membered aryl, or 5-14-membered heteroaryl, said 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl optionally monosubstituted or polysubstituted with one or more RY.

28. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 24 or 25, wherein R3represents C-R9R9'R9", where R9, R9', and R9" are independently -H, -Ci-ealkyl, -Ci-ealkyl-OH, -Ci -ealky I-O-CH3, -(C=O)-NH2, -(C=O)-NH-CH3, -(C=O)- N(CH3)2, -Ci-6alkyl-CF2H, and -Ci-ealkyl-CFs.

29. A compound of Formula (I) a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 26 or claim 28, wherein one of R9, R9', and R9" is -H, and wherein the other two of R9, R9', and R9" are not -H.

30. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 24 to 29, wherein one of X1and X2is O or N, and the other of X1and X2is C.

31. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 24 to 29, wherein X2is C.

32. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 24 to 29, wherein m is 1 and wherein Z is C or N.

33. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 24 to 29, wherein m is 2, and wherein one occurrence of Z is N or C, and the other occurrence of Z is C.20308-WO-PCT / 30175-102410 10634. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 24 to 29 wherein R6and R7independently represent - H, -Cl, or -F.

35. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 24 to 29, wherein R8is RQ, and wherein RQis selected from halogen, Ci-Ce alkyl, Ci-Ce alkoxy, and Ci-ehaloalkyl.

36. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in claim 35, wherein RQis selected from -F, methyl, -CH2-CH2-O-CH3, and -CH2-O-CH3.

37. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 24 to 34, wherein two R8combine to form a spiro cyclopropyl group.

38. A compound of Formula (II), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof, as defined in any one of claims 24 to 37, wherein n is an integer ranging from 0 to 3.

39. A compound of Formula Ill-a or Ill-b, a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereofwherein:R1represents -F, -Cl, -Br, -I, -CN, -Rw, -ORW, -OC(=O)RW, -NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, - S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX, optionally C1-C2 alkyl, C1-C2 haloalkyl, or cyclopropyl;R3is selected from -CR9R9R9", wherein R9, R9', and R9" are independently RY, or Ci-ealkyl or Ci-eheteroalkyl optionally substituted with one or more RY, optionally wherein two of R9, R9', and R9" together form a 3-14- membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl, said 3-14-membered cycloalkyl, 3-14-membered heterocycloalkyl, 5-14-membered aryl, or 5-14-membered heteroaryl optionally monosubstituted or polysubstituted with one or more RY;R6, and R7independently of one another represent -F, -Cl, -Br, -I, -CN, -NO2, -SF5, -Rw, -ORW, -OC(=O)RW,- NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX,20308-WO-PCT / 30175-102410 107R8independently at each occurrence represents -F, -Cl, -Br, -I, -CN, -NO2, -SF5, =0, -RQ, -ORY, -OC(=O)RY,-NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ, optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;or two occurrences of R8together form 3-6-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; 3-6-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; phenyl, unsubstituted, mono- or polysubstituted with R11; or 5-6-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11;A1, A2. A3, and A4represent, independently of one another and in each case, N, CH, or CR8;E represents O, S, NH, NR8,Rwand Rxindependently of one another in each case independently represent-H;-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or 3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RQin each case independently represents-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;6-14-membered aryl, unsubstituted, mono- or polysubstituted with R11; wherein said 6-14-membered aryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11; wherein said 5-14-membered heteroaryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RYand Rzindependently of one another in each case independently represent -H or -RQ,or RYand Rztogether form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted with R11;and wherein R11is independently selected from, at each occurrence, halogen, carbonyl, hydroxy, amino, cyano, nitro, sulfate, sulfonate, sulfonyl, phosphate, phosphonate, phosphonyl, Ci-Ce haloalkyl, Ci-Ce alkyl,20308-WO-PCT / 30175-102410 108Ci-Ce heteroalkyl, and Ci-Ce alkoxy.

40. A compound of Formula (IV), a stereo-isomeric form, a physiologically acceptable salt, solvate and / orpreferably for use in the treatment of pain or epilepsy or methods of treating pain or epilepsy; whereinT represents O or S;J represents N or C-R6;R1represents -F, -Cl, -Br, -I, -CN, -Rw, -ORW, -OC(=O)RW, -NRWRX, -NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX;R3represents -OH or -RY;Q represents a ring selected from 5-8-membered cycloalkyl, saturated or unsaturated, 5-8-membered heterocycloalkyl, saturated or unsaturated, 6-8-membered aryl, and 5-8-membered heteroaryl;n is an integer ranging from 0 to 10, or from 0 to 8, or from 0 to 6, or from 0 to 5, or from 0 to 4, or from 0 to 3, or from 0 to 2, or from 0 to 1;R6and R7independently represent -F, -Cl, -Br, -I, -CN, -NO2, -SF5, -RW, -ORW, -OC(=O)RW,-NRWRX, - NRWC(=O)RX, -SRW, -S(=O)RW, -S(=O)2RW, -C(=O)RW, -C(=O)ORW, or -C(=O)NRWRX,R8independently at each occurrence represents -F, -Cl, -Br, -I, -CN, -NO2, -SF5, =O, -RQ, -ORY, -OC(=O)RY,- NRYRZ, -NRYC(=O)RZ, -SRY, -S(=O)RY, -S(=O)2RY, -C(=O)RY, -C(=O)ORY, or -C(=O)NRYRZ, optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;or two occurrences of R8together form 3-6-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; 3-6-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; phenyl, unsubstituted, mono- or polysubstituted with R11; or 5-6- membered heteroaryl, unsubstituted, mono- or polysubstituted with R11;whereinRwand Rxindependently of one another in each case independently represent-H;-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce- heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or20308-WO-PCT / 30175-102410 1093-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RQin each case independently represents-Ci-Ce-alkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;-Ci-Ce-heteroalkyl, saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered cycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered cycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;3-14-membered heterocycloalkyl, saturated or unsaturated, unsubstituted, mono- or poly substituted with R11; wherein said 3-14-membered heterocycloalkyl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;6-14-membered aryl, unsubstituted, mono- or polysubstituted with R11; wherein said 6-14-membered aryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11; or5-14-membered heteroaryl, unsubstituted, mono- or polysubstituted with R11; wherein said 5-14-membered heteroaryl is optionally connected through -Ci-Ce-alkylene- or -Ci-Ce-heteroalkylene-, in each case saturated or unsaturated, unsubstituted, mono- or polysubstituted with R11;RYand Rzindependently of one another in each case independently represent -H or -RQ, or RYand Rztogether form a 4, 5, 6, 7 or 8 membered heterocycle containing 1 to 3 heteroatoms selected from N, O and S, saturated or unsaturated, unsubstituted or mono- or polysubstituted with R11;and wherein "mono- or polysubstituted with R11" in each case independently means substituted with one or more, e.g. 1, 2, 3, 4, or more substituents independently of one another selected from (that is, R11is independently at each occurrence selected from) -F, -Cl, -Br, -I, -CN, -Ci-e-alkyl, -CFs, -CF2H, -CFH2, -CF2Cl, -CFCl2, -Ci-e-alkylene-CFs, -Ci-6-alkylene-CF2H, -Ci-e-alkylene-CFFF, -C1-6-alkylene-O-CF3, -Ci-6-alkylene-O-CF2H, -Ci-6-alkylene-O-CFH2, -Ci-6-alkylene-NH-Ci-6-alkylene-CF3,-C1-6-alkylene-N(C1-6-alkyl)-C1-6-alkylene-CF3, -C(=O)-Ci-6-alkyl, -Ci-6-alkylene-C(=O)-Ci-6-alkyl, -C(=O)OH, -Ci-6-alkylene-C(=O)-OH, -C(=O)-OCi-6-alkyl, -Ci-6-alkylene-C(=O)-OCi-6-alkyl, -C(=O)O-Ci-6-alkylene-CF3,-C(=O)-NH2, -Ci-e-alkylene-C(=O)-NH2, -C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-C(=O)-NH(Ci-6-alkyl), -C(=O)-N(Ci-6-alkyl)2, -Ci-6-alkylene-C(=O)-N(Ci-6-alkyl)2, -C(=O)-NH(OH), -Ci-6-alkylene-C(=O)-NH(OH), -OH, -Ci-6-alkylene-OH, =0, -OCF3, -OCF2H, -OCFH2, -OCF2CI, -OCFCb, -O-Ci-6-alkyl, -Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-6-alkylene-O-Ci-6-alkyl, -O-Ci-6-alkylene-NH2, -O-Ci-6-alkylene-NH-Ci-6-alkyl, -O-Ci-6-alkylene-N(Ci-6-alkyl)2, -O-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-O-C(=O)-Ci-6-alkyl, -0-C(=0)-0-Ci-6-alkyl, -Ci-6-alkylene-O-C(=0)-0-Ci-6-alkyl, -O-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-O-C(=O)-NH(Ci-6-alkyl), -O-C(=O)-N(Ci-e-alkyl)2, -Ci-6-alkylene-O-C(=O)-N(Ci-6-alkyl)2, -O-S(=O)2-NH2, -Ci-6-alkylene-O-S(=O)2-NH2, -0-S(=0)2-NH(Ci-6-alkyl), -Ci-6-alkylene-O-S(=O)2-NH(Ci-6-alkyl), -O-S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-O-S(=O)2-N(Ci-6-alkyl)2, -NH2, -NO, -NO2, -Ci-6-alkylene-NH2, -NH(Ci-6-alkyl), -N(3- 14-membered cycloalkyl)(Ci-6-alkyl), -N(Ci-6-alkyl)-Ci-6-alkylene-OH, -N(H)-Ci-6-alkylene-OH, -Ci-6-alkylene-NH(Ci-6-alkyl), -N(Ci-6-alkyl)2, -Ci-6-alkylene-N(Ci-6-alkyl)2, -NH-C(=0)-Ci-6-alkyl, -Ci-6-alkylene-NH-C(=O)-Ci-6-alkyl, -NH-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-NH-C(=O)-O-Ci-6-alkyl, -NH-C(=O)-NH2, -Ci-6-alkylene-20308-WO-PCT / 30175-102410 110NH-C(=O)-NH2, -NH-C(=O)-NH(Ci-6-alkyl), -Ci-6-alkylene-NH-C(=O)-NH(Ci-6-alkyl), -NH-C(=O)-N(Ci-e- alkyl)2, -Ci-6-alkylene-NH-C(=O)-N(Ci-6-alkyl)2, -N(Ci-6-alkyl)-C(=O)-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6- alkyl)-C(=0)-Ci-6-alkyl, -N(Ci-6-alkyl)-C(=O)-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-O-Ci-6- alkyl, -N(Ci-6-alkyl)-C(=O)-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH2, -N(Ci-6-alkyl)-C(=O)-NH(Ci-6- alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-C(=O)-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -Ci-e- alkylene-N(Ci-6-alkyl)-C(=O)-N(Ci-6-alkyl)2, -NH-S(=O)2OH, -Ci-6-alkylene-NH-S(=O)2OH, -NH-S(=O)2- Ci-e-alkyl, -Ci-6-alkylene-NH-S(=O)2-Ci-6-alkyl, -NH-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-NH-S(=O)2-O-Ci- e-alkyl, -NH-S(=O)2-NH2, -Ci-6-alkylene-NH-S(=O)2-NH2, -NH-S(=O)2-NH(Ci-6-alkyl), -Ci-e-alkylene-NH- S(=O)2-NH(Ci-6-alkyl), -NH-S(=O)2N(Ci-6-alkyl)2, -Ci-6-alkylene-NH-S(=O)2N(Ci-6-alkyl)2, -N(Ci-6-alkyl)- S(=O)2-OH, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-OH, -N(Ci-6-alkyl)-S(=O)2-Ci-6-alkyl, -Ci-6-alkylene-N(Ci- 6-alkyl)-S(=O)2-Ci-6-alkyl, -N(Ci-6-alkyl)-S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-O-Ci-6- alkyl, -N(Ci-6-alkyl)-S(=O)2-NH2, -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH2, -N(Ci-6-alkyl)-S(=O)2-NH(Ci-6- alkyl), -Ci-6-alkylene-N(Ci-6-alkyl)-S(=O)2-NH(Ci-6-alkyl), -N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -Ci-e- alkylene-N(Ci-6-alkyl)-S(=O)2-N(Ci-6-alkyl)2, -SH, =S, -SF5, -SCF3, -SCF2H, -SCFH2, -S-Ci-e-alkyl, -Ci-e- alkylene-S-Ci-6-alkyl, -S(=0)-Ci-6-alkyl, -Ci-6-alkylene-S(=O)-Ci-6-alkyl, -S(=O)2-Ci-6-alkyl, -Ci-6-alkylene- S(=O)2-Ci-6-alkyl, -S(=O)2-OH, -Ci-6-alkylene-S(=O)2-OH, -S(=O)2-O-Ci-6-alkyl, -Ci-6-alkylene-S(=O)2-O- Ci-e-alkyl, -S(=O)2-NH2, -Ci-6-alkylene-S(=O)2-NH2, -S(=O)2-NH(Ci-6-alkyl), -Ci-6-alkylene-S(=O)2-NH(Ci- e-alkyl), -S(=O)2-N(Ci-6-alkyl)2, -Ci-6-alkylene-S(=O)2-N(Ci-6-alkyl)2, 3-14-membered cycloalkyl, -Ci-e- alkylene-(3-14-membered cycloalkyl), 3 to 14-membered heterocycloalkyl, -Ci-6-alkylene-(3 to 14-membered heterocycloalkyl), -phenyl, -Ci-6-alkylene-phenyl, 5 to 14-membered heteroaryl, -Ci-6-alkylene-(5 to 14- membered heteroaryl), -O-(3- 14-membered cycloalkyl), -O-(3 to 14-membered heterocycloalkyl), -O-phenyl, -O-(5 to 14-membered heteroaryl), -C(=O)-(3-14-membered cycloalkyl), -C(=O)-(3 to 14-membered heterocycloalkyl), -C(=O)-phenyl, -C(=O)-(5 to 14-membered heteroaryl), -S(=O)2-(3-14-membered cycloalkyl), - S(=O)2-(3 to 14-membered heterocycloalkyl), -S(=O)2-phenyl, -S(=O)2-(5 to 14-membered heteroaryl).

41. A compound of Formula (IV), a stereo-isomeric form, a physiologically acceptable salt, solvate and / or polymorph thereof according to Formula IV-a, IV-b, IV-c, or IV-d:

42. A pharmaceutical composition comprising a compound according to any one of claims 24 to 41.

43. The compound according to any one of claims 24 to 41 or the pharmaceutical composition according to claim 42, for use in the treatment of pain or epilepsy.20308-WO-PCT / 30175-102410 11144. The compound or pharmaceutical composition for use in the treatment of pain according to claim 43, wherein the pain is selected from nociceptive pain, inflammatory pain, and neuropathic pain; preferably post-operative pain or migraine pain.

45. A method of treating pain or epilepsy, comprising administering to a patient in need thereof a therapeutically effective amount of a compound as defined in any one of claims 24 to 41, or the pharmaceutical composition according to claim 42.

46. The method of claim 45, wherein the pain is selected from nociceptive pain, inflammatory pain, and neuropathic pain; preferably post-operative pain or migraine pain.20308-WO-PCT / 30175-102410 112